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Abstract 
Background: The psychological impact of stroke is well recognised as being of 
clinical importance.  Historically, this field has received less attention than the 
physical consequences of stroke, but work designed to develop our 
understanding of post-stroke psychology is now well underway.  Much of the 
current research of post-stroke psychology is overly limited however; little 
attention has been paid to the potential impact of the pre-stroke state on post-
stroke psychology.  As a consequence, fundamental information in relation to 
the pre-stroke state is lacking, ranging from the prevalence and relevant risk 
associations of various psychological and physical conditions, to the validity and 
optimal use of pre-stroke state assessment methods.  The purpose of this thesis 
is to improve our understanding of the pre-stroke state in relation to these 
under-researched areas.   
 
Method: I conducted a series of studies designed to improve our understanding 
of the pre-stroke state in the areas of prevalence, risk association, and method 
of assessment.  Specifically, I conducted a diagnostic test accuracy study to 
evaluate the psychometric properties of two informant questionnaires that can 
be used to assess pre-stroke cognition: the Informant Questionnaire for Cognitive 
Decline in the Elderly (IQCODE) and Acquired Dementia 8 (AD8).  
 
I conducted a systematic review and meta-analyses to establish pre-stroke 
depression prevalence and investigate its association with post-stroke 
depression.  Based on the findings of this, I explored the potential use of 
informant tools for pre-stroke depression assessment by comparing the 
diagnostic test accuracy of the Stroke Aphasic Depression Questionnaire (SADQ) 
against the Geriatric Depression Scale (GDS), and the diagnostic test accuracy of 
the best performing informant questionnaire against that of medical records.  
 
I conducted secondary analysis of existing data held in two databases to 
investigate pre-stroke functioning and pre-stroke frailty.  The Anglia Stroke 
Clinical Network Evaluation Study database was utilised to assess the validity of 
the pre-stroke modified Rankin Scale (mRS) as a measure of function and explore 
if reported predictive validity of the tool could be influenced by differences in 
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post-stroke care pathway.  The Glasgow Royal Infirmary research database was 
used to investigate the prevalence of pre-stroke frailty, the validity of a Frailty 
Index for pre-stroke frailty assessment, and a risk association between pre-
stroke frailty and acute post-stroke cognition.  
 
Findings: I found that the IQCODE and AD8 are valid tools for assessing pre-
stroke cognition.  However, when utilised at recommended published cut-points 
the IQCODE is more specific, while the AD8 is more sensitive to cognitive 
impairment.  There is also potential that application of differing cut-points could 
improve performance when used in a pre-stroke context.   
 
My systematic review and meta-analysis suggested that pre-stroke depression 
prevalence is around 17% and its presence significantly increases odds of post-
stroke depression.  In addition, there is evidence that the most commonly used 
method to assess pre-stroke depression, patient medical records, is likely to lack 
sensitivity to pre-stroke depression.  
 
I explored the use of the SADQ and GDS informant tools for assessment of pre-
stroke depression.  I found that both tools are valid measures of pre-stroke 
depression, but the GDS has favourable diagnostic test accuracy properties in 
comparison to the SADQ; comparative test accuracy performance with medical 
records is inconclusive, but seems to favour the GDS.   
 
Pre-stroke mRS evaluation suggests it has moderate validity as a measure of pre-
stroke functioning and has predictive validity that could not be accounted for by 
differences in care pathway.  
  
Pre-stroke frailty prevalence is around 28%, rising to ~80% if the pre-frailty state 
is considered, and the Frailty Index is a valid measure of pre-stroke frailty that 
can be completed in almost all stroke patients.  Pre-stroke frailty also has an 
association with lower acute post-stroke cognition that is independent of other 
established risk factors.   
 
Conclusions: In conclusion these findings develop our overall understanding of 
the pre-stroke state.  The IQCODE and AD8 are both valid tools for assessment of 
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pre-stroke cognition; however, they demonstrate contrasting strengths when 
employed at their recommended cut-points and these cut-points may not be the 
most optimal when these tools are utilised for pre-stroke assessment.   
 
Pre-stroke depression appears prevalent, existing in around one in six stroke 
patients, and it increases the odds of patients experiencing post-stroke 
depression.  It is possible that informant assessment for detection of pre-stroke 
depression can outperform patient medical records and the GDS appears to 
outperform the SADQ in the pre-stroke context; however further work is 
required to confirm this.   
 
The pre-stroke mRS is a valid measure of function but has only moderate validity 
overall and may not be ideally suited to assessment of function in a pre-stroke 
context. Pre-stroke frailty may exist in around one quarter of stroke patients, 
and utilisation of a Frailty index approach appears to be valid.  The presence of 
pre-stroke frailty may also contribute to the poor cognitive performance often 
observed in patients following acute stroke based on an independent association 
with lower cognitive performance; hence identification of pre-stroke frailty 
could be of importance to our understanding of post-stroke psychology.   
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Preface: Background and thesis outline 
 
The epidemiology and impact of stroke 
 
Stroke is a major cause of adult disability in both Europe and the United States 
of America.  The UK alone has over 1.2 million stroke survivors with around 
100,000 strokes occurring per annum. (1)  
 
The majority (59%) of strokes occur in older adults; however, around a quarter 
of strokes happen in people of working age. (2)  Indeed, over a third (38%) of 
first-time strokes occur in adults between the ages of 40 to 69 and first-time 
strokes now occur at an earlier age in comparison to 10 years ago. Between 
2007-2016, the average age of stroke occurrence declined from 71 to 68 years 
for males and 75 to 73 years for females. (3) 
 
Stroke is often not a singular event. One in four stroke patients experience a 
second stroke within 5 years (4) and 1 in 20 have another stroke while still in 
hospital. (5)  Further strokes typically exacerbate the consequences patients 
experience, and regularly result in death. 
 
Stroke is suggested to be the second most common cause of death, constituting 
10% of all deaths in the developed world. (6, 7)  Forty-thousand stroke-related 
deaths occur in the UK, each year.   Death rates from stroke in women are twice 
that seen from breast cancer. In men, annual deaths from stroke are two times 
greater than deaths from prostate and testicular cancer combined. (8-10) 
 
However, most patients do not die following stroke.  Eighty-five percent of 
stroke patients in England, Wales and Northern Ireland survive their stay in 
hospital. (5) 
 
Those who survive stroke experience a broad range of impairments; stroke 
causes a greater range of disabilities than any other condition. (11)  Motor and 
sensory impairments are among the most commonly recognised: The Stroke 
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Association’s latest State of the Nation report suggests that almost two thirds 
(65%) of stroke survivors in the UK leave hospital with a disability. (11) 
 
Around three quarters of stroke survivors have arm or leg weakness. (12) 
 
Sixty percent of stroke survivors have visual problems immediately after their 
stroke; 20% experience visual issues up to three months after stroke. (13) 
 
Around half of all stroke patients have difficulty with swallowing. (12) This can 
inhibit ability to eat and drink and increases risk of pneumonia. (14) 
 
Around 50% of stroke survivors experience problems with bladder control. (12) 
 
Around a third of stroke survivors experience difficulties with communication 
due to aphasia.  (15) 
 
The presence of these impairments increase pressure on health services. Four 
out of ten stroke survivors leave hospital requiring help with daily living 
activities but almost a third receive no social service visits. (5)  In Scotland, 
more than half of stroke survivors need support from other people to be able to 
walk. (16)  Around half of stroke survivors in England, Wales and Northern 
Ireland require speech and language therapy during their hospital stay. (5) 
 
Estimated stroke costs to the UK are around £9 billion a year as a society. This 
includes £2.4 billion a year in informal care costs, £1.3 billion in lost income due 
to care, disability and death, and over £800 million in benefit 
payments. (17) 
 
There are also costs on a personal level for the stroke patients and their 
families.  Forty-two percent of people report a negative change in their 
relationship with their partner after a stroke; a quarter state that stroke had a 
negative impact on their family. (18)  Stroke increases the likelihood of 
unemployment by two to three times in people of working age, up to 8 years 
after their stroke. (19)  Around 1 in 6 stroke survivors experience a loss of 
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income and almost a third of stroke survivors report increased daily living 
costs.(18) 
 
The Psychological Impact of Stroke 
 
Consequences of stroke also encompass alterations to patient psychology. (20)  
Increased emotionalism and issues with fatigue, cognition, anxiety and 
depression are common.  
 
Stroke survivors and their carers have consistently highlighted the importance of 
psychological issues. (21) Disorders of psychology have been associated with 
increased mortality risk (22), impaired daily functioning (23), reduced post-
stroke quality of life (24) and adverse effects on rehabilitation engagement. (25)  
The financial impact of psychological issues in stroke is also substantial. For 
instance, disorders of depression and mood are expected to cost the National 
Health Service £3billion per annum by 2026 in England alone. (26)   
 
It has become increasingly apparent in recent years that identification of 
psychological disorders is essential to our ability to understand the full 
consequences of a stroke.  Once psychological impairments are identified and 
understood, interventions could be developed with the objective of diminishing 
their impact upon patient well-being and service costs.  
  
Despite this, the psychological consequences of stroke have traditionally 
received less attention in research than motor and sensory deficits. Therefore, 
psychological problems were recently identified as a priority area for stroke 
research. (27)  
 
 
Thesis outline 
 
The purpose of this thesis is to enhance our understanding of psychological 
problems in stroke.  This work will focus on two prominent issues of psychology 
in stroke in particular: cognition and mood. 
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The opening chapter outlines our current state of knowledge regarding the 
psychological impact of a stroke in relation to cognition and mood.  Chapter 2 
discusses the relevance of the largely under-researched pre-stroke state in this 
context.  Our understanding of both psychological and physical pre-stroke 
conditions that are important to fully comprehend psychological problems in 
stroke are discussed, before concluding with the specific aims of the thesis.  The 
subsequent chapters describe studies designed to address these aims; and a 
closing chapter provides a summary and discussion of my overall findings, 
suggested future directions, and a conclusion. 
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CI: Confidence Interval 
 
DSM: Diagnostic and Statistical Manual 
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GPcog: General Practitioner Assessment of Cognition 
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GC: Gillian Cuthbertson 
 
GDS: Geriatric depression scale 
 
GDS-SF: Geriatric depression scale short form 
 
GRADE: The Grading of Recommendations Assessment, Development and 
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MDD: Major Depressive Disorder 
 
MEWS: modified early warning score 
26 
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SCID: Structured Clinical Interview for Depression 
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STARDem: Standards for Reporting of Diagnostic Accuracy studies in Dementia 
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VIF: Variance inflation factors 
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1. What do we know about the psychological 
impact of a stroke? 
1.1 What is cognition and what is depression? 
Before beginning the discussion of the psychological impact of stroke, it is 
important to define what specifically is being referred to by the terms 
‘cognition’ and ‘depression’. 
 
Cognition is the mental process of acquiring knowledge and understanding 
through thought, experience and senses.  It includes the domains of memory, 
language, attention, executive functioning and visuospatial processing.  
Cognitive impairment is the disruption of functioning of any one of these 
domains.  The most severe form of cognitive impairment is that of dementia.  
Dementia is an umbrella term that encapsulates a range of neurodegenerative 
disorders (e.g. Alzheimer’s disease; Vascular dementia; Lewy body dementia; 
Frontotemporal dementia), which are chronic, progressive and cause multi-
domain cognitive impairment.  Dementia is not specifically classified by the 
Diagnostic and Statistical Manual (DSM) version IV (28) but can be inferred as 
consisting of memory impairment, plus one or more of aphasia, apraxia, agnosia, 
and executive dysfunction.  Moreover, these cognitive deficits must impair daily 
functioning and represent a significant decline from previous levels of 
functioning; however, they must also not be better explained by disorders such 
as major depressive disorder (MDD) or schizophrenia, nor be attributable to an 
acute fluctuating disorder, such as delirium. (29)  Fundamentally, dementia 
differs from non-dementia cognitive impairment in that it implies a continued, 
progressive deterioration in cognition that substantially disrupts daily 
functioning and will ultimately result in death. 
   
Depression, meanwhile, is a disorder of mood.   The most severe form of 
depression is major depressive disorder, which is diagnosed, according to the 
DSM-5 (30) if someone experiences feeling sad and/or a loss of interest or 
pleasure in everyday activities, plus 3-4 additional symptoms during the same 2-
week period.  Additional symptoms include reduced/increased appetite, 
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reduced/increased sleep, severe fatigue, feelings of worthlessness or guilt, 
feeling agitated/slowed down, diminished ability to concentrate/make every-
day decisions, and recurrent thoughts of death/suicidal ideation.  For MDD to be 
diagnosed, the presence of such symptoms must also cause clinically significant 
distress or impact daily functioning, such as ability to perform at work or 
interactions with peers. Milder forms of depression (such as minor depressive 
disorder) can also be diagnosed in which only 2-4 of the aforementioned 
symptoms are present, provided one of them is feelings of sadness or loss of 
interest/pleasure in everyday activities; and longer-term or season-specific 
depressions such as persistent depressive disorder or seasonal effective disorder 
reflect the presence of the aforementioned symptoms over prolonged periods of 
time (often months or years).   
 
In addition to the traditionally recognised depressive disorders, vascular forms of 
depression may exist.  Although not acknowledged by the DSM, vascular 
depression is thought to be organic in nature, occurring as a consequence of 
vascular damage to the frontal-subcortical regions of the brain.(31) Its symptoms 
largely overlap with MDD, and while low mood or anhedonia must be present, it 
is more prominently characterised by issues with psychomotor slowing, apathy, 
and cognitive impairment (particularly impaired executive functioning and 
reduced processing speed) than is typically seen in MDD.(32)   
 
  
1.2 Current understanding of the natural history of 
psychological impact of stroke  
Considerable research has taken place in recent years designed to develop our 
understanding of post-stroke psychological effects.  Typically, research into the 
impact of stroke on cognition and mood has attempted to establish prevalence, 
risk factors, post-stroke trajectories of recovery or further decline, and specific 
cognitive domains affected following stroke.   
 
This section will outline our current understanding of each of these areas in 
relation to post-stroke cognition and depression.   
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1.2.1 Cognition and dementia 
1.2.1.1 Prevalence 
Current evidence suggests that the majority of stroke patients experience 
impairment or decline in cognition.(33) Linden et al., (2004)(34) report cognitive 
impairment can be identified in around 61% of patients 20 months after stroke.  
This is two-times higher than the rate (31%) they observed in an age-matched 
control population.  However, reported prevalence rates in this field have been 
highly heterogeneous.  Patel et al., (2003)(35) reported that rates of vascular 
cognitive impairment varied from 15-39% based on clinical setting and time-
frame assessed (3 months-3 years); while Pohjasvaara et al., (1997)(36) found 
further variation dependent upon age group, with rates varying from 45.7% in 55-
65-year olds, up to 74.1% for 75-85 year olds. 
      
In similar vein, post-stroke dementia prevalence rates range from 7.4% to 41.3% 
across studies.(37)  Rates of dementia found in stroke are typically higher in 
hospital settings (20.3%-26.5%) than in population settings (7.4%).  Post-stroke 
dementia in first-ever stroke survivors is reported as 10%; while 33% of recurrent 
stroke survivors develop post-stroke dementia. (37)  By comparison, dementia 
prevalence is reportedly 7% in the general older adult population. (38)   
 
Efforts to establish prevalence of dementia or cognitive impairment in stroke 
and determine how these rates compare against those of the general older-adult 
population are often confounded by varying definitions applied between 
studies.(28, 39)  However, the general trend is that dementia presents an even 
greater burden in the stroke population than it does in the older-adult 
population.   
 
1.2.1.2 Risk factors 
A number of demographic and clinical risk factors have been associated with 
increasing risk of post-stroke cognitive impairment and dementia.   
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Demographic risk factors include increasing age and low levels of education.(40-
42)  Cited clinical risk factors are numerous, but inconsistent.  Atrial fibrillation, 
(40) hypertension,(43) myocardial infarction (44) and diabetes (45) have all been 
associated with increased risk of cognitive impairment and dementia in stroke 
populations.  However, Elkins et al., (2004)(46) point out that any proposed risk 
association may not be attributable to a single risk factor; rather, increased risk 
may be the product of the number and combination of risk factors that are 
present.  Moreover, any risk may in fact be indirect; for instance, some risk 
factors may increase risk of stroke (re)occurrence, which in turn increases risk of 
cognitive impairment or dementia. (33) 
 
Stroke-related factors are regarded as the greatest determinants of post-stroke 
dementia. (37, 47)  Stroke severity, stroke recurrence, and stroke location have 
all been implicated in onset of post-stroke dementia. (37) Investigations have 
also taken place into the influence of stroke-type. (48) Cerebral strokes appear 
to affect cognition more than brainstem strokes.(37)  Lacunar strokes that affect 
the deep lying subcortical regions of the brain, however, appear just as 
disruptive to cognition as cerebral strokes. (49) This may be related to lacunar 
strokes’ position on the spectrum of small vessel disease, which itself is 
associated with cognitive impairment via diffuse structural damage. (49)  
 
1.2.1.3 Trajectories 
Continued cognitive decline is common post-stroke; the cumulative dementia 
incidence rate is reported to be 3% per annum, when recurrent strokes are 
factored in. (37)  However, there is evidence that the trajectories of impairment 
are variable.  (see Figure 1-1)  
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Figure 1-1. Trajectories of cognitive impairment after stroke 
 
 
 
Likelihood and extent of deterioration can be influenced by existent risk factors 
such as older age, lower education and recurrent stroke. (50-52) Importantly 
however, not all post-stroke cognition follows a descending trajectory and there 
is evidence of recovery.  For instance, Desmond et al., (1996)(53) found that 
19/151 patients experienced recovery of cognitive function, and this 
improvement was apparent for most within the first 3 months.  Similarly, Del ser 
et al., (2005)(51) found that 7.8% of patients experienced improvement in 
cognitive status at 24 months, while Rasquin et al., (2005)(50) reported that 20% 
of patients with post-stroke mild cognitive impairment (MCI) at 1 month 
demonstrated normal cognitive function at later assessment.   
 
1.2.1.4 Domains affected 
Strategic lesions can theoretically induce cognitive impairment of any kind, and 
global cognitive impairment is common post-stroke; however, the most 
frequently affected cognitive domains in stroke patients appear to be speed of 
information processing (SOIP) and attention. (54) This is particularly the case 
early after stroke (i.e. first month), in which as many as 70% of stroke patients 
reportedly experience impairments in SOIP and attention. (55)  By contrast, 
visual and verbal memory may be the least affected domains following stroke, 
with impairments reportedly occurring in around 15% and 30% of stroke patients, 
respectively. (55) Albeit, some studies have found memory impairments existent 
in up to 60% if stroke patients, 3 months following stroke. (56) 
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Interestingly, trajectories of recovery seem to vary by domain.  Hurford et al., 
(2013)(55) found that the most prominent early impairments also demonstrated 
the greatest recovery potential.  Specifically, impairments in attention and SOIP 
declined from 70% in the acute period to <40% at 3 months.  The least affected 
cognitive domains—visual and verbal memory— meanwhile, demonstrated the 
lowest recovery potential, with no statistically significant change in prevalence 
taking place between the acute period and 3 months.   This may suggest that, in 
many cases, existent memory impairments following stroke reflects underlying 
neurodegeneration that pre-dates the stroke. (55) However, research on domain-
specific recovery potential has been inconsistent.  Lesniak et al., (2008)(57) 
found that recovery was greatest in the domains of executive functioning, 
aphasia and long-term memory; whereas deficits in attention and short-term 
memory tended to persist. In contrast, Snaphaan and De Leeuw (2007)(58) found 
that prevalence of memory impairment declined from 23-55% at 3 months to 11-
31% at 1 year.  Therefore, no firm conclusion can be drawn at present as to 
underlying nature of any given form of post-stroke cognitive impairment. 
 
1.2.2 Depression 
1.2.2.1 Prevalence 
Depression following stroke appears to be highly prevalent and rates are 
reportedly several times that of the general older adult population; (59, 60) 
albeit, similar to post-stroke cognition, the specific rates are often 
heterogeneous across studies.  This variability is typically attributed to 
variations in assessment type, study setting, follow-up time from stroke, and 
study setting. (61) 
 
The most frequently reported pooled prevalence of depression after stroke is 
~30%. (59, 62)  However, Ayerbe et al., (2013)(63) report more than 50% of 
stroke patients are expected to experience post-stroke depressive symptoms, if 
not necessarily clinical depression.  When restricted to cases of major 
depression only, rates of post-stroke depression are suggested to be around 17%. 
(64) 
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Alteration of prevalence over time is an area of active debate.  Some (65) 
suggest that most cases of depression following stroke occur inside the first 
year, with prevalence deteriorating over time; whereas others suggest a stable 
prevalence rate of ~30% up to 10 years post-stroke. (63)  
 
1.2.2.2 Risk factors 
A large variety of variables have been investigated as potential risk factors for 
depression after stroke.  Attempts have been made by several systematic 
reviews to pinpoint the most important risk factors; however, their conclusions 
are often conflicting. (59, 62, 64, 66-69) 
 
Sociodemographic risk factors including age, sex, lifestyle and lack of social 
support have been related to onset of post-stroke depression. (70, 71)  
Psychological factors such as cognitive impairment, anxiety, personality type, 
subjective experience of stroke, and patient coping strategies have all been 
associated with post-stroke depression, along with functional risk factors like 
post-stroke disability and level of independence. (59, 66) 
 
Demonstrated associations between many of the aforementioned variables and 
post-stroke depression onset have been argued to indicate that depression after 
stroke is largely a product of the experience and psychological consequences of 
the stroke. (59)  However, others champion an organic aetiology to post-stroke 
depression. (62) 
 
The organic theories of post-stroke depression posit that depression may be 
induced as a direct consequence of biological damage provoked by brain injury.  
In support of this, stroke lesion size and lesion location have been implicated in 
development of post-stroke depression, the latter particularly in the first 2 
months following stroke. (64, 72) Specifically, left-sided strokes that produce 
lesions in the frontal lobe and basal ganglia have been linked to development of 
post-stroke depression; and severity of depressive symptoms have been linked to 
lesion proximity from the left frontal pole. (72) However, most subsequent 
studies have failed to replicate the observed association between stroke lesion 
location and post-stroke depression (73) and some have even found associations 
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between depression and lesions in the contralateral hemisphere. (74)  Reasons 
for these contrasting results have been attributed to the way in which 
depression is assessed across studies, as well as variability in study setting, 
neuroimaging methods applied, exclusion of aphasic patients, and definition of 
lesion location. (72, 73)  Perhaps less controversially, extent of subcortical 
vascular damage (and subcortical small vessel disease) has also been associated 
with onset of post-stroke depression. (31) It is argued that post-stroke 
depression may be induced via vascular damage that causes interference to 
subcortical frontal lobe circuits and monoaminergic and serotonergic pathways, 
disrupting the emotional circuits of the brain.   
 
1.2.2.3 Trajectories 
Current research describes substantial recovery potential from depression after 
stroke.  Specific rates are uncertain however, with reported recovery at 1 year, 
following a depressive episode in the first 3 months post-stroke, ranging from 
15%-57%. (63) 
 
Although a relatively quick recovery from a first instance of post-stroke 
depression is common for many patients, recurrence appears highly likely and 
can occur even after a long period of remission. (63)  Ayerbe et al., (2013)(63) 
report that 38% of stroke patients experience a recurrent bout of depressive 
symptoms at 2 years; and most patients appear to experience recurrence of 
depressive symptoms generally, some of which reoccur as long as 15 years after 
the stroke event.   
 
Recovery potential may however vary depending upon the nature of the 
depression; depressive disorders thought to be induced by vascular damage are 
proposed to demonstrate a more chronic nature and greater frequency of 
recurrence. (75) 
 
1.2.3 Summary and conclusions 
Overall, research to date suggests that psychological issues in stroke are 
substantial.  While our specific understanding of the aetiology and natural 
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history of post-stroke cognitive impairment and depression is limited due to 
heterogeneous findings, the evidence broadly suggests that a majority of 
patients will experience psychological issues.  Investigations into risk factors for 
post-stroke psychological problems have been extensive and it is clear that 
factors beyond the stroke itself are relevant.   However, there is currently 
limited agreement as to the most pertinent risk factors for both post-stroke 
cognition and mood impairment.  Finally, the evidence suggests that trajectories 
of cognitive impairment and depression following stroke are not straightforward.  
In general, it seems that while recovery is possible for both conditions, 
deterioration in cognition is common although can vary depending on the domain 
affected, while recurrence of depression likely.   
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Chapter 2. The pre-stroke state 
As evidenced in chapter 1, psychological problems in stroke are substantial and 
there is much scope to improve our understanding of these issues. There are 
numerous areas of study that would help develop our comprehension of 
psychological problems in stroke.  A very relevant, but to date particularly 
overlooked area is the pre-stroke state.   Much of the current stroke-psychology 
literature is overly limited, frequently focusing upon post-stroke variables’ 
contribution to psychological disorders, with little attention given to the 
influence of pre-stroke factors.  Consequently, the contribution of the pre-
stroke state to post-stroke psychology is less well understood. Improving our 
understanding of the pre-stroke state could broaden our perspective of the 
psychological problems that stroke patients experience, including aetiology and 
natural history.  Both psychological and physical pre-stroke conditions are 
important to consider in this regard.  This chapter will outline what we know 
regarding several pre-stroke variables and their relevance to the post-stroke 
psychological state. Specifically, the chapter will discuss risk associations, 
prevalence, and means of assessment of four pre-stroke conditions (cognitive 
impairment, depression, functional impairment/disability and frailty), as well as 
highlighting limitations regarding our understanding of these areas.  Addressing 
these limitations will be the focus of subsequent chapters of this thesis.   
 
2.1 Pre-stroke cognitive impairment and dementia 
2.1.1 Risk association and Prevalence 
While the stroke itself appears to be the major determinant of post-stroke 
dementia (37), presence of pre-stroke cognitive impairment has been regularly 
associated with increasing risk of post-stroke cognitive impairment and 
dementia.(37, 47)   The prevalence of any pre-stroke cognitive impairment (e.g. 
MCI plus dementia prevalence combined) is not well described; however, a 
systematic review of the literature (37) suggests the prevalence of pre-stroke 
dementia lies between 9-14%, depending on setting.   This may even be an 
underestimation as many of the studies on which these rates are based employ 
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retrospective methods to determine dementia prevalence. (37)  There are a 
number of issues with this assessment approach that may hinder our 
understanding of pre-stroke cognition and, consequently, our wider 
understanding of psychological issues in stroke.  The specific issues with current 
pre-stroke cognition assessment are outlined in detail in section 2.1.2.  
 
2.1.2. Methods of assessing pre-stroke cognitive 
impairment and dementia 
Pre-stroke cognition can be assessed objectively via neuropsychological tests, 
provided they are conducted before the stroke occurrence.  This is the optimal 
approach; however, it is difficult to establish pre-stroke cognition in this way as 
neuropsychological assessments are not routinely conducted within the general 
population; hence, the pre-stroke cognitive state is typically assessed 
subjectively via a retrospective interview or questionnaire.   
 
When patients are cognitively impaired, their ability to provide insight into their 
own cognitive issues as well as any deterioration over time is often lacking; 
therefore, reports from ‘informants’ (third parties that knows the patients well) 
are preferred over patient self-reports. As such, completing a retrospective 
interview/questionnaire with an informant is a favourable method employed to 
establish pre-stroke cognition.  
 
There are many informant tools that might be used for assessment of pre-stroke 
cognition.  (see Figure 2-1) The Informant Questionnaire of Cognitive Decline in 
Elderly (IQCODE); the Ascertain Dementia 8 questions (AD8); the General 
Practitioner Assessment of Cognition (GPCog); and the Blessed Dementia Scale 
(BDS) are typical examples.  However, these tools were designed to establish 
‘present day’ cognition, not retrospective cognition that predates a particular 
medical event; moreover, there are potential stroke-specific issues with the use 
of such tools when employed to assess premorbid cognition.  This section will 
outline some of the key issues concerning the retrospective informant approach 
for assessment of pre-stroke cognition by detailing the evidence regarding the 
psychometric properties of informant-based tools.  
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The IQCODE is the most commonly employed tool in stroke. (76) Historically, the 
IQCODE was designed to detect cognitive decline in community dwelling older 
adult populations. (77) It is a 32-item questionnaire that asks an informant 
questions concerning how their friend/relative’s cognition has changed over the 
past 10 years.  It operates on a 5-point ordinal scale and generates a score 
ranging from 1 (much improved) to 5 (much worse); scores closer to 5 suggest 
greater cognitive impairment.  
 
As it is the most commonly employed tool, I will use our current understanding 
of the IQCODE’s psychometric properties and application as an exemplar of the 
status of pre-stroke cognition assessment and the wider issues of this area.   
 
Figure 2-1. Common Informant tools for assessing cognition 
 
Informant Questionnaire Cognitive Decline in the 
Elderly (IQCODE) 
Ascertain Dementia 8 questions (AD8) 
Deterioration Cognitive Observee (DECO) 
Blessed Dementia Scale (BDS) 
General Practitioner assessment of Cognition (GPCog) 
Concordant Informant Dementia Scale (CIDS) 
Symptoms of Dementia Screener (SDS) 
Short Memory Questionnaire (SMQ) 
Brief Cognitive Scale (BCS) 
Dementia Questionnaire (DQ) 
 
 
2.1.2.1 Psychometric properties of the IQCODE 
A number of key variables are deemed important for the operational use of a 
measurement tool according to the theory of psychometrics (78): validity, 
reliability, acceptability, feasibility and responsiveness.  (see Table 2-1) 
Extensive work has been conducted on the psychometric properties of the 
IQCODE.  Research to date highlights uncertainty regarding 3 of the 
aforementioned properties.   
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Table 2-1. Description of the core psychometric properties 
 
PSYCHOMETRIC 
PROPERTY 
 
Validity The degree to which a tool measures what it purports 
to measure. 
Concurrent validity The extent to which a tool’s results correspond to 
other. 
measures associated with the outcome of interests 
(i.e., functional disability). 
Construct validity A tool’s association with other tools that measure the 
same, or a similar construct. 
Predictive validity Ability of the tool to predict future events. 
Reliability Refers to a tool’s consistency in scoring over multiple 
assessments. 
Inter-rater reliability Consistency of scoring across different assessors. 
Intra-rater reliability Consistency of scoring within the same assessor. 
Acceptability The acceptability is the willingness of the participant 
to undergo/take part in the assessment. 
Feasibility The practicality or reasonableness with which a tool 
can be used. Can incorporate measures of 
acceptability to rater and patient. 
Responsiveness The ability of the scale to detect change after 
repeated testing (either improvement or further 
decline).   
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Validity: 
Validation work has compared the IQCODE against measures of cognitive change, 
neuropathology, neuroimaging and neuropsychological assessment and shown 
significant, moderate correlations with each; (79) factor analysis suggests the 
tool is a measure of general cognitive decline. (79)  In acute care settings, 
sensitivity and specificity for detection of dementia, based on meta-analysis, 
(77) is reported to be 91% and 66%, respectively (at a cut-point of 3.3 or 
closest).  The overall reported diagnostic test accuracy evidence is comparable 
to that of direct-to-patient, objective cognitive assessments such as the Mini-
Mental State Examination (MMSE);(80) and there is even evidence that the tool is 
less susceptible to influences of education and cultural norms than objective 
cognitive assessments. (79) 
 
However, IQCODE validation studies are often limited by the incorporation of the 
IQCODE score into the gold standard reference assessment to which it is 
compared during diagnostic test accuracy evaluation.  This lack of blinding and 
cross contamination is a major source of bias regarding the IQCODE’s reported 
diagnostic properties, typically resulting in overestimation of the tool’s 
accuracy. (81)  In addition, population restrictions are frequent in IQCODE 
diagnostic test accuracy studies, which limits the generalisability of the reported 
rates.  Furthermore, evidence related to the IQCODE’s ability to detect non-
dementia level cognitive impairment is sparse and inconsistent (82-85), and 
there are indications that other informant tools (e.g. AD8) may outperform the 
IQCODE in the context of diagnosing non-dementia level cognitive impairment. 
(82)  
 
Added to these general issues regarding the contemporary evidence of the 
IQCODE’s validity are matters that pertain more specifically to stroke.   For 
instance, McGovern et al., (2016) found that there are no validation studies 
investigating use of the IQCODE (or any informant tool) as a means of assessing 
pre-stroke cognition, despite its widespread use for this purpose. This is 
concerning since it is not uncommon for tools to perform differently across 
medical populations. (86)  Indeed, stroke populations often demonstrate a 
greater prevalence of specific conditions that can influence the tool’s diagnostic 
test accuracy, than are found in the general geriatric population.   
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To elaborate, vascular problems (e.g. small vessel disease, previous-stroke) are 
common in stroke populations (87) and are believed to primarily impair the 
cognitive domains ‘executive functioning’, ‘speed of information processing’, 
and ‘attention’. (76) Yet, the IQCODE has a memory-based focus to its items.  
Thus, there is greater potential for individuals with predominantly non-memory-
related cognitive problems to go unrecognised, reducing the sensitivity of the 
tool.   
 
The IQCODE describes change in performance on various functional tasks as a 
means of determining presence of cognitive impairment.  Depression can also 
influence many of the functional tasks described; (79) and, as depression is a 
risk factor for stroke, (88) pre-stroke depression may be more common in stroke 
populations than in non-stroke populations.  Similarly, certain functional tasks 
may not be performed as well as before due to onset of physical disabilities (e.g. 
learning how to use a new gadget or machine around the house; handling money 
for shopping; handling financial matters), which again may be more common in 
stroke than in non-stroke populations. (89)  These latter two conditions may 
consequently impact upon the specificity of the tool when applied to a stroke 
population.  
 
Acceptability and Feasibility: 
Investigations as to the acceptability and feasibility of the tool also highlight 
difficulties.  The IQCODE was designed for use in a community dwelling 
population where informants are at hand and assessors have time to address 
queries.  In a busy, secondary acute care setting however, suitable informants 
may not be as readily available, and staff may not have the time to supervise 
completion/answer queries, potentially adversely affecting the tool’s validity.  
While small scale studies with dedicated research assistants can achieve 
informant tool completion rates of around 80% (90), McGovern et al., (2016)(76) 
report a typically high non-completion rate of the IQCODE when used in stroke 
research, and Smeeth et al.,(2001)(91) report that postal forms of the 
questionnaire are associated with missing data.   
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This propensity for non-completion suggests that either the acceptability or 
feasibility of the questionnaire may be limited.   The reasons for this are 
unclear. While direct cognitive assessments often demonstrate poor 
acceptability due to issues such as distress arising from deficient performance, 
or the high mental demand required for completion, informant questionnaires do 
not obviously entail such issues.  It may be that informants feel the questions 
are not relevant to their relative or are too vague to be answered acceptably.  
There are currently no qualitative analyses of people’s experience with these 
questionnaires to enlighten in this area.  On this basis, recent reviews (77) have 
called for more work to establish how feasible informant tools are in secondary 
care settings. 
 
Heterogeneity of use and optimal tool selection: 
On a final note, a major limitation of the IQCODE is that there is little guidance 
as to why it should be selected over any of a number of informant tools.  There 
are a vast range of informant tools for cognitive assessment available, and the 
extent of choice can be reflected in heterogeneous operationalisation of 
cognitive assessment tools in practice. (92)  To date, there have been no direct 
comparisons of informant tools that determine the suitability of their use in 
stroke.  As such, tool selection is often arbitrary, which contributes largely 
avoidable heterogeneity to the field.  Added to this, employment of such 
informant tools frequently  demonstrates inconsistency of application. (92)  
Variable cut-off points for dementia diagnosis are employed for the IQCODE (e.g. 
3.3-4.1). (77)  Cut-off points define the properties of the tool in relation to 
sensitivity and specificity.  Reducing a cut-off point to improve sensitivity may 
increase identification of patients with cognitive impairment; however, resultant 
specificity will inevitably suffer.  This heightens misidentification risk of 
cognitively unimpaired individuals as demented.  Heterogeneity of application is 
therefore another pernicious issue regarding the current utilisation of the 
IQCODE as a means of assessing pre-stroke cognition and could unnecessarily 
induce misdiagnosis clinically as well as further exacerbate inconsistency in 
stroke-cognition research. 
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2.1.3 Summary and conclusion 
Despite its obvious relevance to understanding post-stroke cognitive impairment, 
a robust and extensive understanding of pre-stroke cognitive impairment is 
lacking.  This is in part related to issues regarding assessment.  Informant tools 
have inherent limitations of various psychometric properties, but the extent of 
these limitations are particularly poorly understood within a stroke context.  
While necessities of pragmatism dictate that a limited retrospective approach to 
pre-stroke cognition assessment must typically be applied, issues with 
psychometric properties are exacerbated by variability of tool selection and 
application.  Arguably, this stems from a lack of any explicit guidance as to 
appropriate tool selection and utilisation as no studies have yet validated and 
compared competing informant tools within the same study or established 
optimal cut-off points.  Overall, the issues with pre-stroke assessment confound 
our general understanding of pre-stroke cognition.  Such problems may however 
be partially alleviated by generating a greater understanding of how well 
cognition assessment tools operate within stroke (both independently and in 
relation to competing tools), thus providing guidance for optimal pre-stroke 
cognitive assessment and reducing unnecessary heterogeneity.  This will be the 
focus of chapter 3.    
 
2.2 Pre-stroke depression 
2.2.1. Risk association and Prevalence  
Our understanding of pre-stroke depression is fundamentally limited in general 
terms.  The vast majority of research in the context of pre-stroke depression and 
its relation to post-stroke psychological conditions is in reference to a posited 
risk association with post-stroke depression. (59, 66-68)  While pre-stroke 
depression is frequently cited, and treated clinically, as a risk factor for post-
stroke depression, the evidence base for the association is inconsistent.  A 
number of studies have failed to find an association  (93-96) and systematic 
reviews that conclude in favour of an association cite evidence that falls short of 
overwhelming (e.g. Kutlubaev et al., (2014)(66) state 5/8 studies found a 
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significant association between pre-stroke depression and presence of post-
stroke depression). Little investigation has been conducted into the reasons why 
some studies find an association where others fail, and there are those who 
doubt that pre-stroke depression is a meaningful risk factor for post-stroke 
depression. (95)  Inadequate regression-model power and differences in 
covariate control or assessment method may be contributing factors to the 
inconsistency, but this requires to be formally investigated.  
  
Similarly, the prevalence of pre-stroke depression is not well described.  Only 1 
study to date has explicitly investigated the prevalence of pre-stroke depression.  
Reid et al., (2010)(97) report 10% of stroke patients are depressed within the 
preceding 6 months of the stroke.  However, a large range (e.g. <1%-52%) of pre-
stroke depression prevalence rates are reported across studies that investigate 
post-stroke depression. (98, 99) This stark variability in reported rates may in 
part reflect differing assessment methods employed.  Indeed, when utilising the 
same patient cohort, but adopting differing pre-stroke depression assessment 
methods, McCarthy et al., (2016)(100) and Wulsin et al., (2001)(98) reported 
considerably differing rates (13% vs 52%).  
   
The lack of an established pre-stroke depression prevalence rate is a missing 
component in our overall ability to comprehend the natural history of post-
stroke depression.  Furthermore, prevalence of pre-stroke depression may 
provide insight regarding the predominant cause of most cases of post-stroke 
depression, as well as the reasons why post-stroke depression is so common (e.g. 
is the prevalence of depression after stroke so high because this population are 
also extremely prone to depression before their stroke?).  As such, this is an area 
that needs addressed.   
 
2.2.2. Methods of Assessing pre-stroke depression 
The specific methods employed for assessment of pre-stroke depression have not 
been thoroughly investigated. Depression assessment tools, such as the Centre 
for Epidemiological Studies Depression scale (CESD), Composite International 
Diagnostic Interview (CIDI), Structured Clinical Interview for Depression (SCID), 
and medical records can all be employed.  However, at present, we have limited 
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insight into what the favoured or optimal approach is, or the psychometric 
properties of the methods employed.  As discussed in section 2.1, inadequate 
guidance in choice and use of assessment typically leads to heterogeneity; and 
clinicians report that lack of knowledge and consensus of the best measures are 
barriers to adopting routine depression screening. (101) This lack of clarity is 
therefore a major gap in the pre-stroke depression literature and could 
ultimately interfere with adoption of future implementation of pre-stroke 
depression screening, should this be identified as beneficial.  Research into pre-
stroke depression assessment methods is therefore warranted.   
 
 
2.2.3 Summary and conclusion 
Pre-stroke depression is a poorly described condition. There are several 
fundamental points that are unestablished: 1) There appears to be a risk 
association with presence of post-stroke depression; however, detractors remain 
and clarification on this point is required.  2) The prevalence of the condition is 
unclear, and the range of reported rates is vast.  3) Both the typical and optimal 
means of assessing pre-stroke depression, along with their respective 
psychometric properties, have not been well described.   
 
An investigation of prevalence, risk association and assessment methods for pre-
stroke depression is therefore required in order to establish fundamental 
information in this area.  This will be the focus of chapters 4 and 5.  
 
 
2.3 Pre-stroke functional impairment/disability  
2.3.1 Prevalence and risk association 
Pre-stroke function is well recognised for its relevance to understanding post-
stroke functional outcomes and suitability for treatment.  It is already 
frequently assessed as part of a suitability assessment for aggressive post-stroke 
treatments, such as thrombolysis and thrombectomy and in gauging suitability 
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for stroke trials. (102, 103) In the context of psychology in stroke, the relevance 
of patient functioning becomes apparent when we consider that a diagnosis of 
dementia (pre or post-stroke) requires identification of functional impairment in 
addition to cognitive impairment.   
 
Pre-stroke functional impairment has been identified as a risk factor for post-
stroke dementia (37) and is reportedly present in 25-54% of stroke patients. (89, 
104) However, there have been a lack of systematic reviews on this topic and, 
similar to pre-stroke depression, there is limited research looking into the 
epidemiology of pre-stroke functional impairment in general.  Much of the 
research to date is based upon measuring pre-stroke function via the pre-stroke 
modified Rankin Scale (mRS), which, as is discussed in detail in section 2.3.2, 
may not be suited for this purpose.  It is therefore unclear how reliable these 
reported prevalence rates and risk associations are.  There is a need for more 
work in relation to fundamental epidemiological information with regards to pre-
stroke functional impairment.  
 
2.3.2 Methods of assessing pre-stroke function/disability 
The most commonly used functional assessment measure in stroke is the 
modified Rankin Scale.  The mRS adopts a 7-point hierarchical ordinal scale to 
measure functional independence.  It was historically designed to assess post-
stroke outcomes for local audit purposes and initially employed to aid 
descriptive analysis of the natural history of stroke and its putative 
treatments.(105)   It was never intended for use in research, or as a measure of 
pre-stroke functioning; yet it has frequently been employed in this way. (89)  
 
Despite its common use as a measure of pre-stroke disability, there has been 
very little clinometric or validation work regarding pre-stroke functional 
assessment.  This is problematic as the wording of the various levels of the 
scale, and the criteria used to distinguish one mRS grade from another, assume a 
previous stroke. Although there is guidance on pre-stroke mRS scoring in those 
with a previous stroke event (106, 107) there is no internationally accepted, 
consensus on how to use mRS as a pre-stroke measure in patients who have 
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never had a previous stroke. (106, 108)   This can cause issues in application 
when the scale is used to measure function before a stroke event.   
 
Work on the psychometric properties of the pre-stroke mRS to date are not 
overly encouraging.  Fearon et al., (2012)(89) reported that the tool has only 
moderate interobserver reliability—albeit this is similar to observed reliability 
when the mRS is used to measure post-stroke functioning.  Predictive validity is 
demonstrated via associations with mortality and length of hospital stay (109)—
though the extent to which this is driven by a differing process of care is 
unclear.  Concurrent validity is reportedly moderate, according to correlations 
with markers of comorbidity;(89) however, there are also concerning 
discrepancies between pre-stroke mRS scores and proportions living 
independently at home. (89)  Moreover, this latter validation work (89) was 
based on a relatively small sample size, and some (106) argue that the pre-
stroke mRS is not fit for purpose as a measure of pre-stroke functional 
assessment.  Further validation work controlling for differences in post-stroke 
care-pathway, in a larger, more generalisable population, is therefore required 
to better establish the mRS’ suitability in pre-stroke functional assessment.   
 
2.3.3 Summary and conclusions 
Pre-stroke function is another area in which fundamental epidemiological 
information is generally lacking. It has been associated with post-stroke 
dementia and available prevalence rates suggest it is present in one-quarter to 
one half of stroke patients.  Its relevance to dementia diagnosis as well as more 
general health outcomes and suitability for treatment is well recognised and it is 
already routinely assessed on this basis.  However, despite not being designed 
for assessment of pre-stroke function, the mRS is the predominant measure 
employed and it has not been well validated when used in a pre-stroke context.  
While establishing fundamental epidemiological information is important, there 
is a pressing need to evaluate the validity of the pre-stroke mRS, not just for our 
understanding of psychological issues in stroke, but for general healthcare use 
and research as well. Validating the pre-stroke mRS will therefore be the focus 
of chapter 6. 
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2.4 Pre-stroke frailty 
Frailty is a condition of emerging interest in clinical practice and research 
generally.  There is currently no accepted operational definition of frailty; 
however, the two predominant positions are the Fried ‘frailty phenotype’(110) 
and the Rockwood ‘accumulated deficits’ concepts of frailty. (111)  The Fried 
perspective views frailty as a unidimensional biological syndrome, characterised 
by physical symptoms including weight loss, exhaustion, slow mobility, limited 
physical activity and weakness.  The Rockwood perspective views frailty as a 
multidimensional construct and state of heightened risk; a by-product of the 
accumulation of age-related health conditions, culminating in a reduced 
physiological reserve.  Regardless of the definition adopted, there is a general 
consensus that frailty is a state of multisystem impairment and reduced 
resistance to stressors that ultimately leads to increased vulnerability to poor 
outcomes. (112)  In addition to a frail status, patients can be in a state of 
‘prefrailty’, defined as a state of heightened risk for becoming frail but not 
currently considered frail.   
 
2.4.1 Risk association and prevalence 
The presence of frailty has been associated with increased risk for onset of 
delirium upon hospital admission along with risk of dementia. (113)  Frailty 
prevalence within the older adult population is thought to be increasing and 
reported rates vary from 4-59% depending on population and definition. (114) In 
the context of stroke however, frailty is a largely overlooked concept.  As such, 
specific prevalence rates and risk associations with post-stroke cognition are 
unestablished.  Risk factors (e.g. hypertension, diabetes) for the onset of frailty 
overlap with those for stroke occurrence;(115) hence there is reason to suspect 
that the burden of frailty in stroke may be substantial.  
  
Furthermore, the Rockwood group propose that the accumulation of age-related 
medical conditions may lead to a state of physiological exhaustion and impaired 
repair mechanisms, thus limiting the body and brain’s ability to respond to, and 
minimise the damage of, further stressors. (116)  In this sense, it is possible that 
a heightened state of brain ‘vulnerability’ may induce more substantial cognitive 
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consequences for patients who are frail before the stroke than those 
experienced by non-frail patients.  While a number of important risk factors for 
post-stroke cognitive impairment have already been established, the prospect of 
a risk association between pre-stroke frailty and post-stroke cognition is yet to 
be investigated.   
 
Establishing the prevalence of frailty in stroke and investigating the possibility of 
a risk association with post-stroke cognition is therefore needed. 
 
2.4.2. Methods of assessing pre-stroke frailty 
Frailty assessment has become routine in general practitioner settings, (117) but 
has not yet been adopted routinely in stroke.  Frailty assessment varies 
depending upon the operational definition adopted.  In total, there are as many 
as 67 different frailty assessment tools available.(118)  The most commonly used 
assessment tools are the Physical Frailty Phenotype (PFP) assessment method 
and the Rockwood Frailty Index (FI). (110, 119) 
  
The PFP method measures 5 physical conditions (weakness, slow gait speed, 
exhaustion, involuntary weight loss, and sedentary behaviour), believed to be 
characteristic of frailty, via a series of tasks and questions.  Weakness is 
assessed via grip strength on a dynamometer; slow gait speed is determined via 
duration to walk 15 feet; exhaustion via the question: “how often in the last 
week did you feel that everything was an effort or that you could not get 
going?”; involuntary weight loss via the question: “have you lost more the 4kg 
(or half a stone) unintentionally over the past year?”; and sedentary behaviour 
via the question: “what is your level of physical activity”.  In the context of 
stroke, grip strength and walking speed may be challenging to measure in a busy 
acute setting or confounded by neurological issues.  Self/informant report 
versions of the PFP assessment are available that alleviate the need for the 
physical components of this frailty measure.  Adoption of self/informant-report 
measures may therefore be a more pragmatic means of measuring phenotypical 
frailty in stroke.  
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Validity of self-report PFP methods are comparable to those methods which 
incorporate the physical assessment and can actually outperform physical 
assessment of PFP assessment in both discriminative ability and predictive 
validity. (120)  However, such validation methods have only taken place in non-
stroke populations; hence it remains to be seen if the validity of such self-report 
tools translates to the stroke setting.  
  
The FI applies the accumulated deficits concept of frailty and establishes frailty 
on a continuous scale ranging from 0-100, based upon the number of 
preselected, age-related health conditions an individual has acquired over the 
life-time.  This assessment method has the advantage of using patient case-
history to establish frailty and can conceivably be formulised for any patient.  
Detractors point out that the process of establishing frailty via patient medical 
records can be time consuming, such that it is not feasible for use in routine 
clinical practice.  However, there is potential for an electronic Frailty Index that 
can be automatically generated for each patient upon admission and may help to 
overcome this limitation. (121)  
 
The FI demonstrates good predictive validity, as long as a minimum of 30 
conditions (meeting distinct requirements) are present.(122)  Moreover, this 
predictive validity is maintained regardless of the conditions selected in the 
index.  The number of, and selection of, conditions on a given index can vary, 
making this method of assessing frailty advantageous for utilisation given 
routinely collected clinical data.  However, just like the PFP approach, this 
method of assessing frailty has not been validated for use in a stroke population.   
 
There is a need therefore to validate predominant frailty assessment methods 
for use in the stroke population.   
 
2.4.3. Summary and conclusion 
Pre-stroke frailty is a largely overlooked concept in stroke: Fundamental 
questions related to prevalence and validity of assessment methods have not 
been answered.  In addition, there is a potentially important relationship 
between pre-stroke frailty and post-stroke cognition that has not been 
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investigated.  The prevalence of pre-stroke frailty, the validity of prominent 
assessment methods, and its risk association with post-stroke cognitive 
impairment will be explored in chapters 7 and 8.   
 
 
2.5. Overall conclusions and specific aims of this 
thesis 
Psychological consequences following stroke are common and undeniably 
important.  However, while our understanding of the psychological impact of 
stroke is developing, we cannot generate a comprehensive and robust 
understanding without greater knowledge of the pre-stroke state.  Fundamental 
questions related to prevalence and risk associations of both psychological and 
physical pre-stroke conditions remain to be answered. Accurate assessment of 
pre-stroke variables is a key component to the investigation of these areas.  
While assessment of the pre-stroke state often requires a limited retrospective 
approach, the basic issues with this method are amplified by lack of knowledge 
regarding optimal tool selection and use, contributing unnecessary heterogeneity 
to an already heterogeneous field.  Methods employed for the assessment of the 
pre-stroke state need validation; and better guidance for appropriate selection 
and application is required: If we do not know how to measure pre-stroke 
variables effectively, we cannot deduce the extent to which this influences post-
stroke psychology. 
 
The aims for this thesis will therefore be: 
1) To establish prevalence and risk associations of pre-stroke variables where 
they are lacking. 
2) To validate prominent assessment tools used to assess the pre-stroke state in 
the domains of cognition, depression, disability and frailty.   
3) To perform comparative analyses of tool performance so as to provide greater 
guidance as to the optimal tools available for assessment of pre-stroke 
conditions.   
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Chapter 3: Validation and comparison of informant 
questionnaires for assessment of pre-stroke 
cognitive impairment; a diagnostic test accuracy 
study. 
3.1 Introduction 
As discussed in chapter 2 section 2.1, the presence of pre-stroke cognitive 
impairment is relevant to post-stroke psychological dysfunction;(37) however, 
much of our understanding of pre-stroke cognition is based upon use of 
informant questionnaires that have not been validated for premorbid assessment 
in stroke.(76)  Moreover, there is little guidance regarding optimal tool selection 
and use when informant tools are utilised in a pre-stroke context; this can be a 
source of unnecessary heterogeneity in the field and makes it difficult for 
clinicians to employ the best assessments for their practice. 
   
The IQCODE is the most commonly used informant tool in stroke. (76) The 
IQCODE-SF is a 16-item version of the IQCODE. Recent reviews (77, 123) have 
demonstrated that the IQCODE-SF has similar diagnostic test accuracy to the 32-
item version; hence the IQCODE-SF is often preferred in the acute stroke unit, 
where time for assessment is limited.  
  
Alternative tools, such as the AD8, exist which have favourable properties over 
the IQCODE-SF.  Specifically, the AD8 is shorter and easier to score than the 
IQCODE-SF.  There is also evidence that it may be more sensitive to detecting 
both dementia and non-dementia level cognitive impairment—though the 
IQCODE-SF may be more specific. (77, 82, 83, 124)  To date, the comparative 
diagnostic test accuracy of these tools has not been examined in stroke. 
   
I therefore sought to validate and compare the diagnostic test accuracy of the 
IQCODE-SF and AD8 when used to detect pre-stroke cognitive impairment in an 
acute stroke population.   
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3.1.1 Hypotheses 
My primary hypothesis was that both informant tools would be valid tools for 
assessing pre-stroke cognitive impairment; overall diagnostic test accuracy 
performance would be significantly above chance level. 
 
My secondary hypothesis was that the pattern of sensitivity and specificity would 
vary between the tools.   
 
 
3.2 Method 
I followed STARDdem (Standards for Reporting of Diagnostic Accuracy studies in 
Dementia) guidelines for conduct and reporting in this study. (125) 
 
3.2.1 Study design 
This is sub-study of the ‘APPLE’ (Assessing Psychological Problems: a 
Longitudinal Evaluation) project.  APPLE is a longitudinal study designed to 
assess cognition and mood over time in a stroke population.  The protocol for 
APPLE can be seen in Appendix 1.   
 
3.2.2 Setting 
Patients admitted consecutively to the acute stroke unit of 7 participating 
hospitals across Scotland were approached to take part between 1st November 
2016 and 1st December 2018.  Participating hospitals were the Glasgow Royal 
Infirmary; Queen Elizabeth University Hospital; Queen Victoria Hospital (Fife); 
University Hospital Monklands; University Hospital Hairmyres; Aberdeen Royal 
Infirmary; Royal Alexandra Hospital.    No restrictions were operated on age, 
time-frame since stroke, prior stroke, stroke-type, stroke-severity or 
comorbidity. All participating sites offered hyper-acute stroke services and 
admitted all patients with suspected stroke to specialist services. 
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3.2.3 Population 
Participation required an eligible informant also willing to take part.  Informants 
had to have known the patient for at least 10 years and see the patient on a 
regular basis (twice per week).  Patients unable to consent to participation (e.g. 
due to severe aphasia or cognitive impairment) were still included if a proxy was 
willing to provide assent consent.  Participants were however excluded if they 
were palliative, or if their informant was unable to speak fluent English.   
Participants were also excluded from analysis if their informant did not 
complete the informant questionnaires or if a gold standard diagnosis could not 
be derived.   
 
3.2.4 Informant tool assessment 
Each participant’s informant was asked to complete the IQCODE-SF (16-item) 
and AD8, which were administered in alternating order from patient to patient 
by the on-site stroke research network nurses, trained in administration of the 
questionnaire.   
 
The IQCODE-SF is a 16-item questionnaire that asks an informant questions 
regarding how their friend/relative’s cognition has changed over the past 10 
years.  It operates on a 5-point ordinal scale and generates a score ranging from 
1 (much improved) to 5 (much worse); scores closer to 5 suggest greater 
cognitive impairment. (see Appendix 2)   
 
The AD8 is an 8-item questionnaire that operates on a binary scale (yes, a 
change/no change; along with a third unscored option of ‘don’t know’) and asks 
the informant to indicate if a change has occurred in their friend/relative’s 
cognition over the past ‘several years’.  Scores closer to 8 suggest greater 
cognitive impairment.  (see Appendix 3) 
 
Informant participants were asked to complete the questionnaires in relation to 
how the patient’s cognition was just before their most recent stroke occurrence.  
Questionnaires were required to be completed within 1 month of patient 
hospital admission; however, this requirement was relaxed towards the end of 
  56 
 
the study to assist participant recruitment.   Questionnaires could be completed 
in the presence of the consenting researcher while the patient was still in 
hospital, or, if necessary, alone following patient discharge and returned via 
post.     
 
3.2.5 Gold standard assessment 
Dementia and mild cognitive impairment (MCI) were diagnosed according to DSM-
IV criteria.(28) 
 
Assessment of pre-stroke cognitive impairment was determined via a 
multicomponent assessment, and discussion between a researcher (MT) and 
stroke consultant (TQ). (See Figure 3-1)  
 
Figure 3-1. Gold Standard assessment process 
 
Following hospital admission for stroke, an initial examination of patient medical 
records was conducted to determine if patients had a formal diagnosis of 
dementia or were on cholinesterase inhibitor drugs before their presenting 
stroke occurred.  If no prior diagnosis or drug use was present, a clinical 
interview, utilising the Clinical Dementia Rating scale (CDR), with the patient 
and/or the informant was conducted by a researcher (MT) with experience in 
dementia/MCI diagnosis and blinded to results of the informant questionnaires.  
The CDR is a structured interview that assesses patients for impairment across 6 
domains (memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care).  Scores on each domain are 
synthesized to establish a global CDR score.  Interviews were conducted either 
face-to-face or via telephone where necessary. A CDR rating of 0 was defined as 
 
 
 
 
 
 
 
 
 
 
 
Initial search of patient 
medical records for prior 
diagnosis of pre-stroke 
dementia or 
cholinesterase inhibitor 
drugs 
Clinical interview 
conducted, utilising the 
CDR, with patient 
and/or informant to 
determine pre-stroke 
cognitive impairment 
Consensus diagnosis 
established via consultation 
between CDR interviewer and 
Stroke Consultant.  Where 
necessary, results of post-stroke 
cognitive assessment, review of 
patient case-notes and 
neuroimaging results were used 
to inform pre-stroke diagnosis 
Figure 3-1: Gold standard assessment process 
Completed within 1 month following patient hospital admission 
for Stroke/TIA 
1 2 3 
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‘no pre-stroke cognitive impairment’; 0.5 defined as ‘pre-stroke MCI present’; a 
rating of 1-3 defined as ‘pre-stroke dementia present’.  Assessment was 
supplemented by a baseline and 1 month post-stroke cognitive assessment with 
the patient (conducted face-to-face only).  This supplementary assessment 
involved the Abbreviated Mental Test-10 (AMT10)(126) (see Appendix 4 ), a mini-
Montreal Cognitive Assessment (mini-MoCA)(127) (see Appendix 4), the Oxford 
Cognitive Screen (OCS)(128), a delirium assessment using the ‘Confusion 
assessment method for the Intensive Care Unit’ (CAM-ICU)(129), and examination 
of case-notes and neuroimaging results where possible (case-note access was 
only available for review by the researcher (MT) and stroke consultant (TQ) at 
the Glasgow Royal Infirmary, Queen Elizabeth University Hospital and Royal 
Alexandra Hospital).  The AMT-10 is a 10-item brief cognitive assessment; it is 
scored out of 10 and scores of <8 suggest cognitive impairment is present. The 
mini-MoCA is a brief cognitive assessment and shortened version of the MoCA; it 
generates a score out of 12, with scores <10 suggesting cognitive impairment is 
present.  The OCS is brief neuropsychological cognitive assessment battery that 
was designed to screen for cognitive impairment following stroke; it assesses 
numerous domains including memory, attention, language and praxis.  The CAM-
ICU is a brief delirium screening tool.  Presence of delirium is defined based on 
an acute change in mental status, plus inattention, and either altered level of 
consciousness or disorder thinking.   
 
Based on this information, a consensus diagnosis was reached via discussion 
between the interviewing researcher (MT) and a stroke consultant (TQ).  If both 
the patient and/or informant were unavailable for clinical interview and access 
to patient medical/case-notes was unavailable, a gold standard diagnosis could 
not be established for the participant.  
 
3.2.6 Clinical and demographic data 
Patient level data was collected via a combination of medical records or patient 
self-report.  Pre-stroke depression (major/minor depressive episode) and anxiety 
disorder (generalised anxiety disorder; panic disorder; 
agoraphobia/claustrophobia; social anxiety; specific phobia) was assessed via 
clinical interview with the patient and/or their informant, by an assessor (MT) 
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trained in using the ‘Structured Clinical Interview for Depression’ version 5 
(SCID-5).  All diagnoses of pre-stroke depressive/anxiety disorders were made in 
accordance with DSM-5 criteria. (30)  The SCID was conducted at the same time-
point as the CDR interview.  Time-frame for mood and anxiety disorder covered 
was the 6 months before the stroke.  The rationale behind this time-frame for 
assessment is outlined in chapter 5, section 5.2.  Stroke severity was assessed 
via the National Institute of Health Stroke Scale (NIHSS),(130) using 
retrospective chart review.(131)  Pre-stroke disability was assessed via the pre-
stroke modified Rankin Scale (pre-stroke mRS).   
 
 
3.2.7 Statistical analysis 
3.2.7.1 Demographic comparison 
I compared clinical and demographic data for patients recruited at the Glasgow 
Royal Infirmary who were included in the analysis of this sub-study against 
patients recruited at the Glasgow Royal Infirmary who were excluded from 
analysis (due to lack of informant).  Group differences were compared for age, 
sex, pre-stroke mRS (dichotomised as disabled (⩾2) vs non-disabled), stroke-type 
(dichotomised as lacunar vs non-lacunar), pre-stroke depression, number of 
medications, post-stroke aphasia, post-stroke delirium, stroke severity (NIHSS), 
diabetes and atrial fibrillation.   Differences between the two groups were 
examined using one-way Analysis of Variance (ANOVA) for linear variables and 
Chi square for categorical variables.    
 
3.2.7.2 Diagnostic test accuracy of Informant assessment 
MedCalc version 18.11 was used for all analyses.  
  
Performance of informant tools were assessed against the gold-standard 
diagnosis.  I investigated the tools’ overall diagnostic accuracy, for both 
‘dementia vs non-dementia’ and ‘any cognitive impairment vs no cognitive 
impairment’, via area under empirical ROC (AUROC) curves using the Delong et 
al., (1988) (132) method.   
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The most commonly applied published cut-point for the IQCODE in stroke is >3.4; 
(76) the AD8 is not frequently used in stroke but has a recommended published 
(and most commonly utilised) cut-point of ≥2. (124)  I constructed the tools’ 
diagnostic properties at these cut-points using 2x2 tables.  McNemar’s test was 
used to statistically compare sensitivity and specificity values when the number 
of observations was >20.  
  
In addition, I determined if the apparent optimal cut-points for each tool 
matched the recommended published cut-points based on the point on empirical 
ROC curve nearest the top left-hand corner of the ROC graph. (81)   
When data was missing from the informant questionnaire, the assessment was 
ruled invalid when >2 questions were not answered.  If ≤2 questions were 
missing, I applied the average score to the 2 missing questions for the IQCODE, 
while missing AD8 responses were scored as ‘No’ responses.  AD8 ‘don’t know’ 
responses were also treated as ‘no’ responses for scoring purposes.  
 
A series of sensitivity analyses were conducted for all ‘any cognitive impairment 
vs no cognitive impairment’ analyses.  I removed patients who were unable to 
complete a CDR interview and did not already have a formal diagnosis of 
dementia.  I also examined if tool properties differed based on order of 
administration; removed cases in which the time-frame for informant assessment 
and/or CDR assessment was >31 days, and assessed if scoring missing/’don’t 
know’ responses on the AD8 as ‘yes’ responses altered the results.   
 
3.3 Results 
3.3.1 Diagnostic test accuracy of informant assessment 
A total of 346 patients admitted to the Glasgow Royal Infirmary were considered 
for participation in the APPLE study. One hundred and fifty-one patients from 
the Glasgow Royal Infirmary agreed to participate in APPLE.  Total numbers 
approached from all sites were not available; however, 301 patients across all 
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sites agreed to take part in the APPLE study (including the 151 recruited via the 
Glasgow Royal Infirmary).  Two-hundred and five were excluded from analysis in 
this sub-study due to lack of an informant or gold standard assessment data, 
leaving a total of 95 patients with informants for analysis of IQCODE-SF and AD8 
diagnostic test accuracy.  Figure 3-2 outlines the recruitment process.  Numbers 
for stage 1, 2 and 3 reflect recruitment at the Glasgow Royal Infirmary only; 
stage 4 reflects the total number of patients available for analysis following 
addition of recruited numbers from all other participating sites.  
 
Clinical and demographic comparisons between those included in analysis vs 
those excluded from analysis (restricted to Glasgow Royal Infirmary only) suggest 
the two groups differed by stroke-type (X2=10.318, p=0.001); specifically, 
excluded patients had a higher proportion of lacunar strokes [22] as compared to 
non-lacunar strokes [57] than those included (57 non-lacunar; 4 lacunar).  There 
were no other differences in tested variables (all p>0.05).   
 
Figure 3-2. Flow diagram of recruitment process (numbers in stages 1, 2 & 3 
restricted to Glasgow Royal Infirmary only) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Acute stroke ward patient at 
Glasgow Royal Infirmary screened 
for participation in APPLE (346) 
Acute stroke ward patient agrees to 
participate in APPLE (151/346) 
Patient ruled out of participating in 
APPLE (195) 
Refused (85); uncertain/non-stroke 
diagnosis (60); inappropriate/too 
unwell (44); No English (3); Left 
hospital before approached (3) Patient has informant who agrees 
to participate in APPLE (69/151) 
Patient has no informant and is 
excluded from analysis in this study 
(82) 
Patients with informant and 
established gold standard diagnosis 
added from other participating 
sites (26/150*; final total=95/301) 
*Patients excluded due to lack of 
informant or unable to derive gold 
standard diagnosis.   
1 
2 
3 
4 
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Six of the recruited patient participants who had no formal pre-stroke dementia 
diagnosis were evaluated for pre-stroke cognitive impairment via baseline post-
stroke cognitive assessment results and case-note review data only.  All other 
patient participants either had a formal diagnosis of pre-stroke dementia 
present in medical records or pre-stroke cognitive impairment diagnosis was 
established involving the CDR interview.  All patient participants had AD8 data 
available (2 contained missing data but could still be utilised) and 94/95 (99%) 
had IQCODE-SF data available (1 contained substantial (>2 unanswered 
questions) missing data and was removed from analysis).  Median time for 
completion of informant assessment following admission was 5 days (range=2-
284); median time for completion of CDR assessment following admission was 7 
days (range=2-284).   Thirty out of 95 (31.5%) patients were cognitively impaired 
before their stroke according to gold-standard diagnosis (13 dementia; 18 MCI); 
6/13 (46.1%) patients had a formal diagnosis of pre-stroke dementia. Population 
descriptive statistics can be seen in Table 3-1.   
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Table 3-1: Population descriptive statistics 
 
Variable Overall* 
Age (Median; 25th-75th 
percentile) 
73 (61-80) 
Sex Male (%) 48/88 (54.5%) 
Stroke-type (%)  
Total Anterior Circulation Stroke  7/82 (8.5%) 
Partial Anterior Circulation 
Stroke  
26/82 (31.7%) 
Lacunar Stroke  9/82 (11.0%) 
Posterior Circulation Stroke  22/82 (26.8%) 
Trans Ischaemic Attack  18/82 (21.9%) 
NIHSS (Median; IQR) 1 (0-4) 
Pre-stroke modified Rankin 
Scale (nn; %) 
 
0 33/85 (38.8%) 
1 14/85 (16.5%) 
2 14/85 (16.5%) 
3 19/85 (22.4%) 
4 5/85 (5.9%) 
Pre-stroke depressive disorder 
(nn; %) 
21/95 (22.1%) 
Pre-stroke anxiety disorder 
(nn; %) 
6/95 (6.3%) 
Post-stroke Delirium 2/95 (2.1%) 
Post-stroke Aphasia (nn; %) 5/88 (5.7%) 
Previous stroke 26/85 (30.6%) 
Diabetes 16/80 (20.0%) 
Atrial Fibrillation 14/82 (17.1%) 
Medication count (Median; IQR) 7 (5-10) 
*Data presented where available; reduced denominator reflects missing values 
for that category.   
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3.3.2 Diagnostic test accuracy data for IQCODE-SF and 
AD8 
3.3.2.1 Any cognitive impairment vs no cognitive impairment 
AUROC curves were 0.85 (95%CI=0.76-0.91), p<0.01, for IQCODE-SF and 0.82 
(95%CI= 0.73-0.89), p<0.01, for AD8.  
  
Sensitivity and specificity values for the IQCODE-SF for any cognitive impairment 
at cut-point >3.4 were 62.1% (95%CI=42.3%-79.3%) and 87.7% (95%CI=77.2%-
94.5%) respectively. For AD8 at cut-point ≥2, sensitivity was 86.7% (95%CI=69.3%-
96.2%) and specificity 70.8% (95%CI=58.2%-81.4%).   McNemar’s test suggested 
the AD8 was significantly more sensitive to detecting any cognitive impairment 
than the IQCODE-SF (difference: 24.1%, 95%CI=5.9%-42.4%; p=0.04).  Specificity 
of the IQCODE-SF was significantly greater than the AD8 (difference: 16.7%, 
95%CI=6.7%-26.6%; p<0.01). 
 
The optimal cut-point based on ROC curve analysis for IQCODE-SF was >3.06, 
giving sensitivity and specificity values of 93.1% (95%CI=77.2%-99.2%) and 63.1% 
(95%CI=50.2%-74.7%), and ≥2 for AD8 (sensitivity and specificity values same as 
published recommended cut-point, described above). (See Figure 3-3)  
 
Additional diagnostic properties, including positive predictive values, negative 
predictive values and likelihood ratios for both informant tools can be seen in 
Table 3-2. 
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Table 3-2: Diagnostic Test Accuracy Properties of the IQCODE -SF and AD8 for 
differentiating any cognitive impairment from cognitively normal 
 
 AD8  IQCODE-SF 
Positive 
likelihood ratio 
2.96 (95%CI=1.98 
to 4.44) 
5.04 95%CI=2.48 to 
10.24) 
 
Negative 
likelihood ratio 
0.19 (95%CI=0.07 
to 0.48) 
0.43 (95%CI=0.27 
to 0.70) 
 
Positive 
Predictive Value 
57.8% 
(95%CI=47.76% to 
67.20%) 
69.2% 
(95%CI=52.56% to 
82.05%) 
Negative 
Predictive Value 
92.0% 
(95%CI=82.01% to 
96.67%) 
83.8% 
(95%CI=76.33% to 
89.28%) 
 
Prevalence (pre-
stroke cognitive 
impairment) 
31.6% 
(95%CI=22.4% to 
41.9%) 
 
30.9% 
(95%CI=21.7% to 
41.2%) 
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3.3.2.2 Dementia vs no dementia 
AUROC for IQCODE-SF was 0.91 (95%CI=0.84-0.96), p<0.01 and 0.85 (95%CI=0.77-
0.92), p<0.01 for AD8.   
 
Sensitivity and specificity values for the IQCODE-SF for dementia vs no dementia 
at cut-point >3.4 were 91.7% (95%CI=61.5%-99.8%) and 81.7% (95%CI=71.6%-
89.4%); AD8 at cut-point ≥2 had sensitivity 92.3% (95%CI=64.0%-99.8%) and 59.8% 
(95%CI=48.3%-70.4%) specificity.  There were only 12 (following removal of 1 
IQCODE-SF with substantial missing data) cases of dementia available for analysis 
of comparative sensitivity, hence formal statistical analysis via McNemar’s test 
was not appropriate.  Eighty-two observations were available for formal 
statistical comparison of specificity.  McNemar’s test suggested IQCODE-SF had 
significantly greater specificity than AD8 (Difference: 20.7%, 95% CI=11.3%-
30.1%; p<0.01).  
 
Optimal cut points suggested by ROC curve analysis were >3.4 for IQCODE-SF 
(sensitivity and specificity values same as at recommended published cut-point 
described above) and >3 for AD8 (sensitivity 92.3%, 95%CI=64.0%-99.8%; 
specificity 80.5%, 95%CI=70.3%-88.4%).  (Figure 3-4) 
 
Additional diagnostic properties for both informant tools can be seen in Table 3-
3. 
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Table 3-3. Diagnostic Test Accuracy Properties of the IQCODE-SF and AD8 for 
differentiating dementia from no-dementia 
 
 AD8  IQCODE-SF 
Positive 
likelihood ratio 
2.29 (95%CI=1.69 
to 3.12) 
5.01 (95%CI=3.08 
to 8.17) 
Negative 
likelihood ratio 
0.13 (95%CI=0.02 
to 0.85) 
0.10 (95%CI=0.02 
to 0.67) 
Positive 
Predictive Value 
26.7% 
(95%CI=21.1% to 
33.1%) 
42.3% 
(95%CI=31.0% to 
54.4%) 
Negative 
Predictive Value 
98.0% 
(95%CI=88.1% to 
99.7%) 
 
98.5% 
(95%CI=91.1% to 
99.8%) 
Prevalence (pre-
stroke dementia) 
13.7% (95%CI=7.5% 
to 22.3%) 
12.8% (95%CI=6.8% 
to 21.2%) 
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IQCODE: Point 
nearest top left-
hand corner 
(circled): >3.06 
AD8: Point nearest 
top left-hand 
corner (circled): >1 
IQCODE: Point 
nearest top left-
hand corner 
(circled): >3.4 
AD8: Point nearest 
top left-hand 
corner (circled): >3 
Figure 3-3. ROC curves and optimal cut-points for IQCODE and AD8 when 
discriminating between any pre-stroke cognitive impairment vs no pre-stroke 
cognitive impairment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. ROC curves and optimal cut-points for IQCODE and AD8 when 
discriminating between pre-stroke dementia vs no pre-stroke dementia 
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3.3.3 Sensitivity analysis 
Removal of 6 cases in which the gold standard diagnosis was determined without 
CDR interview left 27 cases of pre-stroke cognitive impairment and 62 non-
cognitively impaired patients for analysis.  Reanalysis without these cases did 
not significantly alter the relationship between the tools’ specificity. AD8 
specificity= 72.6% (95%CI=59.8%-83.1%); IQCODE-SF specificity= 90.3% 
(95%CI=80.1%-96.4%)  (size difference=12.9%, 95%CI=3.4%-22.4%; p=0.02); 
however, the difference in sensitivity was no longer statistically significant; AD8 
sensitivity= 85.2% (95%CI=66.3%-95.8%), IQCODE-SF sensitivity= 61.5% 
(95%CI=40.6%-79.8%);  size difference=23.1% (95%CI=3.7%-42.5%); p=0.07). 
AUROC curves for both tools were largely unaltered: AD8 AUROC=0.82 
(95%CI=0.72-0.89), p<0.01; IQCODE-SF AUROC= 0.84 (95%CI=0.74-0.91), p<0.01. 
   
The IQCODE-SF was completed first for 49/95 patients (16 cases of pre-stroke 
cognitive impairment); the AD8 completed first for 46/95 patients (14 cases of 
pre-stroke cognitive impairment).  Comparison of assessment administration 
order did not alter the pattern of the differing sensitivity and specificity values 
of the IQCODE-SF and AD8. When completed first, IQCODE-SF sensitivity at cut-
point>3.4 was 66.67% (95%CI=38.4%-88.2%), specificity was 94.1% (95%CI= 80.3%-
99.3%), AUROC=0.87 (95%CI=0.75-0.95); AD8 sensitivity at cut-point ≥2 when 
completed second was 85.7% (95%CI=57.2%-98.2%), specificity was 74.3% (95%CI= 
56.7%-87.5%), AUROC=0.82 (95%CI=0.68-0.91), p<0.01 .  AD8 sensitivity when 
completed first was 90.9% (95%CI=58.7%-99.8%), specificity was 72.4% 
(95%CI=52.8%-87.3%), AUROC=0.83 (95%CI=0.69-0.92),p<0.01; IQCODE-SF 
sensitivity when measured second was 54.6% (95%CI=23.4% to 83.3%), specificity 
was 79.3% (95%CI=60.3%-92.0%), AUROC=0.82 (95%CI=0.67-0.91), p<0.01.   
 
I also removed 13 cases in which the informant questionnaires and/or the gold 
standard clinical interview assessment took place >31 days following hospital 
admission.  The pattern of sensitivity and specificity differences for both tools at 
recommended published cut-points remained the same. From a total of 82 AD8 
cases and 81 IQCODE-SF (24 pre-stroke cognitive impairment), AD8 sensitivity 
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was 88.0% (95%CI=68.8%-97.5%), specificity was 71.2% (95%CI=57.9%-82.2%); 
IQCODE-SF sensitivity was 70.8% (95%CI=48.9%-87.4%), specificity was 91.5% 
(95%CI=81.3%-97.2%).  McNemar’s test suggested the difference in sensitivity was 
no longer significant after removal of these cases (difference=16.0%, 95%CI=-
2.2%-34.2%; p=0.22); difference in specificity remained statistically significant 
(difference: 20.7%, 95%CI=10.3%-31.1%; p<0.01)  AUROC values remained largely 
unchanged (AD8 AUROC: 0.83, 95%CI=0.73-0.90, p<0.01; IQCODE-SF AUROC: 
0.87, 95%CI=0.78-0.94, p<0.01).  
 
Finally, analysis was rerun with ‘unknown’ or missing responses for the AD8 
scored as ‘yes’; sensitivity (86.7%, 95%CI=69.3-96.2) and specificity (69.2%; 
95%CI=56.6%-80.1%) values at recommended cut-points did not change; AUROC 
was also unchanged (0.82, 95%CI= 0.73-0.89; p<0.01). 
 
 
3.4 Discussion 
3.4.1 Diagnostic test accuracy of Informant assessment 
My data suggests that both the AD8 and IQCODE-SF are valid tools for pre-stroke 
cognition screening in the acute stroke setting.  Both tools performed 
significantly above chance level for discriminating between cognitively impaired 
and non-cognitively impaired patients and also between dementia and no-
dementia; both tools demonstrated good (>0.8) overall discriminability for both 
patient groups.  This is reassuring as employment of informant tools is a common 
approach for pre-stroke cognition assessment in both stroke research and clinical 
practice. (76) 
 
The IQCODE-SF and AD8 have typically applied published cut-points of ≥3.4 and 
≥2 respectively.  Previous research (82) has suggested that the AD8 may be more 
sensitive to detection of dementia and mild cognitive impairment than the 
IQCODE at these cut-points.   
 
I similarly found that the AD8 was significantly more sensitive to cognitive 
impairment than the IQCODE-SF at their most commonly applied cut-point, but I 
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found no evidence that it was more sensitive to dementia.  This is not surprising 
as my ‘cognitively impaired’ group was predominantly made up of patients with 
MCI.  The AD8 was originally designed to detect very mild dementia—equating to 
a CDR score of 0.5, which is also frequently applied to patients demonstrating 
MCI;(133) its recommended cut-point reflects that intent. The IQCODE on the 
other hand was developed to detect dementia-level cognitive impairment, with 
no explicit predisposition towards the milder end of the cognitive impairment 
spectrum.  This may explain the observed discrepancy regarding the two tools’ 
respective differences in sensitivity to dementia vs any cognitive impairment at 
recommended published cut-points.  
 
These findings are consistent with the IQCODE’s tendency to correlate with brief 
screening tests (which are also often insensitive to milder forms of cognitive 
impairment) over in-depth neuropsychological assessments (which tend to be 
more sensitive to mild cognitive impairment). (79) Typical utilisation of the 
IQCODE-SF at published cut-points in the stroke setting may therefore result in 
significant numbers of non-dementia level cognitively impaired patients passing 
unrecognised.  On the other hand, the IQCODE-SF was significantly more specific 
than the AD8 to both any cognitive impairment and dementia; hence typical 
utilisation of the IQCODE-SF should produce fewer false positives.    
  
While differences in sensitivity and specificity of the two tools are apparent at 
recommended cut-points, I would note that the overall (AUROC) diagnostic 
accuracy of the tools were comparable. This is consistent with previous 
research, which has reported similar AUROC values for the AD8 and IQCODE-SF. 
(82)  These comparable AUROC values suggest that the observed differences in 
sensitivity and specificity could be balanced out via application of alternative 
cut-points.  In this study, a cut-point of >3.06 appears optimal should the 
IQCODE-SF be utilised for assessing cognitive impairment in populations with 
high numbers of non-dementia level cognitive impairment; while the AD8 may 
perform better at a cut-point of ≥4 if the objective is to identify dementia only.  
However, while it is conceivable that alterations to cut-points may be beneficial  
when a tool is employed in a different population and context,(90) I would 
highlight that ostensible optimal cut-points often vary from study to study (123, 
124) and variability in cut-point application is a source of the heterogeneity 
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commonly observed in stroke-cognition research. (76)  Further work is therefore 
required in order to determine if there are alternative optimal cut-points for use 
of the IQCODE-SF and AD8 in stroke.  For the time-being, I would suggest that 
clinicians and researchers do not diverge from the most commonly applied 
published cut-points, until more concrete recommendations can be made.   
  
3.4.2 Clinical recommendations 
The IQCODE-SF and AD8 appear to have contrasting properties when used at 
their recommended published cut-points.  The IQCODE-SF is currently the 
preferred informant tool for assessing cognition in stroke (76) and is the more 
specific of the two tools; however, it is debatable whether sensitivity or 
specificity should be prioritised in cognitive screening.  Early detection of 
cognitive impairment has been associated with improved quality of life and 
reduced need for care-home admission. (134)  On the other hand, misdiagnosis 
can be highly distressing and must also be acknowledged.  
 
While both the IQCODE-SF and AD8 may be able to achieve a high degree of 
sensitivity or specificity (depending on the cut-point applied), the AD8 is both 
shorter and easier to score—these are highly advantageous properties in a busy 
acute setting.  The data does not allow for a definitive recommendation of one 
tool over the other; however, it is possible that AD8 may be more be more 
optimally suited for use in stroke than the more commonly used IQCODE-SF.  
This possibility requires further validation.     
 
3.4.3 Strengths and limitations 
I have conducted a highly inclusive study that is not limited by the strict 
exclusionary criteria that are typically applied in stroke research.  I have 
followed best practice guidelines for conducting diagnostic test accuracy 
research and present results that have ‘real world’ clinical value. However, 
there are some important limitations that should be considered. 
 
The sample size is small, and the majority of participants are from a single site; 
hence, these findings may not generalise to the wider stroke population.  While 
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my comparison of clinical and demographic data for included vs excluded APPLE 
patients was reassuring (only differing by stroke-type), larger studies are needed 
to confirm our observations regarding informant tool diagnostic test accuracy 
performance in stroke. 
 
The confidence intervals regarding the size of sensitivity difference between 
IQCODE-SF and AD8 for detecting any cognitive impairment when used at 
traditional cut-points are wide; it is possible that the difference between the 
two tools is as minor as 6%, which may not be clinically meaningful.   
 
The gold standard assessment is imperfect and complicated by the retrospective 
nature of the assessment, as well as potentially confounded by cognitive 
complications of the stroke.  Moreover, not all patients had a complete gold 
standard assessment as they were lacking a clinical interview and some patients 
were assessed longer than 1 month following stroke.  My resultant sensitivity 
analyses altered the statistical significance level in the comparisons of 
sensitivity such that the observed difference was no longer significant at the 
traditional level of p<0.05.  However, this could be a consequence of the 
reduced statistical power, and the general pattern of higher sensitivity of the 
AD8 compared to the IQCODE-SF remained.   
 
Finally, while blinding to questionnaires was enforced to minimise bias, the 
informant participated in the gold-standard assessment via CDR interview.  As 
such, it is uncertain to what extent informant answers to CDR interview 
questions may have been biased by prior completion of the questionnaire or 
vice-versa.   
 
3.5 Conclusions 
The IQCODE-SF and AD8 are both valid measures of pre-stroke cognitive 
impairment in the acute stroke setting. However, the AD8’s shorter duration, 
ease of scoring, and possible heightened sensitivity to non-dementia level 
cognitive impairment at the recommended published cut-point may make it 
more suited to the busy acute stroke unit than the IQCODE-SF.  Further work is 
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required to confirm these observations as well as to determine if alternate cut-
points exist for optimal utilisation of these tools in acute stroke.   
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Chapter 4. Pre-stroke depression: a systematic 
review and meta-analysis of prevalence and risk 
association with post-stroke depression. 
 
4.1 Introduction 
As discussed in chapter 2, section 2.2, in order to better understand the natural 
history and mechanistic development of post-stroke depression, it is important 
to have an understanding of pre-stroke depressive problems.  However, 
prevalence rates of pre-stroke depression are not well established, and the 
reported risk association is inconsistent.  We currently have little insight as to 
the reasons for this inconsistency. 
 
In a literature that is seemingly disparate with potentially biased papers, a 
comprehensive review, critical appraisal and synthesis can aid our understanding 
of the topic.  The primary aim of this review was to summarise the prevalence of 
pre-stroke depression reported across the literature.  The secondary aim was to 
summarise the association between pre-stroke depression and post-stroke 
depression.   
 
4.2 Method 
A systematic review of the literature based upon a pre-registered protocol 
(PROSPERO identifier: CRD42017065544) was conducted. All aspects of planning, 
conduct and reporting were guided by the Meta-analysis Of Observational Studies 
in Epidemiology (MOOSE) consensus statement. (135) All aspects of title 
searching, data extraction and risk of bias assessment were performed by two 
independent researchers trained in systematic review (MT, OM).  Decisions were 
made by consensus with recourse to a third arbitrator as necessary (TQ).    
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4.2.1 Search Strategy 
Initial scoping of the literature suggested that pre-stroke depression was rarely 
the primary focus of original research and was more often described as a co-
variate in studies that investigate post-stroke mood disorder.  Thus, my search 
strategy adopted two complementary approaches to the literature.  A specific 
search with a focus on pre-stroke depression was performed (search A) as well as 
a more sensitive search with a focus on post-stroke depression, to identify 
papers from which data on pre-stroke depression could be obtained (search B; 
see Appendix 7). 
 
As the emphasis was on published, peer-reviewed journals, I did not search grey-
literature beyond the scope of the included search engines and hand searches.  
There were no restrictions placed on the basis of language; however foreign-
language studies were only included if they could be translated into English.  
 
Search A: A search syntax incorporating commonly used terms to describe pre-
stroke depression (see Appendix 5) was created and multidisciplinary databases 
across a variety of platforms were searched: Medline (OVID), Embase (OVID), 
PsychInfo (EBSCO), Web of Science (Thomson Reuters), Cinahl (EBSCO) from 
inception to July 2017.  This was supplemented by hand searches of references 
of identified papers and relevant reviews.   
  
Search B: For the review of post-stroke depression, I used a search strategy that 
had informed a recently published systematic review on the topic. (59)  Studies 
and relevant reviews identified via the search were hand searched for additional 
studies. I then screened the studies reporting prevalence of pre-stroke 
depression.   
 
4.2.2 Inclusion/Exclusion criteria 
Study designs: Observational studies, published in peer reviewed journals, that 
had a focus on mood, and that reported pre-stroke depression prevalence were 
included. The focus was on studies assessing pre-stroke depression 
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retrospectively, and over a period that could reasonably be thought to 
encapsulate life-course depression prevalence.  
  
As I was interested in the natural population frequency of pre-stroke depression, 
any studies that recruited exclusively from clinical trials or that artificially 
enriched the population with ‘cases’ to allow matched case-control analyses 
were not included.  Studies that prospectively assessed depression at a pre-
stroke baseline and then followed patients up until an index stroke were also 
excluded if they did not assess depression at least every 2 years or more.  Due to 
the typically sporadic time-frame covered for assessment of depression before 
stroke occurrence, prolonged periods with no assessment are liable to 
underestimate overall pre-stroke depression prevalence by systematically 
missing interim incident depression.   
 
Exposures: Studies were accepted if they defined depression according to 
recognised clinical criteria that were current at the time of the primary paper 
(for example, Diagnostic and Statistical Manual of Mental Disorders version III/IV; 
International Classification of Diseases version 10); or if they defined depression 
using a cut-off point on a validated scale designed for assessing depression or 
depressive symptoms.  Any defined form of depression, including minor 
depression, was included.   Due to the often lax reporting of pre-stroke 
depression, it can be unclear how a study has defined the depression prevalence 
that they present (e.g. DSM IV major depression prevalence only or a 
combination of major depression, minor depression and dysthymia).  Therefore, 
where studies did not operationalise the pre-stroke depression definition, but 
defined post-stroke depression consistent with our criteria, the pre-stroke 
depression data were included and coded on the assumption that pre-stroke 
depression was defined according to the same criteria that was applied for post-
stroke depression.   Moreover, data were included if the pre-stroke depression 
assessment method employed was likely to include a definition that was 
consistent with the described criteria (e.g. utilisation of medical records to 
determine a prior clinical diagnosis of ‘depression’; self-report of a prior clinical 
diagnosis of ‘depression’). 
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Patients/participants: Studies were included where patients had a stroke or 
Transient Ischaemic Attack (TIA) of any form consistent with the World Health 
Organisation (WHO) definition. (136)  Studies were excluded if they: 1) excluded 
patients with depression; 2) were restricted to a selected stroke cohort (e.g. 
females only; highly restricted age groups); 3) had mixed populations (e.g. 
stroke and non-stroke populations in study sample) unless the stroke specific 
data could be extracted separately; 4) only used antidepressant prescription as 
evidence of depression; 5) if the depression rates could not be separated from 
other mental health disorders (e.g. “psychiatric history”); 6) had excessively 
non-generalisable exclusion criteria (e.g. exclusion of vascular risk factors, such 
as hypertension or diabetes, common to the typical stroke population).  
 
4.2.3 Study selection 
Studies identified from electronic databases were exported to Covidence 
software (version 1.0, Veritas Health Innovation, Australia) for screening.  After 
de-duplication, titles and abstracts were screened for relevance.  Potentially 
relevant full texts were reviewed against the inclusion/exclusion criteria.  
To assess validity of the search strategy, a third researcher (TQ) who was 
independent of the search pre-specified five important papers or reviews that 
were relevant to the pre-stroke depression topic - Ayerbe et al., (2013) (59); De 
Ryck et al., (2014) (67); Hackett et al., (2005) (137); Robinson & Jorge., (2016) 
(62); Reid et al., (2010) (97). Validity was assessed by describing how many of 
these titles were returned on initial searching.   
 
4.2.4 Assessment of risk of bias 
Risk of bias (RoB) was assessed at study level.  The potential important biases 
vary for my two review aims, so I used differing approaches to RoB assessments 
for each.  For the first aim of describing prevalence of pre-stroke depression, I 
utilised the Critical Appraisal Skills Programme (CASP) cohort study tool, 
adapting it for our purpose.  Specifically, I judged potential RoB based upon the 
focus of the paper, cohort recruitment method, stroke diagnosis method, pre-
stroke depression assessment method and study population inclusion/exclusion 
criteria.  
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For the secondary aim of describing association between pre-stroke depression 
and post-stroke depression, a stroke-specific RoB assessment tool was adopted 
for use in studies describing risk factors. (138)  This tool assessed RoB according 
to the following criteria: covariates controlled for; event-covariate ratio; control 
for collinearity; and, as a secondary category, I incorporated control for post-
stroke care pathway.  Rationale for our model assessment can be seen in 
Appendix 6. 
 
4.2.5 Data extraction and analyses 
The reported numbers of patients with pre-stroke depression along with the 
total sample size, setting, time-frame covered, country, first ever stroke 
(yes/no), means for assessment of pre-stroke depression, and definition of pre-
stroke depression were extracted from each study.  Where studies defined 
multiple forms of pre-stroke depression in their sample (e.g. major depression, 
minor depression, dysthymia), each subtype of depression was grouped together 
to form one whole depression sample. Additional data regarding post-stroke 
depression assessment method and covariates controlled were extracted only for 
studies included in my investigation into the risk association between pre-stroke 
and post-stroke depression.    
 
All data were extracted to a pre-specified template and stored on an electronic 
spreadsheet (Excel, version 2016, Microsoft, USA).  Where data were not 
available from the primary paper, author teams were contacted.  
Meta-analyses were conducted using Comprehensive Meta-Analysis software 
version 3 (Biostat, USA).   
 
The primary meta-analysis was designed to give a summary estimate of 
prevalence of pre-stroke depression.  Due to my expectation that the true pre-
stroke depression prevalence rate would vary within the population, I created a 
random-effects model to generate a pooled estimate of prevalence. 
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The second meta-analysis pooled adjusted odds ratios and confidence intervals 
of pre-stroke depression association with post-stroke depression from all studies 
utilising multiple regression analysis into a random effects model.   
Heterogeneity was assessed through visual inspection of forest plots and by 
describing I2. 
 
Publication bias for pre-stroke depression/post-stroke depression association 
analysis was determined by visually examining a funnel plot. 
 
The overall strength of the summary data on prevalence rates and the pre-stroke 
depression/post-stroke depression association was judged using GRADE 
(The Grading of Recommendations Assessment, Development and Evaluation) 
criteria. (139)  
 
Pre-specified subgroup analysis describing the effect of method of assessment 
for pre-stroke depression on prevalence rate was conducted.  Studies were 
separated by assessment and data pooled where the assessment method utilised 
had relevant data from a minimum of five studies.  Random-effects ANOVA was 
run, to explore the contribution of assessment method to observed 
heterogeneity of reported prevalence rates between studies.   
  
If any study was overly influential on pooled pre-stroke depression rate or odds 
ratios, and presented ‘outlier’ data then sensitivity analysis was performed, 
removing the outliers and re-running the analyses.  I also conducted pooled-
prevalence-related sensitivity analyses based on time-frame covered in studies, 
utilisation of a screening method only to assess pre-stroke depression, and type 
of depression included within the sample (e.g. major depression only).   
 
 
Figure 4-1 Outlines the study screening process. 
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Figure 4-1. Flow chart of Systematic search 
 
4.3 Results 
After excluding duplicates, our combined searches identified a total of 11884 
studies.  A total of 29  studies (93, 95, 96, 99, 100, 140-163) met the inclusion 
criteria (164993 patients; see Table 4-1).  I requested additional data from seven 
authors and received data from one (Acknowledgements).  Validity of my search 
strategy was supported as all pre-specified papers were identified in the initial 
search.  
  
Figure 4-1: Flo  chart of systematic search 
Focused search           
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Databases 
searched: Medline, 
Embase, PsychInfo 
Web of Science, 
Cinahl (1948-July 
2017) 
Databases searched: 
Embase, Medline, 
Web of science, Psych 
Info (2011-July 2017) 
 
Title and abstract 
screening: 486 
Title and abstract 
screening: 11398 
 
Studies included:15 
 
Studies included:14 
 
Total studies included:29 
Full text screening for 
inclusion/exclusion: 234 
 
 
Full text 
screening: 983 
 
 
Ayerbe et 
al. (2013) 
full text 
studies 
screened: 
46 
Reasons for exclusion:  
Foreign language  
Ungeneralizable pop.  
Excluded previous depression  
Duplicate patient population  
Non-published paper 
No specific pre-stroke depression 
prevalence rate  
Non-retrospective pre-stroke 
depression assessment 
Overly restricted pre-stroke 
depression assessment time-frame  
Post-stroke depression 
search 
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 Table 4-1. Summary of included studies describing pre-stroke depression 
 
Citation Pre-stroke 
depression 
assessment 
method 
Time 
period of 
depressi
on 
assessme
nt 
covered 
Study 
setting 
Country First 
ever 
stroke 
populati
on 
Pre-stroke 
depression 
prevalence/to
tal sample 
size 
Aben et 
al., (2006) 
Clinical 
interview 
Not 
stated 
 
Outpatient Netherlan
ds 
Yes 41/189 (22%) 
Barra et 
al., (2016) 
Medical 
records 
Not 
stated 
Hospital/Reh
ab* 
Norway No 11/393 (3%) 
Caiero et 
al., (2006) 
Medical 
records 
Life-time Hospital/Reh
ab* 
Portugal No 38/178 (21%) 
Castellano
s-Penido 
et al., 
(2011) 
Informant 
report 
not 
stated  
Hospital/Reh
ab* 
Spain No 13/89 (15%) 
De Ryck 
et al., 
(2013) 
1)Self-
report  
2)Medical 
records/cha
rts 
3)Screening 
(CESD+) 
1) & 2) 
life 
history 
3) 1 week 
prior to 
stroke 
Hospital/Reh
ab* 
Europe No 30/125 (24%) 
Dou et 
al., (2015) 
Self-report  Not 
stated  
Hospital/Reh
ab* 
China No 37/271 (14%) 
Gillen et 
al., (2001) 
Informant 
report 
Life 
history  
Hospital/Reh
ab* 
USA No 35/243 (14%) 
Hackett 
et al., 
(2006) 
Self-report Not 
stated  
Community New 
Zealand 
No 90/739 (12%) 
Jorgenese
n et al., 
(2016) 
Medical 
records  
Up to 5 
years 
prior to 
stroke 
Community  Denmark Yes 37426/157243 
(24%) 
Kim et 
al., (2014) 
Self-report  Not 
stated 
 
Hospital/Reh
ab* 
Korea No 17/423 (4%) 
Kocer et 
al., (2011) 
1)Clinical 
interview  
2)Medical 
records  
1) 
previous 
1year 
2) 
previous 
10 years 
Hospital/Reh
ab* 
Turkey No 27/148  (18%) 
Kootker 
et al., 
(2016) 
Medical 
records/cha
rts 
Not 
stated 
Hospital/Reh
ab* 
Netherlan
ds 
No 17/331 (5%) 
Liu et al., 
(2017) 
Self-report Not-
stated 
Hospital/Reh
ab* 
China No 2/562 (0.4% 
McCarthy 
et al., 
(2016) 
1)Medical 
records  
2)Self-
report 
Not 
stated 
 
Community USA No 43/322 (13%) 
Ng et al., 
(1995) 
Clinical 
Interview  
Not 
stated  
Hospital/Reh
ab* 
Singapore  No 12/52 (23%) 
Paolucci 
et al., 
(2006) 
Self-report Not 
stated  
Hospital/Reh
ab* 
Italy No 90/1064 (8%) 
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Pohjasvaa
ra et al., 
(1998) 
Medical 
records 
Not 
stated  
Hospital/Reh
ab* 
Finland No 52/277 (19%) 
Prisnie et 
al., (2016) 
1)Self-
report  
2)Some via 
clinical 
interview 
1) Not 
stated  
2) life 
history 
Outpatient Canada No 29/122  (24%) 
Schottke 
et al., 
(2015) 
Clinical 
interview  
Life 
history 
Hospital/Reh
ab* 
Germany No 31/289 (11%) 
Sienkiewic
z-Jarosz 
et al., 
(2010) 
Medical 
records 
Not 
stated  
Community Poland Yes 20/242 (8%) 
Singh et 
al., (2000) 
Self-report Not 
stated 
Community Canada Yes 13/81 (16%) 
Slater et 
al., (2012) 
Medical 
records 
Not 
stated  
Hospital/Reh
ab* 
Canada No 22/123 (18%) 
Tang et 
al., (2005) 
Medical 
records  
Not 
stated 
Hospital/Reh
ab* 
China No 7/189 (4%) 
Tang et 
al., (2011) 
1)Self-
report   
2)Medical 
records 
Not 
stated 
Hospital/Reh
ab*  
China No 17/591 (3%) 
Tse et al., 
(2017) 
Screening 
(CIDI)# 
Life-
history 
Hospital/Reh
ab* 
Australia No 20/98 (20%) 
Verdelho 
et al., 
(2004) 
1)Medical 
records 
2)Self-
reports 
Not 
stated 
Hospital/Reh
ab* 
France No 18/108 (17%) 
Vermeer 
et al., 
(2017) 
Self-report Not 
stated 
Outpatients Canada No 12/202 (6%) 
White et 
al., (2014) 
Medical 
records 
Not 
stated  
Hospital/Reh
ab* 
Australia No 16/134 (12%) 
Zhang et 
al., (2010) 
1)Clinical 
interview 
2)Self-
report 
 
Life 
history 
Hospital/Reh
ab* 
China No 28/165 (17%) 
*Acute Hospital or Rehabilitation hospital; #CIDI=Composite International 
Diagnostic Interview; +CESD= Centre for Epidemiological Studies Depression. 
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4.3.1 Prevalence of pre-stroke depression 
Pooled prevalence of pre-stroke depression was 11.6% (95%CI=9.2%-14.7%; 29 
studies; total participants n=164993).  There was substantial heterogeneity 
across studies (I2=95.8). (see Figure 4-2)  
 
RoB assessment of studies suggested potential bias in reported pre-stroke 
depression rates in all included studies. (see Table 4-2) Particular issues were 
around validity of the pre-stroke depression assessment (25 studies (83%) were 
at high or uncertain risk of bias) and external validity of the included 
participants (25 studies (83%) were at high or uncertain risk of bias), the latter 
primarily due to excluding patients with pre-stroke dementia/cognitive 
impairment (13 studies; 44%). Seventeen (59%) studies had an uncertain risk of 
bias in stroke assessment. 
 
Figure 4-2. Forrest plot of pooled pre-stroke depression prevalence 
 
Footnote: The plot indicates variability in reported prevalence rates 
between studies and an overall pooled prevalence of 11%. 
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Table 4-2. Risk of bias assessment for studies describing prevalence of pre-
stroke depression 
 
Citation Focus on 
pre-stroke 
depression 
Acceptable 
recruitment  
Acceptable 
stroke 
assessment 
Acceptable pre-
stroke 
depression 
assessment  
Population 
risk of bias 
Aben et al. (2006) 
 
     
Barra et al. (2016) 
 
     
Caiero et al. (2006) 
 
     
Castellanos-Penido et al. 
(2011) 
     
De Ryck et al. (2013) 
 
     
Dou et al. (2015) 
 
     
Gillen et al. (2001) 
 
     
Hackett et al. (2006) 
 
     
Jorgensen et al. (2016) 
 
     
Kim et al. (2014) 
 
     
Kocer et al (2011) 
 
     
Kootker et al. (2016) 
 
     
Liu et al. (2017) 
 
     
Mcarthy et al. (2016) 
 
     
Ng et al. (1995) 
 
     
Paolucci et al. (2006) 
 
     
Pohjasvarra et al. (1998) 
 
     
Prisnie et al. (2016) 
 
     
Schottke et al. (2015) 
 
     
Sienkiewicz-Jarosz et al. (2010) 
 
     
Singh et al. (2000) 
 
     
Slater et al. (2012) 
 
     
Tang et al. (2005) 
 
     
Tang et al. (2011) 
 
     
Tse et al. (2017) 
 
     
Verdelho et al. (2004) 
 
     
Vermeer et al. (2017) 
 
     
White et al. (2014) 
 
     
Zhang et al. (2010) 
 
     
Colour code: High risk of bias; unclear risk of bias; low risk of bias 
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GRADE evaluation suggested that the strength of evidence to support my 
summary estimate of prevalence was ‘very low’ (see Appendix 7). 
 
There was substantial variation in the method of pre-stroke depression 
assessment employed across studies. Pre-stroke depression was assessed using at 
least five different methods; eight studies utilised more than one method for 
assessing depression (see Table 4-1). The most commonly used methods were 
medical records/charts (utilised in 14 studies) and self-reports (utilised in 12 
studies).  The standard of reporting of assessment method within studies was 
mixed; most studies provided only minimal details of assessment method 
employed. 
   
I described summary estimates of pre-stroke depression based on assessment 
method for self-reports, medical records/charts and clinical interviews.  
Prevalence was 10.7% (95%CI=7.4%-15.2%); 9.4% (95%CI=6.2%-14.0%) and 17.3% 
(95%CI=13.1%-22.6%) respectively (see Figure 4-3).  Random-effects ANOVA 
suggested that method of assessment was an important contributor to between-
study heterogeneity (P=0.02).   
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Footnote: The plot indicates heterogeneity in prevalence rates across all 
assessment types.  Pooled prevalence rates for self-reports and medical 
records are very comparable and both considerably lower than pooled rate of 
studies utilising clinical interview methodology. 
 
 
4.3.2 Sensitivity analysis 
No outliers were apparent in the analyses; however, three studies were 
identified that were restricted in duration of pre-stroke assessment (i.e. ≤1 
year) and hence had been excluded, but otherwise met my inclusion criteria. 
(164-166)  Sensitivity analysis was performed by inserting these three studies 
into my primary pre-stroke depression prevalence meta-analysis; the resultant 
pooled rate (11.8%; 95%CI= 9.6-14.5,) suggests that excluding such studies had 
minimal impact upon our reported rate.  In addition, as one study(160) 
established a pre-stroke depression prevalence rate via a screening method, 
which could be more indicative of depressive symptoms, rather than depression 
Figure 4-3. Forrest plot of prevalence by assessment method 
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per se, I performed sensitivity analysis by removing this study; resultant pooled 
rates (11.4%; 95%CI= 8.9%-14.5%) suggest inclusion of this study did not bias my 
analysis.  Only two studies explicitly reported that they limited their reported 
sample to major depression only (95, 149); hence I also removed these two 
studies.  Again, resultant pooled rate (11.4%; 95%CI= 8.9%-14.6%) suggests that 
restriction to major depression only had minimal impact upon overall pooled 
rate.   
  
4.3.3 Association with post-stroke depression  
The association between pre and post-stroke depression was described in 24 
studies (83%); (see Appendix 8) 14 (58%) reported significant associations. (see 
Appendix 8)  Multiple logistic regression analyses were described in 15 studies 
(see Appendix 8) and 11 (73%) reported significant associations. (see Appendix 
10)  The resulting funnel plot did not suggest publication bias. (see Figure 4-4)  
Assessment methods employed to assess pre and post-stroke depression were 
variable, as were chosen covariates included in regression models. (see Appendix 
9)     
 
The papers describing association models were at risk of bias (see Table 4-3). In 
particular, no studies controlled for post-stroke care-pathway.  Three out of four 
studies employing multiple regression models that failed to observe a risk 
association were underpowered (96, 140) or failed to control for important 
covariates (95); one study had a very small pre-stroke depression prevalence. 
(141)  
 
Odds ratio data were available for nine studies in total.  However, one study 
(100) was removed from analysis due to a lack of symmetry of log values.  This 
left eight studies with a combined sample size of 37483 for meta-analysis.  
Random-effects analysis suggested a pooled odds ratio of 3.03 (95% CI of 2.30-
3.98) (Figure 4-5). One study (159) appeared to be a clear outlier; hence 
sensitivity analysis was performed by removing this study and rerunning analysis.  
This did not meaningfully alter the strength of association (2.85; 95%CI=2.70-
3.02).  
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GRADE evaluation suggested that the strength of evidence to support our 
summary estimate of association was ‘very low’ (see Appendix 10). 
 
 
 
Footnote: The relatively symmetric pattern of odds ratio data suggests no 
publication bias is present.  
Figure 4-4: Funnel plot assessing publication bias of odds ratio data reported in 
studies 
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Table 4-3. Risk of bias assessment of multiple logistic regression models 
employed to evaluate pre-stroke depression/post-stroke depression 
association 
 
Citation Common Covariates 
controlled for (post-
stroke function/stroke 
severity) 
Event-ratio size 
acceptable 
Stepwise or 
collinearity 
controlled for 
Care 
pathway 
covariate 
controlled 
for 
Aben et al. (2006) 
 
    
Barra et al. (2016) 
 
    
Caiero et al. (2006) 
 
      
De Ryck et al. (2013) 
 
    
Hackett et al. (2006) 
 
     
Jorgensen et al. 
(2016) 
 
    
Mcarthy et al. (2016) 
 
    
Ng et al. (1995) 
 
    
Paolucci et al. (2006) 
 
    
Pohjasvarra et al. 
(1998) 
 
    
Schottke et al. (2015) 
 
    
Tang et al. (2011) 
 
     
Verdelho et al. (2004) 
 
    
White et al. (2014) 
 
    
Zhang et al. (2010) 
 
    
Colour code: High risk of bias; low risk of bias 
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Figure 4-5. Forrest plot of odds ratios for developing post-stroke depression 
(PSD) based upon presence of pre-stroke depression 
 
 
Footnote: Forrest plot shows a general consistency that pre-stroke 
depression increases odds of post-stroke depression.  Pooled odds ratio 
indicates odds of post-stroke depression increase by 3 when pre-stroke 
depression is present.  
 
 
4.4 Discussion 
4.4.1 Prevalence 
The primary aim of this review was to describe the natural stroke population 
prevalence of pre-stroke depression based upon data from typical stroke 
settings.  My results suggest a pooled pre-stroke depression prevalence rate of 
~12%, which is identical to the 12% mood disorder prevalence rate most 
commonly reported in the general population. (167)  This is somewhat surprising 
given that depression is a risk factor for stroke. (168)  Pre-stroke depression was 
assessed in diverse ways across studies and that there was a significant trend 
towards increasing prevalence with increasing complexity of testing. This 
indicates that the more one looks for pre-stroke depression, the more it is 
discovered, which is in keeping with research suggesting variable detection of 
pre-stroke depression according to assessment method employed. (98, 100, 154, 
163)  On this basis, the 17% pre-stroke depression rate, evident when in-depth 
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interviews were utilised to investigate presence of pre-stroke depression, may 
be more reflective of the actual pre-stroke depression prevalence, existent 
within the stroke population.    
 
Comparing pre-stroke depression rates (17%) to recent estimates of post-stroke 
depression (39-52%) (59) demonstrate that rates of depression after stroke are 
several multiples higher than the rates of depression present before a stroke.  
These results suggest that the majority of cases of post-stroke depression are 
not simply the re-manifestation or ‘unmasking’ of pre-stroke depression.  My 
findings are therefore in line with suggestions that the majority of cases of post-
stroke depression are the product of the experience and consequences of the 
stroke itself. (59) 
 
4.4.2 Risk Association 
As a secondary aim, I described the association between pre-stroke depression 
and post-stroke depression.  Recent findings prompted suggestions that the pre-
stroke state is “not a meaningful predictor” of depression after stroke.(95)  My 
meta-analysis results suggest that pre-stroke depression at any point over the 
life-time increases odds of post-stroke depression by as much as  3.0 (95%CI=2.3-
4.0), when compared to those without pre-stroke depression.  Notably, of the 
fifteen studies that utilised multiple logistic regression analysis to investigate 
the association, two of the four studies that failed to find an association were 
underpowered in their event-per variable ratio; (96, 140) one study (95) failed to 
control for important covariates, and one reported a very low rate of pre-stroke 
depression. (141)  I would therefore suggest it is inaccurate to conclude that the 
pre-stroke state is not a meaningful predictor of depression after stroke and 
would encourage researchers to include pre-stroke depression as a case-mix 
adjuster in all future studies of post-stroke depression.   
 
4.4.3 Strengths and Limitations 
I present a methodologically robust synthesis of the published literature, 
following best practice in conduct of observational systematic review. However, 
quality of primary data mandated a low GRADE rating: prevalence rates reported 
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across studies were heterogeneous and studies had risk of bias.  Specifically, the 
limitations of the available papers may risk underestimating pre-stroke 
depression rates.  Particular issues were regarding sensitivity of pre-stroke 
depression assessment and exclusion of patients with pre-stroke cognitive 
impairment.  The pooled rate may alternatively be inflated by inclusion of rates 
that reflect depressive symptoms rather than depression per se; although, my 
sensitivity analysis indicates that such rates were not overly influential towards 
the pooled prevalence that I report.  More significantly, I cannot say for certain 
what form of depression the pooled rate describes, as explicit definitions of pre-
stroke depression were lacking.  Typically employed assessment methods (i.e. 
medical records, self-reported prior diagnosis, clinical interview) could 
conceivably incorporate any form of clinical depression (e.g. major depression, 
minor depression and dysthymia all inclusive), or may be predominantly 
constrained to major depression only.  Clearer reporting in this regard would 
benefit the field. 
 
Similarly, my assessment of the pre-stroke/post-stroke depression association 
has methodological limitations.  Authors may have been more likely to give odds-
ratios where an association was apparent; hence our summary quantitative 
analysis is at risk of reporting bias, albeit this was not evident in the 
corresponding funnel plot. Studies were heterogeneous in both covariates 
controlled for and assessment method utilised for both pre and post-stroke 
depression assessment, which could potentially bias or confound reported 
associations; for instance, strength of reported odds ratios may be heightened or 
diluted due to differences in control for stroke severity, or ability to accurately 
detect pre-stroke depression within a sample.  Taking all this into account, my 
GRADE estimate of confidence in this evidence was ‘very low’.  I would also note 
that no included studies controlled for the possible influence of alterations in 
care pathway following assessment of pre-stroke depression.  It seems plausible 
that recording pre-stroke depression, clinically, would result in greater use of 
pharmacological treatment, likelihood of referral for psychological assessment, 
or more frequent assessment for post-stroke depression. (97, 157)  As a result, 
although current evidence is favourable regarding a relevant risk association 
between pre-stroke depression and post-stroke depression, we must remain 
cautious and changes to the approach for investigating this association are 
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needed.  In particular, I would advise future studies seeking to assess risk factors 
for post-stroke depression to be aware of the potential care-pathway related 
confound and encourage greater consistency of depression assessment (both pre 
and post stroke).  
 
Finally, I used two complementary approaches to inform my literature search, 
one specific search designed to find papers with a focus on pre-stroke depression 
and a more sensitive search with a post-stroke depression focus. Through various 
internal and external validity checks I believe I have captured all the relevant 
studies.  However, it is possible that I may have missed prospective cohort 
studies with depression and stroke data where these variables are only available 
as secondary outcomes data and there have been no specific publications 
relating to depression and stroke.  
 
4.4.4 Future Directions 
My findings suggest avenues for further research.  Optimal methods for assessing 
pre-stroke depression should be established, particularly as differences in 
assessment tool properties could interfere with correct identification of risk 
associations or result in improper patient care plans.   Secondly, it would be 
beneficial to ascertain whether depression severity (e.g. major depression only 
vs “any depression”) is a source of variance for the risk of developing depression 
after stroke.  Finally, the literature presents a clear correlation between pre-
stroke depression and post-stroke depression; however, the specific aetiology of 
this association remains unknown.  Previous studies have suggested that genetic 
factors may play a role.(59)  The presence of particular psychological 
characteristics may also be relevant.  For instance, selective attention towards 
negative attributes can lead to depression following disease (169) and is also a 
characteristic attributable to depression.  Hence, a prior history of this cognitive 
style may increase the likelihood that this way of thinking will arise post-stroke, 
thus heightening risk of developing depression after stroke.  Understanding the 
nature of the pre-stroke/post-stroke depression association should therefore 
help to tailor better treatment methods.   
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4.4.5 Clinical Implications 
Stroke patients are at considerable risk of developing depression and having 
depression prior to the stroke event only serves to further heighten this risk.  On 
this basis, it is important that clinicians are aware of the relevance of pre-stroke 
depression to the potential development of depression after a stroke, as well as 
the prevalence of the condition within their patient population (likely 1 in 6).   
Clinicians should also be aware of the potential limitations of relying upon 
medical records or patient self-reported diagnoses as means of identifying pre-
stroke depression.  It is likely that reliance upon such methods will fail to 
identify a substantial number of patients with the condition.    
 
4.5 Conclusions 
It seems clear from the existent literature that the prevalence of pre-stroke 
depression is strikingly lower than the depression prevalence observed after a 
stroke.  Nevertheless, it appears that pre-stroke depression is an important and 
relevant clinical variable regarding the development of post-stroke depression.  
I would suggest that in those patients where pre-stroke depression is apparent, a 
high index of suspicion for post-stroke depression would be appropriate.  
 
In a research context, efforts to investigate pre-stroke depression are currently 
hampered by the challenge of reliably assessing it: the most commonly employed 
methods utilised to detect pre-stroke depression are at risk of underestimating 
the prevalence of the condition.  Utilisation of more thorough assessments of 
pre-stroke depression along with a careful consideration of relevant confounds 
and adequately powered statistical models are essential to the enablement of a 
more developed and nuanced understanding of pre-stroke depression and its 
relationship with post-stroke depression.   
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Chapter 5. Can informant tools be used to assess 
pre-stroke depression?  An investigation of 
diagnostic test accuracy. 
5.1 Introduction 
Based on my findings in chapter 4, pre-stroke depression appears to exist in 
around 1 in 6 patients and its presence is associated with increased risk of post-
stroke depression.  However, assessment method employed contributes variance 
and there does not appear to be an agreed upon optimal method for assessing 
pre-stroke depression.  Of the 5 different methods utilised in the studies 
included in my review, clinical interviews are likely the most robust method, but 
they are not suitable for routine use in busy acute stroke units.  Medical records 
were the most commonly adopted method to identify pre-stroke depression; 
however, the differential prevalence rates observed suggest that medical 
records lack sensitivity to pre-stroke depression.   There is a need, therefore, to 
identify methods more suited to routine pre-stroke depression assessment. 
 
There are a large number of brief patient self-report depression screening 
assessments available; (see Figure 5-1) however, their use in stroke is limited by 
confounding conditions such as aphasia, cognitive impairment, and delirium. 
(170) 
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Figure 5-1: Common Depression assessment tools 
 
Geriatric depression scale (GDS) 
Hospital anxiety and depression scale (HADS) 
Patient Health Questionnaire (PHQ) 
Signs of Depression Scale (SoDS) 
Visual Analogue Mood Scales (VAMS)  
Yale Single Question 
General Health Questionnaire (GHQ) 
Center for Epidemologic Studies Depression Scale (CESD) 
Brief Assessment Schedule Depression Cards (BASDEC) 
Beck Depression Inventory (BDI) 
Aphasia Depression Rating Scale (ADRS) 
 
 
 
 
Informant assessments may be a viable and inclusive alternative.  This approach 
is widely utilised in stroke to assess pre-stroke cognitive impairment but is not 
typically employed to assess pre-stroke mood.  In contrast to cognitive 
assessment, specific informant questionnaires for assessment of depression in 
stroke have been developed, such as the Stroke Aphasic Depression 
Questionnaire (SADQ). (171)  Twenty-one-item and 10-item versions of the scale 
exist, as well as a hospital-specific variation (SADQH-10).  Reported sensitivity 
and specificity for detection of depression ranges from 70-100 and 69-81, 
respectively. (172) Additional psychometric properties are also favourable: the 
tool takes just 4 mins to complete, supporting feasibility; it has good test-retest 
reliability, and internal consistency; while concurrent validity is supported based 
upon strong correlations with other measures of depression. (173-175)  A recent 
review(172) identified the SADQ as the only tool to meet psychometric and 
clinical criteria for assessment of ‘any depression’ in stroke.    
 
Alternatively, the Geriatric Depression Scale (GDS) (176) is a commonly used 
depression screening tool designed specifically for use in older adult 
populations; (170) it was recently identified as a suitable direct-to-patient 
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depression screening tool for use in stroke.(172)  A short-form informant version 
(GDS-SF) of the tool is freely available (177) and takes ~5 minutes to 
complete.(172)  Moreover, the GDS-SF has demonstrated sensitivity >80% and 
specificity >60% for depression assessment in stroke. (172) 
 
As both the SADQ and the GDS were designed to assess ongoing mood, it is 
unclear if this validity translates to evaluating premorbid mood as is necessary 
for pre-stroke depression assessment.   I therefore aimed to investigate and 
compare the diagnostic test accuracy of the SADQ-H10 and an informant version 
of the GDS-SF as a means of assessing pre-stroke depression in an acute stroke 
setting.  As a secondary aim, I sought to compare this diagnostic test accuracy 
against that of the more commonly employed method of pre-stroke depression 
assessment—patient medical records. 
 
5.1.1 Hypothesis 
For my primary aim, I hypothesized that the informant assessment approach 
would be a valid method for assessment of pre-stroke depression, with both 
tools performing significantly above chance level when discriminating between 
(pre-stroke) depressed and non-depressed patients.  
  
For my secondary aim, I hypothesised that the informant method would 
demonstrate significantly superior sensitivity to patient medical records when 
assessing pre-stroke depression. 
 
5.2 Method 
This study utilised the same participant pool, design and inclusion/exclusion 
criteria as that described in chapter 3, section 3.2. Details of assessment are 
described below.   
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5.2.1 Informant tool assessment 
Each participant’s informant was asked to complete the SADQ-H10 and GDS-SF, 
which were administered in alternating order from patient to patient, by stroke 
research nurses trained in administration of the questionnaires. The SADQ-H10 
involved 10 questions related to mood in the previous week and operates 
according to a 4-point Likert scale (not at all this week, 1-4 days this week, 4-6 
days this week, every day this week).   Items are scored from 0-3 and totalled 
out of 30.  A score of >5 suggests depression is present.  The GDS-SF involves 15 
questions related to mood and each question is scored according to a binary 
scale (yes/no; plus, a ‘don’t know’ option).  Scores for each question are 
totalled to give a score out of 15.  A score of >5 suggests depression is present.  
(see Appendices 11 and 12) 
 
Informants were asked to complete the questionnaires in relation to how the 
patient’s mood was before their most recent stroke occurrence.  Time-frame for 
completion was within 1 month following admission; however, this requirement 
was relaxed towards the end of the study to assist recruitment.  Questionnaires 
could be completed in the presence of the consenting researcher while the 
patient was still in hospital; or, if necessary, alone following patient discharge 
and returned via post.     
 
5.2.2 Gold standard assessment 
Major and minor depression were diagnosed according to DSM-5 criteria. (30) 
 
Presence of a pre-stroke (major or minor) depressive episode was determined 
for each patient, via a clinical interview with the patient and/or the informant.  
All interviews were conducted utilising the Structured Clinical Interview for 
Depression (SCID) by a researcher (MT) trained in use of the SCID and blinded to 
results of the informant questionnaires.  As informant tools are designed to 
screen for evidence of present low mood, rather than a history of low mood, the 
time-frame examined within the clinical interview for prior depressive episode 
occurrence was limited to the 6 months before the stroke; depressive episodes 
at any point in the life-time was not assessed via gold standard interview.  
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Interviews were conducted either face-to-face (preferentially) or via telephone 
(where necessary).  As with the informant questionnaires, the SCID interview 
was initially required to be completed within 1 month following patient hospital 
admission for the stroke; however, this requirement was relaxed towards the 
end of the study.  Following SCID interview, a consensus diagnosis was reached 
via discussion between the interviewing researcher (MT) and a stroke consultant 
(TQ). In contrast to the gold standard assessment process described in chapter 3, 
section 3.2, we did not adopt any means of establishing a diagnosis of ongoing 
pre-stroke depression if the SCID was not completed; hence, if both the patient 
or the patient’s informant could not participate in the SCID assessment, the gold 
standard diagnosis could not be established for this patient.   
 
5.2.3 Assessment of pre-stroke depression via medical 
records 
As I was interested in the comparative diagnostic test accuracy performance of 
informant questionnaires to that of medical records for assessment of pre-stroke 
depressive episodes, patient medical records were also examined to identify 
pre-stroke depression.  Patients were considered to have a recent pre-stroke 
depressive episode if they had a prior diagnosis of major/minor depressive 
disorder and were taking an anti-depressant drug in the 6 months before the 
stroke.  Anti-depressant drugs used in the UK were identified on the British 
National Formulary.  The specific drugs searched for can be seen in Table 5-1. 
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Table 5-1. Anti-depressant drugs searched for on the British National 
Formulary 
 
Drug name 
 
Amitriptyline hydrochloride Sertraline 
Clomipramine hydrochloride Tranylcypromine 
Dosulepin hydrochloride Trazodone hydrochloride 
Doxepin Trimipramine 
Duloxetine Venlafaxine 
Escitalopram Vortioxetine 
Imipramine hydrochloride Sertraline 
Isocarboxazid Paroxetine 
Lofepramine Fluoxetine 
Mianserin hydrochloride Citalopram 
Mirtazapine Venlafaxine 
Moclobemide Escitalopram 
Nortriptyline Paroxetine 
Reboxetine  
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5.2.4 Clinical and demographic data 
Patient level data was collected via a combination of medical records or patient 
self-report.   Stroke severity was assessed via NIHSS using retrospective chart 
review. (130)  Pre-stroke disability was assessed via the pre-stroke modified 
Rankin Scale (pre-stroke mRS).  Pre-stroke cognitive impairment was assessed 
via the method described in chapter 3 section 3.2.   
 
5.2.5 Statistical analysis 
MedCalc version 18.11 was used for all analyses.  I adopted a 2-stage approach 
to analysis.   
 
5.2.5.1 Stage1 
In the first stage, performance of informant tools were evaluated against the 
gold standard assessment diagnosis.  The Area Under the Receiver Operating 
Characteristic (AUROC) curve for each informant tool was determined via 
empirical Receiver Operating Characteristic (ROC) curves using the Delong et al., 
(1988)(132) method and compared using Pairwise comparisons.   Next, I 
established the sensitivity and specificity, along with associated 95% confidence 
intervals, of the two informant tools for detecting a prior depressive episode at 
commonly used cut-points via 2x2 tables.  I then compared the sensitivity and 
specificity values of each tool statistically when there were >20 cases for 
comparison, using McNemar’s test.  Following this, I investigated if the 
recommended published cut-points (>5) were the optimal cut-points for 
assessing pre-stroke depression within our population, based on the point 
nearest the top left-hand corner of the ROC graph. (81) Where an alternate cut-
point was suggested, I repeated the analysis to evaluate sensitivity and 
specificity at optimal cut-points. 
   
Where data was missing, I applied the average score of the answered questions 
to the unanswered question/s on the SADQ-H10, provided no more than 2 
questions were unanswered. For the GDS-SF, I scored missing responses as ‘no’ 
responses.  If more than two questions were unanswered for either tool, the 
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questionnaire data was discarded.  ‘Don’t know’ responses for the GDS-SF were 
also treated as ‘no’ responses for scoring purposes.   
  
Stage 1 sensitivity analysis 
 
I conducted a series of sensitivity analysis to explore potential influences upon 
my results by altering data then rerunning analysis in the following ways: 
 
To ensure that any differences in informant tool diagnostic test accuracy 
properties were not overly influenced by assessment order, I sub-grouped the 
informant tools by order of administration and compared resultant sensitivity 
and specificity values of the two groups. 
 
I ran a sensitivity analysis to determine if results changed based on scoring 
‘don’t know’/missing responses as a ‘yes’.   
 
I investigated the influence of time-frame on diagnostic test accuracy by 
removing cases where completion of informant questionnaires or gold-standard 
was >31 days following stroke.   
 
5.2.5.2 Stage 2 
Based upon diagnostic test accuracy performance of the two tools in stage 1, for 
the stage 2 analysis I selected the best performing tool and evaluated the 
relative performance of the selected informant tool against that of medical 
records (dichotomised as depression present/depression not present) for 
assessing pre-stroke depression, again using the SCID diagnosis as the gold 
standard comparator for both methods.  I generated sensitivity and specificity 
scores for medical records using 2x2 tables, then used McNemar’s test to 
compare these values against those of the chosen informant tool when employed 
at its recommended published cut-point (>5).   
 
When selecting the best performing tool, priority was given to the tools’ 
respective performance at their most commonly used recommended cut-point, 
and a greater emphasis was placed on sensitivity of the tools, over specificity. 
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5.3 Results 
5.3.1 Stage 1: Comparison of SADQ and GDS-SF 
informant 
The population numbers were as described in chapter 3; however, 2 additional 
patients were assessed between 1st Dec 2018 and 31st Dec 2018 so were added to 
the population.  Six patients described in chapter 3 as being unable to 
participate in the clinical interview were excluded from analysis of this study.  
This left a total of 91 patients with informants for diagnostic test accuracy 
evaluation of the SADQ-H10 and GDS-SF. Seventy out of 91 (77%) patients 
included in analysis in this study were recruited from the Glasgow Royal 
Infirmary.  
 
There was missing data for the SADQ-H10 in 3/91 (4%) patients; missing data in 
1/90 (1%) was too extensive such that the data could not be utilised.  Missing 
data was present for 10/91 (11%) GDS-SF’s; the missing data was substantial in 
2/91 (2%) and so could not be utilised.  This left SADQ-H10 data available for 90 
patients and GDS-SF assessments available for 89 patients.  The GDS-SF 
contained ‘don’t know’ responses in 36/91 (40%) forms.  Median time for 
completion of informant assessment following admission was 5 days; Median 
time for completion of gold standard assessment following admission was 7 days.  
A total of 18 patients were depressed before their stroke (13 major depressive 
episodes, 5 minor depressive episodes) according to ‘gold standard’ diagnosis.  
Population descriptive statistics can be seen in Table 5-2. 
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Table 5-2: Population Descriptive Statistics 
 
Variable Overall 
Age (Median; 25th-75th Percentile) 73 (61-80) 
Sex Male (%) 46/84 (54.8%) 
Stroke-type (%)  
Total Anterior Circulation Stroke  6/77 (7.8%) 
Partial Anterior Circulation Stroke  25/77 (32.4%) 
Lacunar Stroke  9/77 (11.7%) 
Posterior Circulation Stroke  21/77 (27.3%) 
Trans Ischaemic Attack  16/77 (20.8%) 
NIHSS (Median; IQR) 1 (0-4) 
Pre-stroke modified Rankin Scale 
(nn; %) 
 
0 31/81 (32.0%) 
1 14/81 (14.4%) 
2 13/81 (13.4%) 
3 18/81 (18.6%) 
4 5/81 (5.2%) 
Pre-stroke cognitive disorder (nn; 
%) 
27/91 (29.7%) 
Post-stroke Aphasia (nn; %) 4/84 (4.1%) 
Previous stroke 22/81 (27.2%) 
Diabetes 15/76 (15.5%) 
Atrial Fibrillation 14/76 (14.4%) 
Medication count (Median; 25th-
75thPercentile) 
7 (5-10) 
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AUROC curve was 0.71 (95%CI=0.60-0.80), p<0.01, for the SADQ-H10 and 0.82 
(95%CI= 0.73-0.90), p<0.01, for the GDS-SF.  Pairwise comparison of AUROC 
curves suggested there was no statistically significant difference between the 
two tools (Difference between areas=0.09, 95%CI=-0.05-0.23; p= 0.19).  A post-
hoc power calculation was conducted to determine if pairwise comparison was 
underpowered to detect a 0.10 difference in AUROC, with 0.8 power and a 20% 
condition prevalence.  Results suggested that 366 patients would be needed to 
determine if the observed difference was statistically significant at p<0.05.  
   
At cut-point >5, sensitivity for the SADQ-H10 for detecting any depressive 
episode in the preceding 6 months before the stroke was 72.2% (95%CI=46.5%- 
90.3%); specificity was 62.7% (95%CI=50.3%-73.6%).  Sensitivity of the GDS-SF for 
depression at a cut-point of >5 was 76.5% (95%CI=50.1%-93.2%); specificity was 
84.7% (95%CI=74.3%-92.1%).  A total of 88 patients had both SADQ-H10 and GDS-
SF data available for statistical comparison of sensitivity and specificity rates.  
There were insufficient numbers with depression [18] to compare sensitivity 
rates statistically; however, McNemar’s test for a difference in specificity 
suggested the GDS-SF had significantly better specificity than the SADQ-H10 
(Difference: 22.2%; 95%CI=11.9%-32.6%), p<0.01.  
 
Empirical ROC curves suggested that the recommended published cut-point for 
the tools were not the optimal cut-point (see Figure 5-2).  I therefore repeated 
the analysis, applying a cut-point of >10 for the SADQ-H10 and >4 for the GDS-
SF.   Sensitivity for the SADQ-H10 was 55.6% (95%CI=30.8%-78.5%); specificity 
was 86.1% (95%CI=75.9%-93.1%).  For the GDS-SF, sensitivity was 82.4% 
(95%CI=56.6%-96.2%); specificity was 79.2% (95%CI=68.0%-87.8%).  McNemar’s 
test for specificity suggested no significant difference between the 2 tools 
(Difference:-7.0%; 95%CI= -16.1%-1.9%), p=0.23. 
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GDS-SF: Cut-point 
nearest top left-
hand corner 
(circled): >4) 
SADQ-H10: Cut-
point nearest top 
left-hand corner 
(circled): >10 
Figure 5-2. Combined ROC curves for SADQ-H10 and GDS-SF 
 
 
 
5.3.1.1 Sensitivity analysis 
SADQ-H10 was administered first with 41 participants (10 cases of gold standard 
defined depression); GDS-SF administered first with 50 participants (8 cases of 
gold standard defined depression).  Sensitivity analysis based on order of 
administration showed that when administered first, at recommended published 
cut-points, GDS-SF sensitivity was 85.7% (95%CI=42.1% to 99.6%), specificity was 
85.7% (95%CI=71.5%-94.6%); AUROC for GDS when administered first was 0.94 
(95%CI=0.84-0.99), p<0.01.  When SADQ-H10 was administered second, 
sensitivity was 87.5% (95%CI=47.4%-99.7%), and specificity was 61.9% 
(95%CI=45.6%-76.4%); AUROC for SADQ-H10 when administered second was 0.81 
(95%CI=0.68-0.91), p<0.01.  When administered second, GDS-SF sensitivity was 
70.0% (95%CI=34.8%-93.3%), specificity was 68.9% (95%CI=49.2%-84.7%); AUROC 
for GDS-SF when administered second was 0.69 (95%CI=0.52-0.82), p=0.06.  
When administered first, SADQ-H10 sensitivity was 60.0% (95%CI=26.2%-87.8%), 
specificity was 56.7% (95%CI=37.4%-74.5%).  AUROC when SADQ-H10 was 
administered first was 0.63 (95%CI=0.46-0.78), p=0.27.   
 
I evaluated if scoring GDS-SF ‘don’t know’/missing responses as ‘yes’ altered 
sensitivity and specificity rates at recommended published cut-points.   
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Sensitivity of GDS-SF did not change (76.5%, 95%CI=50.1%-93.2%); however, 
specificity was slightly reduced when adopting this method (73.6%, 95%CI=61.9%-
83.3%).  AUROC curve was 0.80 (95%CI=0.71-0.88), p<0.01.   
 
I removed 12 cases in which the informant questionnaire and/or gold standard 
assessment was completed >31 days following hospital admission for stroke.  
Results suggest inclusion of these cases did not substantially influence test 
accuracy. Sensitivity and specificity rates at recommended published cut-points 
were: SADQ-H10 sensitivity=73.3% (95%CI=44.9%-92.2%), specificity=65.1% 
(95%CI=52.0%-76.7%), AUROC=0.73 (95%CI=0.61-0.82), p<0.01; GDS-SF 
sensitivity=71.4% (95%CI= 41.9%-91.6%), specificity=87.3% (95%CI=76.5%-94.4%), 
AUROC curve=0.84 (95%CI=0.734-0.911), p<0.01.   
 
5.3.2 Stage 2: Comparison with medical records 
Based upon the above properties, the GDS-SF was selected for comparison 
against the use of medical records to detect depression in the 6 months before 
the stroke. Medical information was available for all 89 patients with GDS-SF 
data. 
 
Sensitivity of medical records to detection of depressive episodes in the 6 
months preceding the stroke was 50.0% (95%CI=26.0%-74.0%); specificity was 
81.9% (95%CI=71.1%-90.0%).   
 
There was insufficient data to compare sensitivity values of the GDS-SF and 
medical records statistically; McNemar’s test of specificity values at both 
recommended and optimal cut-points suggested no significant difference (Size 
difference: 2.8%; p=1.00) between the two methods.   
 
Additional diagnostic test accuracy properties for both informant tools at their 
recommended published cut-points (>5) along with use of medical records can be 
seen in Table 5-3.  
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Table 5-3: Properties of 3 assessment methods 
 
 SADQ-H10  GDS-SF Medical records 
Positive 
likelihood ratio 
1.79 (95%CI=1.20 
to 2.68) 
5.01(95%CI= 2.73 
to 9.16) 
2.77 (95%CI= 1.41 
to 5.44) 
Negative 
likelihood ratio 
0.47(95%CI=0.22 
to 1.00) 
0.28 (95%CI=0.12 
to 0.66) 
0.61 (95%CI= 0.38 
to 0.98) 
Positive 
predictive value 
30.9% 
(95%CI=23.1% to 
40.1%) 
54.2% 
(95%CI=39.2% to 
68.4%) 
40.9% (95%CI= 
26.1% to 57.6%) 
Negative 
predictive value 
89.6% 
(95%CI=79.9% to 
94.9%) 
93.9% 
(95%CI=86.6% to 
97.3%) 
86.8% (95%CI= 
80.3% to 91.3%) 
Prevalence (pre-
stroke 
depression) 
20.0% 
(95%CI=12.3% to 
29.6%) 
19.1% 
(95%CI=11.5% to 
28.8%) 
20.0% (95%CI= 
12.3% to 29.8%) 
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5.4 Discussion 
5.4.1 Informant tool comparative diagnostic test accuracy 
On the surface, my results offer preliminary support regarding the validity of 
informant tools as a method for assessing pre-stroke depression.  As 
hypothesised, both tools’ overall diagnostic test accuracy performance (AUROC) 
was significantly above chance level, suggesting the SADQ-H10 and GDS-SF 
informant tools are a valid means of assessing pre-stroke depression.   The 
AUROC of the two tools differed by ~10% in favour of the GDS-SF and suggest the 
GDS-SF has ‘good’ (0.80-0.89) discriminability between patients with pre-stroke 
depression and those with no pre-stroke depression, while the SADQ-H10 has 
‘fair’ (0.70-0.79) discriminability.  However, this difference was not statistically 
significant.  It is likely that the lack of statistical significance is related to the 
lack of power in my study sample.  Regardless, future studies are required to 
confirm if indeed the GDS-SF has an overall superior diagnostic test accuracy for 
pre-stroke depression than the SADQ-H10. 
 
Comparative performance of the tools at most commonly applied recommended 
cut-points also favoured the GDS-SF over the SADQ-H10.  The GDS-SF 
demonstrated significantly fewer false positive diagnoses than the SADQ-H10 and 
while I could not statistically compare sensitivity values, the presenting rates 
were highly similar.  This increased specificity suggests the GDS-SF offers an 
important clinical advantage over the SADQ-H10.  Utilisation of this tool may 
minimise the number of patients misidentified as having had a pre-stroke 
depressive episode. 
 
To my knowledge, there is no prior research on the diagnostic test accuracy 
properties of these tools for assessment of pre-stroke depression.  The observed 
sensitivity and specificity values are however broadly consistent with previous 
findings regarding tool validity when used to assess post-stroke depression.  At 
cut-point >5, the SADQ-H10 has reported sensitivity rates ranging from 70-100% 
and specificity ranging from 69-78%. (174, 178) However, this performance is 
described in studies that employed other depression screening tools as the 
reference standard; (172) as such, they arguably do not reflect the tool’s ability 
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to assess depression per se, but rather, depressive symptoms.  My findings 
therefore add to the SADQ-H10 validity literature, suggesting the SADQ-H10 can 
discriminate between stroke patients with and without DSM-5 defined major and 
minor depression—albeit in a pre-stroke context.  I would note, however, that 
while my findings suggest the SADQ-H10 can discriminate such patients, its 
overall performance for this purpose is relatively weak, consistent with Leeds et 
al., (2004)(173) who question the tool’s validity when utilised with non-aphasic 
patients.  
  
The diagnostic test accuracy of the GDS-SF has previously been questioned.(86)  
Roger and Johnson-Greene (2009)(179) reported a GDS-SF sensitivity of just 46% 
for DSM-IV defined major or minor depression when utilised in a stroke 
rehabilitation population. My results support the use of the GDS-SF as a tool 
capable of detecting cases of depression and are more consistent with the 
findings of Lee et al., (2008)(180), who  report a GDS-SF sensitivity rate of 84%; 
though, as a caveat, our lower bound confidence intervals suggest GDS-SF 
sensitivity could be as low as 50%, thus more research is required to establish 
the GDS-SF sensitivity values in general.   
 
Alternate cut-points for both tools may be more suited to assessment of pre-
stroke depression than the recommended published cut-points.  Indeed, it is 
possible that the differences in specificity between the tools could be allayed by 
application of a higher, optimal, cut-point for the SADQ-H10. However, altering 
the cut-point may come at a substantial cost to the sensitivity of the SADQ-H10.  
In relation, Meader et al., (2013)(86) suggest that the GDS-SF has substantial 
heterogeneity of use in the literature already, leading to notable variation in 
comparative performance; therefore, as discussed in chapter 3, section 3.4, I do 
not recommend that researchers and clinicians stray from the published cut-
points until further work is conducted.   
 
5.4.2 Comparison with medical records 
Despite being the most commonly utilised method to detect pre-stroke 
depression in the studies that were included in my systematic review, medical 
records may be a suboptimal means of assessment.  I hypothesised that our 
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chosen informant tool would be significantly more sensitive to pre-stroke 
depression than medical records.  My results are inconclusive in relation to this 
hypothesis due to a lack of statistical power; however, they are suggestive that 
medical records may lack sensitivity regarding ongoing pre-stroke depressive 
episodes, consistent with the results in chapter 4.   
 
Nevertheless, I would acknowledge that, while it is possible that medical records 
have a tendency to miss cases of ongoing pre-stroke depression, the observed 
specificity values were good and comparable to the GDS-SF.  Moreover, medical 
records are capable of identifying patients that do not exhibit ongoing (pre-
stroke) depressed mood, but who have a prior, historic diagnosis of depression.  
In the current evidence base, it is not clear that a previous, but dormant, history 
of depression is any less of a risk factor for post-stroke depression than recent 
(e.g. prior 6 months), or ongoing depressive episodes. (97, 142, 164)  Hence, 
such patients are likely also of clinical relevance.  I therefore do not envisage 
any circumstance where informant tools should be utilised as a replacement for 
medical records when screening for pre-stroke depression, but rather they could 
be a helpful supplement.  A larger study is necessary to confirm these 
speculations. 
 
5.4.3 Strengths and limitations 
I have conducted an inclusive study, following best guidelines for evaluating tool 
diagnostic test accuracy.  However, there are some important limitations to our 
study beyond those described in chapter 3, section 3.4.3.  
  
Most prominent is the lack of statistical power—a consequence of the limited 
patient numbers with depression in my sample.  This restricted the precision 
with which I could report the sensitivity rates of the respective assessment 
methods and prohibited any formal statistical sensitivity comparisons between 
the tools.  
 
Assessment order may have influenced overall diagnostic test accuracy 
evaluation as both tools’ diagnostic properties appear to have been influenced 
by this.  In fact, when the SADQ-H10 was administered first and the GDS-SF 
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second, I failed to find evidence that either tool performed statistically 
significantly above chance level (AUROC was not statistically significantly above 
0.5).   This poses serious questions regarding both tools’ general validity as 
measures of pre-stroke depression and limits the certainty of the statistically 
significant results we report in our primary analysis.  It is unclear why 
administration order would alter test accuracy to this extent and the result may 
be simply be a product of the reduced power in this particular analysis (only 41 
cases).  Regardless, this warrants further investigation and the possibility 
justifies incorporation of alternating administration order into this study’s 
design.   
 
In addition, the SADQ-H10 is designed to be administered 2 times for each 
patient with scores >5 for 2 consecutive weeks indicating depression.  In this 
study, informants were only required to complete the SADQ-H10 once; hence 
this tool was utilised in an unconventional way, beyond simply adopting a 
retrospective approach to assessment. 
 
Finally, the gold standard assessment was imperfect.  As in chapter 3, 
informants contributed to both questionnaire and interview-based assessment 
methods and it is unclear how much this may have biased diagnostic test 
accuracy results.  While informant assessment of cognition is often shown to be 
more reliable than patient self-report (181), it is less clear if this is also true of 
mood assessment in stroke.  There is therefore a particular potential for bias in 
patients with post-stroke aphasia where only the informant was able to take part 
in clinical interview.  Moreover, employing a retrospective approach to gold 
standard assessment whereby patients/informants were asked to recall mood in 
the 6 months leading up to the stroke is vulnerable to recall bias; and patients 
with pre-stroke cognitive or physical problems may experience mood issues 
differently to those without (182), which may have confounded the SCID 
interview in these cases.  
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5.4.4 Clinical implications 
It is yet to be established if pre-stroke depression assessment is a clinically 
beneficial practice. In theory, it could support tackling the burden of post-stroke 
depression.  
 
Post-stroke depression is prevalent (59) but often undiagnosed and inadequately 
treated; (68) therefore, post-stroke mood screening is recommended. (183, 184)  
However, recognition can be confounded by somatic issues that may be 
symptoms of the stroke or a consequence of hospital admission (e.g. fatigue, 
aches and pains, altered sleep).(185)  Some mood screening tools do not adopt 
somatic items for this reason (186-188) but most depression tools incorporate 
somatic items into their assessment (176, 189-191) and there is evidence that 
somatic items are among the best differentiators between stroke patients with 
and without depression. (192) 
  
Incorporation of a pre-stroke depression assessment to post-stroke mood 
screening may help to establish those patients who exhibited somatic symptoms 
before the stroke and hence help differentiate from patients only experiencing 
such symptoms post-stroke, potentially aiding depression diagnostic accuracy.  It 
could also elucidate those most likely to exhibit depression following stroke, 
highlighting patients suitable for preventative treatment—albeit this must be 
tempered with the potential risks of administering anti-depressant treatment in 
stroke.(193)  As typical barriers to mood screening include lack of knowledge 
and consensus for tool selection (194), my results should assist appropriate 
adoption of pre-stroke depression assessment in the acute stroke setting, if 
indeed this is established as a viable and useful practice.   
 
5.4.5 Future studies 
Validity is only one component in the makeup of the psychometric properties of 
pre-stroke depression informant questionnaires; feasibility, acceptability and 
reliability are also relevant. (78) 
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I offer some limited data on feasibility which suggests that, while missing data is 
relatively common (particularly in the GDS-SF), these questionnaires can still be 
completed in the vast majority of patients who have an informant available.  
However, acceptability may be compromised: almost half of GDS-SF assessments 
contained ‘don’t know’ responses, suggesting informants may struggle with 
evaluating a person’s pre-stroke mood, generally.  On this basis, adopting an 
informant approach to pre-stroke mood assessment may only be preferable when 
patient self-report assessment is not possible or deeply limited due to confusion 
or aphasia. Further work on the optimal method, wider psychometric properties, 
and benefits of pre-stroke depression assessment are required to clarify these 
outstanding queries.   
 
5.5 Conclusions 
In conclusion, informant tools appear to be a valid measure of assessing recent 
pre-stroke depression, albeit my data are limited by low power and some 
potential sources of bias and confounding that must be clarified before any firm 
conclusions can be made.  There is preliminary evidence that the GDS-SF may 
have greater diagnostic test accuracy for pre-stroke depression assessment than 
the SADQ-H10; but also, that the most commonly applied cut-points may not be 
optimal.  Consistent with my findings in chapter 4, medical records appear to 
miss cases of pre-stroke depression.  While I could not confirm statistically that 
the GDS-SF offers greater sensitivity, the substantial difference in sensitivity 
rates indicates that this may be the case.  This is a promising avenue for further 
research into pre-stroke depression assessment but requires a larger study 
sample for confirmation.   On the basis of our study limitations, I cannot draw 
any firm conclusions regarding the use of informant tools for assessment of pre-
stroke depression and encourage further research into this area. 
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Chapter 6. Pre-stroke modified Rankin Scale: 
evaluation of validity, prognostic accuracy and 
association with treatment. 
6.1 Introduction  
As well as clinical utility, robust measures of pre-stroke function are needed for 
psychological research.  Dementia diagnosis requires identification of problems 
in both cognition and everyday functioning.  As discussed in chapter 2, section 
2.3, pre-stroke functioning has been associated with post-stroke dementia risk, 
hence measuring pre-stroke function has relevance to understanding 
psychological problems in stroke; however, its importance stretches beyond this.  
It is often employed as exclusion criterion or case mix adjuster for trials and 
international registries.  (102, 195)  This approach recognises that even the best 
treatment is unlikely to improve function to better than the pre-stroke state.  
Pre-stroke disability may also have important prognostic utility, although data on 
this have been conflicting. (89, 109)  
 
While the need to describe pre-stroke function is apparent, the method of 
achieving this is less certain.  The modified Rankin scale (mRS) is a measure of 
global disability that is commonly used as a functional outcome for stroke 
studies,(196) and has also been used to evaluate pre-stroke disability 
levels,(197).  Pre-stroke mRS has been used extensively in research, audit and 
service planning. (102, 195, 198).  In practice, decisions on treatment are often 
based on premorbid function. (199) 
 
Use of pre-stroke mRS for these purposes is potentially problematic as the 
clinical properties of the pre-stroke mRS have not been as thoroughly 
investigated as traditional post-stroke mRS,(200).  While validation studies of 
pre-stroke mRS exist,(89) limited sample sizes leave questions around 
generalisability, and it is unclear to what extent reported predictive validity 
may be driven by differences in care-pathway. (109)  
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There is therefore a need for further validation work on the pre-stroke mRS and, 
based on the current usage of pre-stroke mRS, key questions emerge:  If pre-
stroke mRS is used to assess prevalent disability, is it a valid measure of this 
construct?  If pre-stroke disability is used as a component item in prognostic 
models, what is the independent contribution of pre-stroke mRS to outcome?  If 
pre-stroke mRS is associated with outcome, can this be explained by differing 
process of care? 
 
In this study, my collaborators and I aimed to use UK multicentre, clinical cohort 
to answer the above important and relevant research questions. Therefore, the 
specific aims of this study were: 
 
1) To assess the ‘validity’ of pre-stroke mRS by comparison with other 
related disability metrics. 
 
2) To assess association of pre-stroke mRS with short and longer term 
mortality prognosis in a ‘real world’ sample. 
 
3) To assess if pre-stroke mRS is associated with a differing process of care. 
 
6.2 Methods 
6.2.1 Population 
We used the data held in the Anglia Stroke Clinical Network Evaluation Study 
(ASCNES).  ASCNES was a multi-centre, prospective cohort study.  ASCNES 
collected clinical data from sequential stroke admissions across 8 acute NHS 
(National Health Service) trusts in the East of England, UK (Norfolk, Suffolk, and 
Cambridgeshire).  Data collection was from October 2009 to September 2011 
inclusive.  Data capture included a 1 year follow-up.  
  
The full details of ASCNES have been described previously. (201)  In brief, 
included patients were aged over 18 years, with stroke confirmed and 
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phenotyped by expert multidisciplinary clinical assessment.  Our population 
included both first ever stroke and recurrent stroke and all included patients 
were treated as per institutional practice and stroke guidelines.  Relevant 
institutional and ethical approvals for use of these data were in place.  
 
6.2.2 MRS assessment   
The ASCNES dataset was based on the modification of the Basic European Stroke 
Register Database but including process of care measures.  Data were collected 
by clinical staff and transferred to an electronic database.  Pre-stroke mRS was 
part of the initial assessment.  All mRS assessments (pre and post-stroke) were 
performed by clinical staff using an unstructured interview and based on history 
taken from patient whenever possible, or their significant others/carers.  The 
participating sites offered no explicit guidance on applying mRS grades as a pre-
stroke measure and final score was at the discretion of the assessor.  (see 
Appendix 13) 
 
6.2.3 Analyses  
We used basic descriptive statistics to describe baseline variables of included 
patients.  As pre-stroke mRS was a key variable we compared those with and 
without pre-stroke mRS against pre-specified variables of age, sex, NIHSS, stroke 
type (ischaemic or haemorrhagic), systolic blood pressure (BP), atrial fibrillation 
(AF), blood glucose and Oxford Community Stroke Project (OCSP) classification.  
 
6.2.3.1 Validity of pre-stroke mRS   
We described concurrent validity of pre-stroke mRS by comparison with other 
baseline clinical and demographic variables that are known to be associated with 
physical function.  Our chosen comparators were, age, co-morbidity burden 
assessed by Charlson comorbidity index,(202), mRS at discharge, pre-stroke 
residence (categorised as: Home, Sheltered housing, Rehabilitation Centre, Care 
home) and receipt of formal care pre-stroke (categorised as: lives alone, lives 
with family, external carers, sheltered housing, institutional care). 
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We described association of pre-stroke mRS with other variables using chi-square 
for proportional data and Spearman rank correlation for nominal data.  We re-
categorised pre-stroke residence as “own home” or other (comprising any form 
of institutional care) and calculated odds-ratios for each pre-stroke mRS grade.  
 
6.2.3.2 Association of pre-stroke mRS and outcomes  
We examined the association between pre-stroke mRS and selected outcomes 
which included mortality at 7 days and 1 year; length of stay (days); discharge 
destination (categorised as per our validity analyses) and post-stroke 
complications of pneumonia and urinary tract infection.  Due to modest numbers 
in pre-stroke mRS 4 and mRS 5, these categories were combined.  We calculated 
univariable associations between pre-stroke mRS and outcomes of interest with 
strength of association described as odds ratio (OR) or beta for length of stay 
data.  To compare pre-stroke mRS with other variables known to have prognostic 
importance we also described association with outcomes for age, sex, stroke 
type, modified early warning score (MEWS), glucose, AF and comorbidity.  We 
then calculated OR for pre-stroke mRS adjusted for other important prognostic 
variables (NIHSS, age, sex). 
 
6.2.3.3 Association of pre-stroke mRS and process of care  
To describe association between pre-stroke mRS and process of care, we 
selected three aspects of acute stroke care that should be standard, are 
recommended in guidelines and have been shown to have utility regardless of 
pre-stroke function.  Our chosen process of care markers were: assessment of 
swallow (in first 24 hours),(203); admission to dedicated stroke unit (SU) (days to 
SU admission from hospital admission and dichotomous yes/no),(204); brain 
imaging (days from admission to imaging and dichotomous yes/no),(205).  
Association of swallow test performed; admission to stroke unit and imaging 
performed with pre-stroke mRS was described for each factor using Mann-
Whitney, association with categorised time to stroke unit admission (days) and 
time to imaging (days) was described using Cuzik test for trend.   
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6.2.3.4 Subgroup analyses   
Recognising the difficulty in applying mRS to a population with no history of 
stroke we performed subgroup analyses, we described our validity and 
prognostic analyses comparing results for those with a previous history of stroke 
against first ever strokes.  Recognising that the wording of the lower mRS grades 
make them more difficult to use as a pre-stroke assessment, we performed a 
further subgroup analysis comparing those with pre-stroke mRS 0-2 to those with 
pre-stroke mRS 3-5.  Our dataset included patients admitted to University 
Teaching Hospitals and smaller ‘General’ Hospitals.  Sites could plausibly assess 
pre-stroke mRS differently depending on training, exposure to research and staff 
mix.   We tabulated pre-stroke mRS stratified by treating centre.  
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6.3 Results 
A total of 2491 patients with stroke were included in the ASCNES dataset.  The 
mean age was 76.4 years (SD, 13.1), 1311 (53%) were female; 2120 (85%) had 
ischaemic stroke.(Table 6-1)  
 
Pre-stroke mRS data was available for 2001 patients.  Median pre-stroke mRS 
was 0 (IQR, 0-2; range:0-5).  Most frequent pre-stroke mRS score was 0. (Table 
6-2)   Pre-stroke mRS data were missing for 488 (24.4%) of the sample.  There 
was no difference between those with and without mRS data for any of our pre-
specified variables, other than OCSP where those with more severe strokes 
(TACS) were more likely to have missing pre-stroke mRS data (<0.05).   Data was 
also missing for those with Atrial Fibrillation (AF) (308; 12.4%), Stroke type (51; 
2%) and Bamford classification (334; 13.4%).    
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Table 6-1. Summary descriptive statistics of ASCNES data 
 
Variable N Mean (SD) / 
median (IQR) 
Min  Max 
Age (years) 2487 76.4 (13.1) 18 101 
Pre-stroke 
Rankin 
2001 0 (0-2)  0(n=1027;51.3%)  5 (n=56; 
2.7%) 
MEWS┼ 2101 1.4 (1.3) 0 7 
NIHSS┼ 673 7 (3-14) 0 36 
Systolic BP 
(mmHg) ┼ 
2406 157.2 (30.5) 60 271 
Glucose 
(mmol/l) ┼ 
2136 7.6 (3.0) 1.4 40.2 
     
 N %   
AF     
  No 1469 59.0   
  Yes  714 28.7   
  Missing 308 12.4   
Stroke type     
  ICH 320 12.9   
  Infarct 2120 85.1   
  Missing 51 2.0    
Bamford     
  LACS 520 20.9   
  PACS 856 34.4   
  POCS 308 12.4   
  TACS 473 19.0   
  Missing 
 
334 13.4 
 
  
Sex     
   Female 1311 52.6   
   Male 1178 47.3   
MEWS= Modified Early Warning Score (scale of 0-6+; higher scores indicate 
greater concern for health based on cardinal vital signs; 1-3=low concern; 4 
or 5=medium concern; 6+=high concern); NIHSS= National Institute of Health 
Stroke Scale; BP=Blood Pressure; AF= Atrial Fibrilation; ICH= Intracerebral 
haemorrhage; ┼measured on admission. 
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Table 6-2. Frequency of pre-stroke mRS score 
 
Pre-stroke mRS rating Score frequency (%) 
mRS 0 1027 (51%) 
mRS 1 367 (18%) 
mRS 2 207 (10%) 
mRS 3 212 (11%) 
mRS 4 132 (7%) 
mRS 5  56 (3%) 
mRS= modified Rankin Scale 
 
 
6.3.1 Validity of pre-stroke mRS   
Of included patients, 1240 (49.8%) were living alone with no carers prior to 
admission.  Median Charlson comorbidity index was 5 (IQR, 4-6).  Age at time of 
stroke, discharge mRS, pre-stroke residence, pre-stroke care and Charlson 
comorbidity index were all associated with pre-stroke mRS (rho>0.40 for 
continuous variables, P<0.0001). (Table 6-3)   
 
Every point increase in pre-stroke mRS was associated with an increased 
association of living in institutional care pre-stroke.  For example, comparing 
pre-stroke mRS 0 and 5, odds ratio (OR) of institutional care pre-stroke was 73 
(95% Confidence Interval [95%CI]:37-143). 
 
On our subgroup analyses looking at those with previous stroke and those with 
lower pre-stroke mRS values, there was no clear and consistent difference 
between groups.  (Table 6-4) 
 
Inspection of pre-stroke mRS classification by treating centre suggested 
differential scoring at lower mRS grades between sites.  The large number of 
sites and modest number of participants in certain grades precluded formal 
comparative analyses. (Table 6-5)  
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Table 6-3. Association of Pre-stroke Rankin and other markers of function 
 
Factor Association p-value 
Age 0.40 (0.36,0.44)1 <0.0001 
mRS on discharge 0.50 (0.46,0.53)1 <0.0001 
Pre-stroke residence 995.52 <0.0001 
Pre-stroke formal care 
received 
761.12 <0.0001 
Charlson co morbidity 
index 
0.41 (0.37,0.44)1 <0.0001 
1 Spearman rank correlation coefficient (95% CI); 2 Chi-squared test (Degrees 
of Freedom=9). mRS= modified Rankin Scale 
 
 
Table 6-4. Association of Pre-stroke Rankin and other markers of function 
sub-grouped by previous stroke 
 
 
 
  
 All No Prev-
stroke 
Prev-
stroke 
mRS 0-2 mRS 3-5 
Factor Association 
Age 0.40 
(0.36,0.44)1 
0.42 
(0.38,0.46) 
0.24 
(0.15,0.33) 
0.30 
(0.25,0.34) 
0.00 *(-
0.09,0.10) 
mRS on 
discharge 
0.50 
(0.46,0.53)1 
0.47 
(0.43,0.51) 
0.54 
(0.47,0.61) 
0.32 
(0.27,0.36) 
0.34 
(0.25,0.42) 
Pre-stroke 
residence 
995.52 803.2 216.4 95.5 63.7 
Pre-stroke 
formal care 
received 
761.12 649.0 145.2 181.8 40.9 
Charlson 
comorbidity 
index 
0.41 
(0.37,0.44)1 
0.40 
(0.36,0.44) 
0.21 
(0.12,0.30) 
0.33 
(0.29,0.38) 
0.06 *(-
0.04,0.16) 
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Table 6-5. Pre-stroke mRS scoring by centre contributing data 
 
 Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Unit 7 Unit 8 
mRS 0 99 
(24.6) 
5 
(23.8) 
128 
(34.5) 
 368 
(52.6) 
148 
(46.3) 
153 
(54.8) 
126 
(50.8) 
mRS 1 68 
(16.9) 
5 
(23.8) 
76 
(20.5) 
 97 
(13.9) 
17 
(5.3) 
65 
(23.3) 
39 
(15.7) 
mRS 2 26 
(6.4) 
4 
(19.1) 
55 
(14.8) 
 61 
(8.7) 
17 
(5.3) 
20 
(7.2) 
24 
(9.7) 
mRS 3 24 
(6.0) 
2 (9.5) 39 
(10.5) 
 76 
(10.9) 
22 
(6.9) 
16 
(5.7) 
33 
(13.3) 
mRS 4 9 (2.2) 4 
(19.1) 
39 
(10.5) 
 38 
(5.4) 
12 
(3.8) 
10 
(3.6) 
20 
(8.1) 
mRS 5 0 (0.0) 1 (4.8) 8 (2.2)  26 
(3.7) 
9 (2.8) 6 (2.2) 6 (2.4) 
Missing 176 
(43.8) 
0 (0.0) 26 
(7.0) 
150 
(100) 
34 
(4.9) 
95 
(29.7) 
9 (3.2) 0 (0.0) 
Data are n (%) for each centre that contributed data to the database, unit 4 
did not contribute pre-stroke mRS data. 
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6.3.2 Association of pre-stroke mRS and outcomes 
Mean length of stay was 16 days (SD, 20).  Discharge to home, with no carers was 
recorded in 689 (28%); 400 (16%) were transferred from acute hospital to a 
rehabilitation facility.  One year mortality was 770 (31%); 7 day mortality 265 
(11%).  Of post-stroke complications, 288 (12%) developed pneumonia and 146 
(6%) urinary tract infection.  Every point increase in pre-stroke mRS was 
associated with greater numbers of poor outcomes for all our chosen outcomes.  
Strength of association was comparable to or higher than other known prognostic 
variables.  Associations held when corrected for other covariates.  For example, 
pre-stroke mRS score of 4 or 5 OR:6.84 (95%CI:4.24-11.03) compared to 0 in 
adjusted model. (See Appendices 14-19) 
 
On our subgroup analyses looking at those with previous stroke and those with 
lower pre-stroke mRS values, there was no clear and consistent difference 
between groups. (Table 6-6.) 
 
6.3.3 Pre-stroke mRS and processes of care   
Of 2383 patients with relevant data, 1674 (70%) had a swallow test performed; 
2287 (96%) had brain imaging, of whom 1520 (64%) were scanned within 24 
hours; and 1886 (79%) were admitted to a stroke unit of whom 1162 (49%) were 
admitted on the same day. There was a difference in pre-stroke mRS between 
those who received swallow assessment (p=0.04) and brain imaging (p=0.0003) 
but not admission to ASU (p=0.21). This difference favoured those with greater 
disability i.e. higher pre-stroke mRS was more likely to receive these evidence 
based aspects of care.  There was no apparent difference in time to stroke unit 
admission or imaging by pre-stroke mRS.  
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Table 6-6. Association between factors and death within 1 year (sub-grouped 
by previous stroke) 
 
 No previous stroke Previous stroke 
 Unadjusted Adjusted Unadjusted Adjusted 
 OR 
(95%CI) 
p-value OR 
(95%CI) 
p-value OR 
(95%CI) 
p-value OR 
(95%CI) 
p-value 
Age 1.08 
(1.07,
1.09) 
<0.001 1.04 
(1.02,1
.06) 
<0.01 1.06 
(1.04,1
.09) 
<0.001 1.05 
(1.01,1
.09) 
0.011 
Male 0.61 
(0.5,0.
74) 
<0.001 0.77 
(0.55,1
.07) 
0.117 0.78 
(0.55,1
.12) 
0.187 0.87 
(0.48,1
.56) 
0.635 
Pre-
stroke 
Rankin 
 Trend:<
0.001 
 Trend:<
0.001 
 Trend:<
0.001 
 Trend:<
0.001 
 
1 vs 
0 
1.96 
(1.43,
2.69) 
 1.58 
(1.03,2
.43) 
 3.15 
(1.69,5
.85) 
 3.86 
(1.62,9
.21) 
 
2 vs 
0 
2.74 
(1.86,
4.05) 
 1.77 
(1.06,2
.95) 
 2.82 
(1.45,5
.48) 
 2.52 
(1.06,5
.99) 
 
3 vs 
0 
5.82 
(4.02,
8.43) 
 3.56 
(2.12,5
.99) 
 4.48 
(2.33,8
.65) 
 4.14 
(1.79,9
.58) 
 
4 or 
5 vs 
0 
12.72 
(8.13,
19.9) 
 8.6 
(4.61,1
6.04) 
 10.21 
(5.31,1
9.64) 
 6.64 
(2.81,1
5.67) 
 
ICH 2.32 
(1.77,
3.03) 
<0.001 3.75 
(2.39,5
.89) 
<0.01 2.2 
(1.29,3
.76) 
0.004 5.22 
(2.27,1
1.98) 
<0.01 
MEW
-S 
1.32 
(1.22,
1.43) 
<0.001 1.18 
(1.05,1
.33) 
0.006 1.3 
(1.13,1
.49) 
 
<0.001 
1.18 
(0.97,1
.45) 
0.104 
Gluc-
ose 
1.08 
(1.04,
1.11) 
<0.001 1.06 
(1.01,1
.12) 
0.027 1.06 
(0.98,1
.14) 
0.136 1.07 
(0.97,1
.18) 
0.173 
AF 2.1 
(1.69,
2.61) 
<0.001 1.59 
(1.14,2
.22) 
0.007 1.88 
(1.28,2
.77) 
0.001 1.7 
(0.97,2
.99) 
0.065 
Charl
son 
inde-
x                  
1.39 
(1.32,
1.46) 
<0.001 1.19 
(1.1,1.
3) 
<0.01 1.28 
(1.16,1
.41) 
<0.001 1.15 
(0.97,1
.36) 
0.1 
OR= Odds Ratio; AF= Atrial Fibrillation; MEWS= Modified Early Warning Score 
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6.4 Discussion 
We sought to assess some of the key clinical properties of the pre-stroke mRS in 
order to address important questions as to its use in clinical research and 
practice.  According to our results, the pre-stroke mRS has a validity that is close 
to what is considered as fair (<0.5)(206), albeit in the absence of a true gold 
standard for pre-stroke function these analyses are open to interpretation and 
the correlation described may be acceptable.  Pre-stroke mRS is a potential tool 
for predicting prognostic outcome following stroke and the relationship between 
pre-stroke mRS scores and prognosis is not related to variations in patient care 
pathways.   
 
Arguably the most important property of pre-stroke mRS is validity; the scale is 
of little utility if it does not measure what it purports to measure.  We assessed 
concurrent validity and found that the pre-stroke mRS demonstrated significant, 
associations with all our chosen measures that should reflect pre-stroke 
disability.  Although significant, the correlation we demonstrated was at best 
moderate in strength.  This finding is similar to that of Fearon et al., (2012)(89) 
who found moderate correlations between pre-stroke mRS and pre-stroke 
comorbidity and frailty but not pre-stroke care needs.  Although there are 
concerns that pre-stroke mRS may not be suited to first stroke events or those 
with good function pre-stroke, our subgroup analyses did not find any convincing 
evidence of this.  Our results should reassure clinicians and researchers that pre-
stroke mRS does capture pre-stroke function, but the moderate associations 
suggest there may be scope for further improvement.    
 
Our results demonstrate that the pre-stroke mRS is a potential prognostic 
indicator.  Although pre-stroke mRS is widely accepted to be an indicator of 
prognosis, there has been very little published work to confirm this. We found 
that as the pre-stroke mRS score increased, patients were more likely to 
experience negative outcomes and this pattern was consistent across all of our 
chosen outcome measures (LOS, discharge destination, mortality & 
complications after stroke).  Furthermore, the strength of association of the pre-
stroke mRS with each outcome variable was comparable or greater than that of 
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all of our other prognostic variables, suggesting that the prognostic utility of 
pre-stroke mRS is at least as strong as other commonly used indicators of 
prognosis.  These findings are broadly consistent with those of Kwok et al., 
(2012)(109) who also found that pre-stroke mRS was a robust predictor of post-
stroke outcome, as measured by mortality and length of stay.  Our findings also 
extend the prognostic predictability of the pre-stroke mRS to that of eventual 
discharge destination and the prevalence of complications post-stroke.   
  
Importantly, we also found that the association between pre-stroke mRS and 
outcome cannot be explained by differing process of care.  Specifically, our 
results reveal that while there is a difference in the process of stroke care 
associated with pre-stroke mRS, this difference indicated that individuals who 
had higher pre-stroke mRS scores were more likely to be provided with access to 
evidence based stroke care.  For instance, significantly more patients with 
higher pre-stroke disability scores received a swallow assessment and brain 
imaging; while there was no difference found in regards to pre-stroke mRS and 
time taken for admission to a stroke unit or for brain imaging. If anything, the 
pattern of care is likely to have reduced the association between pre-stroke mRS 
and outcome.  It is therefore reassuring that the relationship between pre-stroke 
mRS and outcome appears to be based purely on the effect of premorbid 
disability on the overall impact of the stroke.  Our data did not allow for more 
sophisticated analyses looking at hospital level confounders such as teaching 
hospital versus non-teaching hospital or staffing levels.  
   
While our results suggest that the pre-stroke mRS has moderate validity as a tool 
for measuring pre-stroke function, more work is required on this property.  
Confidence in the ability of the pre-stroke mRS to detect premorbid disability is 
low and Bruno and Switzer (207) have gone as far as to say that the pre-stroke 
mRS is not fit for purpose in this regard.  Future studies that focus on comparing 
the pre-stroke mRS with a more detailed assessment of pre-stroke function 
would help to resolve this question of validity.   
 
Our study had a number of strengths.  We had a large participant pool that 
allowed a multitude of comparisons between variables enabling revealing 
insights into the clinical properties of pre-stroke mRS.   Our sample was also 
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taken from a ‘real world’ patient pool of consecutive, unselected stroke 
admissions, providing good generalisability of our results to the wider 
population.   
 
However, I acknowledge some limitations of our study.  Most notably, around 
20% of our sample did not have pre-stroke mRS scores.  Further analyses 
revealed that there were no significant differences of characteristics in the 
missing-data group compared with the data-intact group with the exception of 
stroke-type.  Missing mRS data were more common for the severe stroke types 
(TACS & PACS).  For a clinical registry, this pattern of missing data is not 
surprising.  The more severe strokes will be less able to engage in assessments of 
pre-stroke status.  Although these missing data create a potential bias, the 
effect is likely to have reduced the associations between pre-stroke mRS and 
outcome, rather than exaggerated it.  Furthermore, the internal relationship 
and effect sizes observed between pre-stroke mRS and other measures are not 
affected by missing data.   I acknowledge that we have no detail on how pre-
stroke mRS was applied at each site.  In the absence of explicit guidance on 
scoring, there is the potential for inter-rater variability in pre-stroke mRS.  
However, potential for variation in scoring is an issue for mRS per se,(108) and 
our data will reflect the way in which pre-stroke mRS is currently used in clinical 
practice, giving our results ‘real world’ validity.   Finally, our validation analysis 
is limited by an imperfect reference standard: constructs such as place of 
residence are a blunt indicator of functional status.   
 
In our analysis of the pre-stroke state we were limited to those assessments that 
had been routinely collected in our dataset.  We did not have comprehensive 
data on potentially important covariates such as NIHSS.  There is no single 
screening tool that will perfectly describe global functional ability.  Assessments 
scales such as the Informant Questionnaire for Cognitive Decline in the Elderly 
(76) and Barthel Index (208) have been used to capture pre-stroke cognitive and 
physical ability and it is unfortunate that these data were not routinely collected 
during the period of our study.  Nonetheless, in the absence of a clear ‘gold 
standard’ of pre-stroke function, the correlations with all of our measures in 
combination provides us with confidence in our validation method.   
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Based on our findings I offer guidance for clinicians and researchers.  As a 
standard mRS is only a moderately valid measure of pre-stroke function, I would 
caution against using this as the sole criterion for assessing suitability for 
research or for interventions.  To try and improve consistency I would 
recommend following published guidance and best practice in 
assessment.(106)  A more comprehensive assessment of pre-stroke function 
could include measures of ability to perform activities of daily living and 
cognitive function.  These assessments need not necessarily add substantial time 
to assessment, for example a short form Barthel Index for use in stroke has been 
described.(208) I would encourage greater use of pre-stroke measures in clinical 
practice, our data on the prognostic utility of mRS reminds us of the importance 
of considering the pre-stroke state.  
 
There are plausible methods to improve the validity of pre-stroke assessment, 
and future research could focus on these areas.  If we continue to use mRS, 
there may be scope to further operationalise the assessment.  Structured 
questionnaire approaches to mRS have been described (209) and a similar 
approach to pre-stroke mRS could have utility.  As mRS was never designed as a 
tool to measure pre-stroke function, perhaps we should move to a more relevant 
measure.  There is increasing interest in tools to describe frailty (118) and these 
may have particular utility in an older adult stroke cohort. 
 
6.5 Conclusions  
In conclusion, we have assessed the prognostic predictability of the pre-stroke 
mRS and its validity as a measure of pre-stroke function.  In combination, these 
results highlight that the pre-stroke mRS can reliably be employed as a tool to 
assist clinicians in service delivery and planning.  We found that the pre-stroke 
mRS is a moderately valid measure of pre-stroke disability and a robust predictor 
of post-stroke prognosis.  In combination, these results highlight that the pre-
stroke mRS can reliably be employed as a tool to assist clinicians in service 
delivery and planning.  The robust nature of the relationship between pre-stroke 
mRS and a number of different outcomes suggests that the pre-stroke mRS not 
only gives an insight into likely mortality or duration in hospital, but may also 
predict the probability that patients will need to be taken into care post-stroke, 
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as well as potential post-stroke complications experienced during the recovery 
period.  Importantly, the prognostic accuracy of the pre-stroke mRS does not 
appear to be related to any variation in the process of care.  Thus, prognostic 
models of stroke which incorporate pre-stroke mRS are likely to have potential 
for future clinical implication.  
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Chapter 7. The prevalence of frailty amongst acute 
stroke patients, and evaluation of method of 
assessment. 
7.1 Introduction 
Stroke and frailty are prevalent conditions in the elderly and are associated with 
mortality, long-term hospitalisation, and disability.(11, 210-214)  Frailty 
assessment is increasingly being incorporated into routine practice in the acute 
care setting.(215)  As I highlighted in chapter 2, section 2.4, frailty may have a 
relevance to our understanding of cognition in stroke.  However, the prevalence 
of frailty and methods for frailty assessment are largely unstudied in the acute 
stroke population. Moreover, as discussed in chapter 6, pre-stroke function is 
often utilised in stroke trials and for assessing suitability for aggressive 
treatments in stroke; yet, my findings suggest that the pre-stroke mRS is a 
limited method for assessing pre-stroke function, and assessment of frailty may 
be a more relevant measure for these purposes.  Hence, establishing frailty 
prevalence and validation of assessment is of importance in stroke.    
 
There are variable methods of frailty assessment, depending upon the definition 
applied.  A Frailty Index can be calculated as a measure of cumulative deficits. 
(119) Alternatively, the frailty phenotype can be detected via self-report 
questionnaire. (120) 
 
I aimed to describe the prevalence of pre-stroke frailty in a ‘real world’ acute 
stroke setting and validate a commonly used method for determining frailty 
status.  My primary focus was frailty assessment using the Rockwood Frailty 
Index approach. I then assessed concurrent, predictive and convergent validity 
of the Frailty Index.  To allow comparison, I also assessed frailty as measured by 
a phenotypic (Fried) approach and using the mRS as a pre-stroke disability 
assessment. 
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7.2 Method 
I conducted a secondary analysis of prospectively collected, cross-sectional, 
anonymised patient level data contained within the Glasgow Royal Infirmary 
patient database.  Full NHS research ethics approval was granted for this project 
(ws/16/0001).  The design, conduct and reporting of this study was informed by 
the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) (216) and STROND (Standards of Reporting of Neurological 
Disorders) guidance. (217)  
 
7.2.1 Setting and population 
I recruited patients consecutively admitted to the acute stroke unit at a single 
urban teaching hospital.  The unit is part of a nationally funded healthcare 
service and admits all stroke and transient ischaemic attack (TIA) patients and 
operates no exclusions around age, disability or comorbidity.   
 
Patient recruitment occurred from May 2016 to Aug 2018.  All patients with 
stroke or TIA were included. Ethical approvals allowed for inclusion of patients 
who were unable to consent to assessment. 
 
7.2.2 Clinical and demographic information 
Clinical and demographic data were collected for each patient at point of 
assessment by trained researchers. Assessments occurred on day of admission up 
to 7 days after admission.   Data collected were a mix of prospective assessment 
and retrospective chart review.  Pre-stroke functioning was established using 
mRS;(218) where a cut-off of ≥2 was used to define disability. In addition, stroke 
severity was determined by National Institutes of Health Stroke Scale 
(NIHSS);(130) delirium was assessed via the ‘4A Test’ screening tool 4AT 
(www.the4AT.com); a cut-off of ≥4 was used to define a positive screen for 
delirium.  Pre-stroke cognition was determined via medical history (prior 
diagnosis of mild cognitive impairment or dementia) and, where possible, 
informant assessment via the informant section of the Geriatric Practitioner 
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assessment of Cognition (GPCOG)(219) utilising a cut-off score of ≥3 (out of 6) as 
indicative of previous cognitive impairment.  Age, medication count, and pre-
stroke care-home residence were established via medical notes.   
 
7.2.3 Pre-stroke frailty assessment 
I utilised two methods for assessment of pre-stroke frailty; one conformed to the 
Rockwood accumulated deficits concept, the other to the Fried ‘frailty 
phenotype’ model. Based on the former, a 33-item Frailty Index was created 
according to recommended guidelines.(122)  (see Appendix 20)  Patient medical 
records were used to identify medical conditions present before the stroke.  
Frailty Index scores were then generated for all patients by two researchers (MT 
and GC).  I created a list of 33 frailty indicator conditions, symptoms or 
problems.  The Frailty Index was created by dividing the number of pre-specified 
conditions on our list that were present before the stroke by the total number of 
conditions defined in the index list (i.e. 33).  Thus, possible scores ranged from 
0.0-1.0, with scores closer to 1.0 suggesting greater frailty. If multiple instances 
of a medical condition were present (e.g. multiple falls, multiple diagnoses of 
cancer), these would be scored once and once only (i.e. a patient with a medical 
history consisting of 1 previous fracture and 2 previous diagnoses of cancer 
would generate a score of 2/33, not 3/33).   Patients were categorised as 
‘robust’, ‘pre-frail’ and ‘frail’ using recommended cut-points of <0.08; 0.08-0.24 
and >0.24, respectively.(220)    
 
An assessment of Fried phenotype frailty was added to the prospective dataset 
after first wave data collection was complete.  I used the self-report ‘Frail non-
Disabled’ questionnaire.(221) (see Appendix 21)   This frailty assessment method 
was introduced to complement (and did not replace) the Frailty Index 
assessment method.  Patients were categorised as frail if they and/or a proxy 
reported any one of the following: unintentional loss of more than 4kg of weight 
over the previous year; self-reported exhaustion for more than two days in the 
week before admission; less than 4 hours of physical activity over a 2-week 
period before admission.  Patients who could not fully complete the self-report 
Frail non-Disabled questionnaire for any reason (e.g. unconscious, too confused, 
severely aphasic) were deemed non-testable.   
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7.2.4 Analyses 
For analysis of prevalence of pre-stroke frailty, I performed a sample size 
calculation based on the formula: 
     
𝑁 =
(𝑧2)𝑃(1 − 𝑃)
𝑑2
 
 
Where N represents the sample size; z is the z-statistic for the level of 
confidence (1.96); P is the expected prevalence (0.15); and d is the allowable 
error (0.05).  
 
I required a minimum of 196 participants to give us an estimate of prevalence 
with 95% confidence. 
  
I described prevalence of ‘frailty’, ‘pre-frailty’ and ‘robust’ status based upon 
observed percentages within the population; confidence intervals were 
generated for each prevalence estimate via z-tests.  As Frail non-Disabled 
questionnaire data were only available for a proportion of patients, I conducted 
a post-hoc logistic regression analysis with Frail non-Disabled 
(testable/untestable) as the dependent variable and stroke severity (NIHSS 
score) as the independent variable to examine cause of missing frailty phenotype 
data.  
  
To evaluate the Frailty Index as a measure of frailty in stroke I conducted a 
series of validity assessments.  I assessed concurrent validity by exploring 
associations between Frailty Index and a series of factors plausibly related to 
frailty: age, sex,(222) number of medications, pre-stroke cognitive impairment 
and care home residence.  I used Spearman’s correlation for continuous 
variables and Chi-square for dichotomous variables.   
 
I assessed predictive validity of the Frailty Index as a measure of pre-stroke 
frailty based on associations with a common complication of stroke that frail 
patients are typically vulnerable to—post-stroke delirium.  I used a logistic 
regression analysis with incident delirium as the dependent variable and score 
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on Frailty Index as the independent variable.  As frail patients are generally 
vulnerable to acute stressors, I also examined if pre-stroke frailty was associated 
with stroke severity (NIHSS) using linear regression analysis with score on NIHSS 
as the dependent variable and Frailty Index as the independent variable. I then 
used multiple regression analyses, controlling for age, sex, and number of 
medications to further explore the associations between scores on the Frailty 
Index and delirium and stroke-severity. All variables were forced into the 
regression model. 
 
I assessed convergent validity describing Chi-square correlation between Frailty 
Index (dichotomised: frail/non-frail), phenotypic frailty (dichotomised: 
frail/robust) and pre-stroke modified Rankin Scale (dichotomised: disabled/non-
disabled).  I also explored agreement between the measures using Kappa 
statistics; and overlap in frailty assessment results were compared for the 
differing frailty measures via 2x2 tables and Venn diagram. 
 
I used SPSS statistics for Windows, version 24.0, Armonk, NY: IBM Corp, for all 
analyses.   
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7.3 Results 
Five-hundred-forty-six patients were included.  Population descriptive statistics 
can be seen in Table 7-1. 
 
Table 7-1. Population demographics 
 
 (Total included=546) 
Age (Years) 
(Mean; S.D.) 
69 (14) 
Sex (Male) 
(Number; %) 
290/540 (54%) 
National Institutes for Health Stroke 
Scale  (Median; IQR) 
3 (1-5) 
Pre-stroke modified Rankin Scale ≥2 
(Number; %) 
216/524 (41%) 
Pre-stroke cognitive impairment   
(Number; %) 
49/277 (18%) 
Pre-stroke medication count 
(Median; IQR) 
7 (4-10) 
Pre-stroke care-home resident 
(Number; %) 
21/546 (3.8%) 
Post-stroke delirium*  
(Number; %) 
138/523 (26%) 
*Diagnosed based on stroke physician impression guided by the ‘4 A’s test’ 
using cut-point of ≥4. S.D.= Standard deviation; IQR=Interquartile range. 
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7.3.1 Frailty prevalence 
Frailty Index data were available for 545/546 (99.8%) patients of whom 151/545 
(28%; 95% Confidence Intervals [CI]:24%-31%) were frail according to Frailty 
Index. A further 276/545 (51%) were pre-frail and 118/545 (22%; 95%CI:46%-55%) 
were robust.  Median Frailty Index score was 0.18 (Inter Quartile Range 
[IQR]=0.09-0.26). 
 
Phenotypic frailty data were available for 258/347 patients; 89/347 (26%) 
patients’ full data were missing due to inability to complete the Frail non-
Disabled questionnaire.  Of patients with data available, 72/258 (28%; 95%CI= 
23%-34%) were frail.  My post-hoc logistic regression analysis indicated that more 
severe strokes were associated with non-completion of the Frail non-Disabled 
questionnaire (Odds Ratio [OR]=1.21, 95%CI=1.13-1.29; p<0.01).  
 
 
7.3.2 Concurrent validity 
Frailty Index scores were significantly associated with all pre-specified pre-
stroke variables.   Specifically, older patients, women, patients on higher 
numbers of medication, patients with pre-stroke cognitive impairment, and 
patients in a care home had significantly higher Frailty Index scores.  Strength of 
correlations are described in Table 7-2. 
 
7.3.3 Predictive validity 
Frailty Index was significantly associated with both the NIHSS (Unstandardised 
Beta=0.085, 95%CI=0.046-0.125; p<0.01) and incident delirium (OR=1.06, 
95%CI=1.04-1.08; p<0.01) on univariate analysis.  Specifically, as Frailty Index 
scores increased so too did NIHSS scores and odds of delirium.  However, after 
controlling for age, sex and medication count, the associations were no longer 
significant. (Table 7-3) 
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Table 7-2. Correlations between pre-stroke variables and Frailty index 
 
Variable Frailty Index 
(Mean score) 
Correlation 
(X2/Rho; p-value) 
Sex (Female)  0.19 
9.19;<.0.01* 
Sex (Male) 0.16 
Pre-stroke care-home 
resident (Yes) 
0.31 
30.92;<0.01* 
Pre-stroke care-home 
resident (No) 
0.17 
Pre-stroke cognitive 
impairment (Yes) 
0.25 
15.92;<0.01* 
Pre-stroke cognitive 
impairment (No) 
0.18 
Age (Years) NA 0.54; <0.01# 
Medication count 
(Number) 
NA 0.58; <0.01# 
*Analysed via Chi-square test (frailty dichotomised at >0.24); #Analysed via 
Spearman’s Rho test (Frailty as continuous scale).   
 
 
Table 7-3. Regression analysis of the association of the Frailty Index with 
stroke severity (NIHSS) and odds of post-stroke delirium onset 
 
Regression 
variable 
NIHSS 
(Beta)* 
(p) 
Delirium 
(OR; 95%CI)% 
(p) 
Frailty Index 
(Score) 
0.09 0.21 
1.03 (1.00-
1.05) 
0.05 
Age  
(Years) 
0.21 <0.01 
1.06 (1.04-
1.08) 
<0.01 
Sex 
(Female) 
-0.01 0.92 
0.86 (0.54-
1.37) 
0.53 
Medication 
count 
(Number) 
0.01 0.93 
1.01 (0.94-
1.71) 
0.85 
*Linear regression; %Logistic regression. All variables were forced into the 
model.  NIHSS = National Institutes of Health Stroke Scale. Frailty entered as 
continuous variable. 
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7.3.4 Convergent validity 
For the 258 patients with Frail non-Disabled questionnaire data available, the 
Frailty Index demonstrated a moderate positive correlation with the Frail non-
Disabled questionnaire (X2=15.76; Cramer’s V=0.25).  Similarly, for the 524 
patients with pre-stroke modified Rankin scale data available, the Frailty Index 
demonstrated a moderate correlation with the pre-stroke modified Rankin scale 
(X2=116.55; Cramer’s V=0.47).  
  
There was only slight agreement between Frailty Index and phenotypic frailty 
(kappa=-0.06) with just 16/81 (20%) frail patients categorized as frail on both 
frailty measures. (Table 7-4) For Frailty Index and pre-stroke modified Rankin 
Scale, agreement was moderate (kappa=0.45) with 110/216 (51%) patients 
classified as disabled according to pre-stroke modified Rankin Scale also 
classified as frail according to the Frailty Index.  There was only slight 
agreement between phenotypical frailty and modified Rankin Scale (kappa=-
0.02) with 28/68 (41%) patients classified as phenotypically frail being classified 
as disabled according to the mRS. (Figure 7-1)  
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Figure 7-1. Frailty and disability overlap based on method of assessment 
 
 
 
 
Table 7-4: Agreement between frailty/disability measures 
 
 Frailty Index  Frail non-
Disabled 
questionnaire 
Modified Rankin 
Scale 
Frailty Index   86 281 
Frail non-
Disabled 
questionnaire 
16  78 
modified Rankin 
Scale 
110 28  
White cells correspond to frailty positive comparisons; grey cells to frailty 
negative comparisons.  
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7.4 Discussion 
7.4.1 Prevalence 
I sought to investigate the prevalence of frailty in stroke.  I found that almost 
80% of patients admitted to an acute stroke unit were either frail or pre-frail 
according to Frailty Index criteria.  Both the Frailty Index and frailty phenotype 
approach gave respective prevalence rates of 28%.  These rates contrast with 
the 14% rate reported within a non-stroke hospital population and the 11% 
prevalence reported in community settings.(114, 223)  My results suggest that 
frailty presents a particularly significant burden in stroke, beyond what is 
typically observed in undifferentiated older adult populations.  The pre-frail 
categorisation is contentious, but that more than half of our sample were 
considered pre-frail before the stroke is particularly relevant.  These patients 
may be at risk of becoming frail following stroke, with the stroke event pushing 
many across a threshold from ‘pre-frail’ to ‘frail’ status.   
 
 
7.4.2 Frailty assessment 
There are different ways to measure frailty.  I chose to primarily evaluate the 
Frailty Index approach as this has been well validated in other acute settings and 
is being adopted in acute care settings; I also anticipated that it would be 
available for the majority of stroke admissions.  My intention was not to create a 
novel tool, rather I operationalised a Frailty Index using the same process that 
was used to develop the electronic Frailty Index that is being introduced in NHS 
England.(121)   
 
Concurrent validity analyses was reassuring, confirming Frailty Index associations 
with variables previously demonstrated to be associated with frailty (age, sex, 
medication count, pre-stroke cognitive impairment and care-home 
residence).(220, 223-225) The core concept in frailty is vulnerability to an acute 
stressor, with adverse outcomes when the person is exposed to acute illness or 
other insult.  In this regard, my assessment of the association of frailty and 
incident delirium offers the most compelling validation, as delirium is considered 
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an exemplar manifestation of the frailty state, albeit this association did not 
hold after controlling for additional variables. 
 
Comparative analyses suggest that method chosen for assessing frailty in stroke 
is important.  There were only modest correlations between the Frailty Index, 
the phenotype measure and pre-stroke modified Rankin Scale.  Similar 
correlations were found by Rockwood’s group in an earlier paper.(220)  Although 
prevalence rates suggested by our two frailty measures were similar, there was 
little agreement regarding which patients were classified as frail: only 20% of 
frail patients were categorised as such by both frailty measures and kappa based 
measures of agreement were little better than chance.  These findings may be 
partly explained by non-completion bias for the phenotype measure, although 
previous studies have also highlighted issues with frailty identification based 
upon definition and assessment methods used.  As few as 9.4% of frail patients 
were categorised as such by both a frailty phenotype and Frailty Index measure 
in one study;(226) while others reported that 30% of patients categorised as frail 
by an Frailty Index were categorised as ‘robust’ according to a Fried phenotype 
measure.(224)  This lack of agreement likely reflects the differences in the 
respective concepts of frailty that are applied by our two measures.  My analyses 
were not designed to suggest a favoured approach to frailty assessment.  An 
important assessment in this regard would be to compare post-stroke outcomes 
according to frailty defined using differing models and this could be the basis for 
future research around stroke and frailty.   
 
7.4.3 Strengths and limitations 
This is a highly inclusive study with sequential recruitment involving patient 
groups (e.g. aphasic, acutely unwell, physically disabled, cognitively impaired) 
that are typically excluded from stroke studies.  I have also incorporated frailty 
measures assessing the two predominant frailty concepts.   
 
However, there are some important limitations to this study.  First of all, while 
inclusive, the population was restricted to a single urban teaching hospital that 
admits a largely socioeconomically deprived and Caucasian population.  As such, 
the observed frailty prevalence rates may not be generalisable to settings with a 
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very different case-mix.(227) The measure of the frailty phenotype may be more 
indicative of frailty symptoms rather than full phenotypical frailty per se.  
Moreover, this measure was introduced during study recruitment and could have 
been biased by missing data.  Finally, comparisons between ‘phenotypic’ and 
‘cumulative deficits’ frailty models should recognise that the two measures were 
never designed to be equivalent.  The Frail non-Disabled scale is intended to be 
used as a screening tool and its properties will differ from a Frailty Index, which 
is said to be diagnostic.   
 
7.4.4 Clinical and research implications 
The timely, accurate and acceptable identification of frailty in practice is a 
current clinical priority.(228-230) Advances have been made in frailty 
assessment in community, care-home and older adult secondary care settings, 
but it is equally important to determine the most suitable methods of assessing 
frailty in stroke.  My results are not definitive and further epidemiological and 
validation work around frailty assessment and stroke is required.  While it would 
be premature to make recommendations around practice or policy based on our 
data, I can offer cautious suggestions. The high prevalence of frailty and pre-
frailty reminds us that vulnerable, older adults are core business in stroke-care.  
There is a danger that this may be forgotten in the move towards increasingly 
aggressive interventional strategies for acute stroke.  The relationship of frailty 
with the complication of incident delirium may suggest that a brief frailty 
assessment could become part of the initial ‘work-up’ in stroke.  This would 
mirror changes in practice in other healthcare settings where front-door frailty 
screening is being introduced.  
 
My results have implications for research.  Pre-stroke modified Rankin Scale is 
often used as exclusion criterion or case-mix adjustor in stroke trials.  The 
modified Rankin Scale was never designed for this purpose and, as suggested in 
chapter 6, it may not be the best measure as it may both under and over-
estimate function. Using a simple measure of frailty as a baseline measure in 
trials could improve efficiency and our data suggest that assessing a Frailty Index 
is relatively simple in an inpatient stroke population. 
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7.4.5 Future directions 
Future studies of frailty in stroke should offer longitudinal follow-up to 
determine the longer-term prognostic validity of frailty measures.  Frailty has 
previously been associated with long-term prognosis in older adult 
populations.(231)  It is highly likely that this will also be the case in the stroke 
population; hence, this is an important area for future research.  Finally, this 
work suggests that different tests of frailty may be assessing differing 
constructs.  We now need more comparative studies of the different frailty 
measures (and concepts) when used in the stroke population.   
 
7.5 Conclusions 
The prevalence of frailty in acute stroke is substantial; the condition appears to 
exist, before the stroke occurs, in around one in every four patients, or around 
three out of every four patients if pre-frailty is included.  Identification of frailty 
may be influenced by assessment method employed.  My results suggest that the 
Frailty Index approach is valid for use in stroke and can be employed for 
assessment of almost all stroke patients; albeit, it has limited agreement with 
other measures of frailty.  More research is needed to describe the optimal 
method of assessing frailty and the prognostic and treatment implications when 
a frailty diagnosis is made in stroke.   
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Chapter 8. Investigating the risk association 
between pre-stroke frailty and acute post-stroke 
cognition. 
8.1 Introduction 
In order to understand the aetiology of post-stroke cognitive impairment it is 
important to identify pertinent risk factors. 
 
Frailty has been associated with development of cognitive impairment (232), 
delirium (113) and vascular dementia (233) in non-stroke populations.  As 
discussed in chapter 2, section 2.4 there are reasons to expect that frail patients 
may experience greater cognitive impairment following stroke than non-frail 
patients.   
 
Specifically, the Rockwood ‘accumulated deficits’ concept, proposes that frailty 
arises from the increasing burden of age-related medical conditions that accrue 
over the life-time. (111)  This accumulation may lead to a state of physiological 
exhaustion and impaired repair mechanisms, thus limiting the body and brain’s 
ability to respond to, and minimise the damage of, further stressors.(116)   As 
stroke is a cognitive stressor, the state of vulnerability induced by frailty may 
heighten the cognitive consequences experienced by patients in the aftermath 
of the event.   
 
Having established in chapter 7 that pre-stroke frailty is prevalent and can be 
identified in most patients using the Frailty Index approach, I therefore sought 
to assess the relationship between pre-stroke frailty and post-stroke cognition in 
the acute period following stroke (see Figure 8-1).  It is possible that any 
association between frailty and post-stroke cognition may be accounted for by 
differences in confounders such as age, pre-stroke cognitive impairment, and 
onset of delirium.  I aimed to investigate if an association between frailty and 
post-stroke cognition was independent of these and other variables that are 
typically associated with post-stroke cognitive impairment.   
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I hypothesised that pre-stroke frailty would be significantly associated with 
lower post-stroke cognition and that this association would be independent of 
other well-established moderators of post-stroke cognitive impairment. 
 
Figure 8-1. The aetiology of acute cognitive impairment following stroke is 
yet to be fully determined.     
 
 
 
8.2 Method 
I conducted a cross-sectional study, using the Glasgow Stroke Research Database 
(GSRD).  The GSRD allows collection of anonymised patient level data and has 
full research ethics approval (ws/16/0001).   
 
I followed guidelines proposed by Riley et al., (2009) (234) regarding prognostic 
factor research related to the design, conduct and analysis of this study.  I 
followed STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) guidance for reporting. (235)  The protocol for this study was 
registered at Research Registry (UIN: researchregistry2712). 
 
8.2.1 Setting and Population 
I utilised the population described in chapter 7 section 7.2.1 However, at the 
time this study was conducted, recruitment was still ongoing; hence only 
patients admitted between May 2016 and December 2017 were included.   
Moreover, this study had further inclusion/exclusion criteria to that described in 
chapter 7 section 7.2.  Specifically, to be included in analysis patients required a 
stroke diagnosis confirmed by a stroke clinician and a cognitive assessment 
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within seven days post-stroke.  I did not exclude any patients based upon age or 
presence of aphasia, dysarthria, previous cognitive impairment or physical or 
sensory disability.  However, patients were excluded from analyses if they had a 
TIA or non-stroke diagnosis or were unable to fully complete the cognitive 
assessment for any reason.   
 
8.2.2 Clinical and demographic information 
As described in chapter 7, clinical and demographic information was collated for 
each patient by trained researchers via patient self-report and medical records.   
Stroke diagnosis and stroke-type (using Oxford Community Stroke Project 
(OCSP)) (48) was confirmed by a stroke consultant.  Stroke severity was derived 
via National Institutes for Health Stroke Scale (NIHSS); where the NIHSS had not 
been completed, scores were generated via retrospective review of medical 
charts (130).   Although retrospective review of medical charts is not the optimal 
means of establishing an NIHSS score, it has been established to be a valid, 
reliable means of assessment. (131, 236) 
   
Delirium was assessed via the ‘4A Test’ screening tool 4AT (www.the4AT.com); a 
cut-off of ≥4 was used to define a positive screen for delirium.  Pre-stroke 
cognition was determined via medical history (prior diagnosis of mild cognitive 
impairment or dementia) and, where possible, informant assessment via the 
informant section of the Geriatric Practitioner assessment of Cognition (GPCOG) 
(219) utilising a cut-off score of ≥3 (out of 6) as indicative of previous cognitive 
impairment. 
 
8.2.3 Cognitive assessment 
All patients admitted to the acute stroke unit also underwent a short cognitive 
assessment utilising a mini-Montreal Cognitive Assessment (MOCA) to generate a 
total score out of 12 points. (127) Higher scores indicate better cognition.  The 
assessment covered the cognitive domains of episodic memory (5-word recall), 
visuospatial and executive functioning (clock draw), language (verbal fluency 
test) and orientation (date).  (see Appendix 4) 
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8.2.4 Pre-stroke Frailty assessment 
I used the Frailty Index, as described in chapter 7, section 7.2.3, for pre-stroke 
frailty assessment. 
 
8.2.5 Statistical analysis 
I used bespoke software (G-Power, version 3.1; (237)) to inform a sample size 
calculation for multiple linear regression.  Based on inclusion of 8 important 
independent variables, a clinically useful, moderate, effect size of F2= 0.10, 
power of 0.80 and a statistical significance level of 0.05, I required a sample size 
of 159 participants for analysis.  
  
I performed a univariate linear regression analysis, with ‘score on cognitive 
testing’ as the dependent variable and pre-stroke Frailty Index score 
(continuous) as the independent variable.  Linear multiple regression analysis 
was then conducted, adjusting for important covariates that were deemed likely 
to vary by frailty status and/or impact upon post-stroke cognition. (37, 232, 238, 
239)  Included covariates were age, sex, stroke severity, stroke-type 
(lacunar/non-lacunar), previous stroke/TIA, delirium, and previous cognitive 
impairment.  Stroke-type was categorised as a nominal variable with 2 levels 
(Lacunar/non-lacunar) on the basis that lacunar strokes and cortical strokes may 
differentially impact cognition.(49)  Each covariate was forced into the model 
regardless of significance in univariate analysis. 
 
CLINE (constant variance, linearity, independence of observations, normality of 
residuals & error-free values) assumptions were checked for each model.  Multi-
collinearity between continuous variables was also assessed. 
 
All models were created using SPSS statistics for Windows, version 24.0, Armonk, 
NY: IBM Corp.  
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8.3 Results 
8.3.1 Patient characteristics 
Of 262 confirmed stroke (this figure does not include confirmed TIA’s admitted) 
patients admitted during recruitment waves between May 2016 and Dec 2017, 
full data were available for 154 patients (59%).  Ninety-four (36%) patients were 
excluded due to being untestable on cognitive assessment, and 14 (5%) were 
excluded due to not completing a cognitive assessment within 7 days following 
admission. Mean Frailty Index score for the population was 18 (S.D.= 11; range= 
0-53); mean age of included participants was 68 years (S.D.= 13; range=32-97); 
median score on cognitive assessment was 8 (IQR=4; range= 0-12); median stroke 
severity was 2 (IQR=3; range=0-21); 92/154 (60%) were male;  frailty prevalence 
based upon Frailty Index dichotomisation at a Frailty Index score of >24 was 
51/154 (33%); 54/154 (35%) of stroke types were partial anterior circulation 
strokes (PACS); 36/154 (23%) had a previous stroke/TIA; 13/154 (8%) were 
cognitively impaired before the stroke (informant assessment data was available 
for 72/154; 47%); 13/154 (8%) screened positive for post-stroke delirium.  Full 
demographic and clinical data for patients can be seen in Table 8-1.  
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Table 8-1. Descriptive statistics 
 
 Number Range 
Mean/median 
(S.D.; IQR) 
Frailty Index 
(Score)  
154 0-53 18 (11) 
Age (Years) 154 32-97 68 (13) 
Mini-MOCA (Score) 
154 0-12 
8 (IQR=4; 
25th=6   
75th=10) 
NIHSS (Score) 
154 0-21 
2 (IQR=3; 25th= 
1 75th=4) 
    
 Number %  
Sex (Male)  93/154 60  
Frailty Index 
dichotomised (Frail 
>0.24) 
51/154 33  
Stroke Type    
TACS 8/154 5  
PACS 54/154 35  
LACS 50/154 32  
POCS 36/154 23  
Unclassified 7/154 5  
Pre-stroke 
cognitive 
impairment 
(Impaired)* 
13/154 8  
Delirium (Screened 
Positive) 
13/154 8 
 
Previous 
stroke/transient 
ischaemic attack 
(Yes) 
36/154 23 
 
Mini-MOCA= Mini Montreal Cognitive Assessment; NIHSS= National Institute of 
Health Stroke Scale; TACS= Total Anterior Circulation Stroke; PACS= Partial 
Anterior Circulation Stroke; LACS= Lacunar Stroke; POCS= Posterior 
Circulation Stroke; *Prior diagnosis of Mild Cognitive Impairment or Dementia 
or ≥3/6 on General Practitioner Cognitive Assessment- informant section 
questionnaire. 
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8.3.2 Associations with cognitive status after stroke 
Results of the univariate and multiple linear regression analyses are presented in 
Tables 8-2 & 8-3. 
 
Pre-stroke frailty was significantly associated with post-stroke cognition 
(Standardised-Beta= -0.40, p<0.001) based on univariate linear regression. As 
Frailty Index scores increased, cognitive scores declined.  Age, sex, NIHSS, 
delirium, pre-stroke cognition and stroke-type were all associated with post-
stroke cognitive score based on univariate analysis (all p<0.05).  Previous 
stroke/TIA was not (p=0.65). 
 
After adjusting for covariates, the association between frailty and post-stroke 
cognition remained significant (Unstandardized Beta= -0.05; Standardised beta=-
0.21; p=0.005).  Additional independent variables associated with post-stroke 
cognition were age (Unstandardized Beta= -0.05; Standardised beta =0.24; 
p=0.002), pre-stroke cognitive disorder (Unstandardized Beta= -2.28; 
Standardised beta=-0.22; p=0.001), delirium (Unstandardized-Beta= -2.81; 
Standardised-Beta= -0.27; p<0.001), and stroke severity (NIHSS) (Unstandardized 
Beta= -0.19; Standardised beta =-0.22; p=0.001).  Stroke-type (p=0.30), previous 
stroke/TIA (p=0.77) and Sex (p=0.57) were not significantly associated with post-
stroke cognition.  The combined model explained 43.5% of the variance in 
cognitive scores (adjusted R-square=0.435) at p<0.001.   
 
Tests of assumptions for the model revealed collinearity between Frailty Index 
scores and age.  However, multicollinearity was not a problem in the model 
according to variance inflation factor (VIF) scores (all <2) (see Table 8-4). All 
other assumptions were satisfied (see Figure 8-2). 
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Table 8-2. Univariate analysis results of selected variables association with 
cognition 
 
Variable Unstandardized 
Beta 
Standardised Beta Significance (p) 
Frailty Index 
(Score)  
-0.10 -0.40 <0.001 
Age (Years) -0.10 -0.47 <0.001 
Sex (Female) -1.05 -0.18 0.026 
Stroke severity 
(NIHSS) 
-0.32 -0.37 <0.001 
Stroke-type 
(Lacunar) 
1.08 0.18 0.030 
Pre-stroke 
cognitive 
impairment 
(Impaired) 
-3.45 0.33 <0.001 
Delirium (Yes) -3.95 0.38 <0.001 
Previous 
stroke/transient 
ischaemic attack 
(Yes) 
-0.25 -0.04 0.654 
Dependent variable=Montreal Cognitive Assessment score. Stroke-type was 
categorised as a nominal variable with 2 levels (Lacunar/non-lacunar).  
Frailty Index, Age, and Stroke severity were entered as continuous variables. 
NIHSS= National Institute for Health Stroke Scale. 
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Table 8-3. Multiple Linear regression output of selected variables’ 
associations with post-stroke cognition 
 Adjusted R-square 
 
Significance (p) 
0.44 <0.001 
    
Variable Unstandardized 
Beta 
Standardised Beta Significance (p) 
Frailty Index (Score) -0.05 -0.21 0.005 
Age (Years) -0.05 -0.24 0.002 
Sex (Female) -0.22 0.04 0.567 
Stroke severity 
(NIHSS) 
-0.20 -0.23 <0.001 
Stroke-type 
(Lacunar) 
0.41 0.07 0.295 
Pre-stroke cognitive 
impairment 
(Impaired) 
-2.28 -0.22 0.001 
Delirium (Yes) -2.81 -0.27 <0.001 
Previous 
stroke/transient 
ischaemic attack 
(Yes) 
-0.12 -0.02 0.774 
Dependent variable=Montreal Cognitive Assessment score.  All variables were 
forced into the model.  Stroke-type was categorised as a nominal variable 
with 2 levels (Lacunar/non-lacunar).  Frailty Index, Age, and Stroke severity 
(NIHSS) were entered as continuous variables. NIHSS= National Institute for 
Health Stroke Scale. 
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Table 8-4.  Results of test for multicollinearity in multiple regression model 
Variable Variance Inflation Factor (VIF) 
Previous stroke 1.050 
Frailty Index 1.434 
Stroke Type 1.083 
Pre-stroke cognitive impairment 1.076 
Delirium 1.118 
Age 1.561 
Sex 1.188 
NIHSS 1.121 
*NIHSS= National Institutes of Health Stroke Scale 
 
 
 
 
 
Figure 8-2. Tests of Assumptions 
 
Normality   Constant Variance   Linearity 
 
Footnote: PP plot and scatter plots indicate all assumptions were satisfied.  
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8.4 Discussion 
8.4.1 Frailty-cognition association 
I investigated the association between pre-stroke frailty and cognition in the 
acute period after stroke.  Pre-stroke frailty was hypothesised to be 
independently associated with lower post-stroke cognition.  My findings support 
this hypothesis.   
 
Those patients who had higher levels of frailty before stroke demonstrated 
significantly lower cognitive scores than those with comparatively lower frailty.  
Moreover, the association was apparent even after adjusting for other well-
established risk factors for post-stroke cognitive impairment, including those 
that often co-occur with frailty.  
 
This frailty-cognition association is consistent with findings from non-stroke 
populations suggesting a potentially important clinical relationship between 
frailty and cognitive impairment.  (232, 240)   
 
It must be highlighted however, that the observed effect size for pre-stroke 
frailty was relatively small, and less than half of the overall variance in post-
stroke cognition was explained by our model despite inclusion of eight 
predictors.  This emphasises that a number of variables contribute in 
combination to the post-stroke cognitive state and no single variable is 
paramount to its outcome.   
 
8.4.2 Mechanisms 
There are several plausible mechanisms by which the observed association 
between pre-stroke frailty and poorer post-stroke cognition may have arisen.  
Frail patients may differ in pre-stroke brain reserve or levels of pre-stroke 
neuroinflammation—each of which could conceivably contribute to lower post-
stroke cognitive performance. (241, 242) 
  157 
 
  
Alternatively, the observed association may not be attributable to a few select 
mechanisms.  Central to the accumulated deficits concept of frailty is that the 
‘system’ of the body and brain is broken down due to an overabundance of 
problems.  As the accumulation of deficits increase, physiological redundancy is 
reduced leading to exhaustion or impairment of the brain’s repair mechanisms; 
thus, prohibiting ability to prevent or minimise further damage.  The specific 
health deficits present matter little; more relevant is the overall number of 
deficits.(243)  In this sense, when a plethora of general age-related health 
deficits combine, the brain may be left in a state of increased vulnerability to 
the cognitive consequences of a stroke.(116)  This ‘brain frailty’ may in part 
explain frail patients’ predisposition to delirium; however, it is noteworthy that 
patients with greater frailty in our study were still found to have lower post-
stroke cognition even after controlling for presence of delirium post-stroke, 
suggesting that the association with lower post-stroke cognition itself cannot be 
attributed solely to delirium.    
 
8.4.3 Strengths and limitations 
I conducted an inclusive, exploratory study with an adequate sample size to 
investigate the association between frailty and post-stroke cognition, controlling 
for multiple relevant covariates. However, there are some important limitations 
worth mentioning.  
 
First, there was no blinding to cognitive scores when generating pre-stroke 
frailty ratings for each patient, creating a potential risk of bias.  In addition, it 
was not possible to control for some potentially important covariates that could 
influence the observed associations with post-stroke cognition, such as 
premorbid Intelligence Quotient (IQ).  Moreover, our assessment of pre-stroke 
cognition was limited by missing data and as such the observed frailty-cognition 
association could be contributed to by the pre-stroke cognitive state.  Finally, 
while the generalisability of included patients is heightened by our very limited 
exclusion criteria, there were few severe strokes included in our analysis and 
patients unable to complete cognitive assessment may often have been the more 
  158 
 
severely cognitively impaired.  Greater inclusion of such patients may influence 
the associations and effect sizes that we report.   
 
8.4.4 Clinical implications and future directions 
My findings emphasise that not all variables that predict post-stroke cognition 
are classically ‘psychological’.  It is therefore important that clinicians are 
aware of the potential influence of frailty on post-stroke cognition and should 
consider incorporating the measurement of frailty into typical clinical 
assessment.  
 
At present, our understanding of the frailty relationship with post-stroke 
cognition is limited by the cross-sectional nature of our study.  Frail patients 
typically show less improvement or stabilisation in cognition over time compared 
to non-frail patients in general older-adult populations. (244)  In this regard, the 
initial cognitive status combined with the frailty status of the patient could 
matter to future cognitive trajectories following stroke.  The long-term effects 
of frailty on post-stroke cognition should therefore be investigated.   
 
It would also be beneficial to determine if other concepts of frailty, for example 
the frailty phenotype (110), are also associated with post-stroke cognition.  
While many patients defined as frail according to the accumulated deficits 
concept will also be frail in a form consistent with the phenotype, as we found 
in chapter 7, agreement between these concepts is far from perfect; hence 
there may be differences in post-stroke cognitive risk based on frailty definition 
adopted.    However, I would also note that there is a high likelihood that many 
stroke patients will not be able to complete a frailty phenotype assessment and 
will therefore be a challenge to investigate this form of frailty in a generalisable 
way. 
 
Finally, replications of my results are important in order to establish if frailty is 
indeed associated with post-stroke cognition, independent of already established 
risk factors.  If these findings are supported, future studies should assess and 
control for frailty when investigating post-stroke cognition as failure to do so 
could confound results. 
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8.5 Conclusion 
There is evidence that frailty is associated with lower post-stroke cognition, 
independent of factors that have previously been associated with post-stroke 
cognitive impairment.  When assessing post-stroke cognition, clinicians and 
researchers should be aware of this potential relationship.  Future studies should 
investigate the influence of frailty on longer term trajectories of post-stroke 
cognition.   
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Chapter 9. Summary, discussion and conclusion 
Psychological issues in stroke are recognised for their importance to overall 
stroke outcomes, but understanding these issues is still very much an ongoing 
task.  In this thesis, I focused upon the relevance of the pre-stroke state and 
conducted a series of studies designed to enhance our knowledge of four pre-
stroke conditions.  The studies described in this thesis used various research 
methods, but all were designed to improve our overall understanding of the 
psychological issues that stroke survivors often experience.   
 
9.1 Pre-stroke cognition 
In chapter 2, section 2.1, I discussed how the lack of validation and guidance 
regarding optimal selection and use of informant tools in a pre-stroke context is 
a problematic area in stroke.  I looked to address this issue in chapter 3 as part 
of a prospective, clinical, cohort study.  I assessed the validity of two prominent 
informant tools, the IQCODE-SF and AD8, and found evidence to suggest that 
they are indeed valid when used to assess pre-stroke cognition.  Both tools were 
near identical in their overall performance for detecting pre-stroke cognitive 
impairment (demonstrating AUROC~0.8), which, given its shorter duration and 
simplicity of scoring, may suggest an advantage of using the AD8 over the 
IQCODE-SF for pre-stroke cognitive assessment.   
 
I also assessed performance of the two tools at recommended cut-points and 
determined whether these matched the optimal cut-point as indicated in my 
dataset.  At their recommended cut-points, the two tools demonstrated 
contrasting strengths.  The AD8 was more sensitive (86.7%) to any cognitive 
impairment than the IQCODE (62.1%), but the IQCODE was more specific (87.7% 
vs 70.8%).  It is debateable whether sensitivity or specificity should be prioritised 
in pre-stroke assessment; however, what is clear is that use of these tools at 
their recommended published cut-points could conceivably result in contrasting 
participant pools.   
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Comparison of recommended published cut-points against optimal cut-points 
according to ROC curves suggest that both tools may perform better by altering 
the cut-point, dependent upon the population studied.  When assessing for any 
pre-stroke cognitive impairment the IQCODE may perform better at a lower cut-
point, while the AD8 may perform better at a higher cut-point when the 
intention is to restrict assessment to identifying dementia patients only.  
Diverging from recommended published cut-points is however contentious and 
has been a source of heterogeneity between studies in the past, likely 
contributing to the heterogeneous results often observed in the stroke-cognition 
literature.  I would therefore suggest that it would be unwise for researchers 
and clinicians to diverge from the recommended published cut-points on the 
basis of these findings.  
 
My results indicate areas for future research.  A future systematic review and 
meta-analysis of performance at varying cut-points could potentially establish 
the optimal use of both the IQCODE and AD8 when used to assess pre-stroke 
cognition; however, this would require more studies of the type I conducted in 
chapter 3 to be completed first.  At the moment, the study presented in this 
thesis is the first to validate the two tools for assessment of the pre-stroke state 
against a clinical gold standard.   In addition, the prevalence of ‘any’ pre-stroke 
cognitive impairment (i.e. dementia plus cognitive impairment no-dementia) 
remains unestablished and would be beneficial for understanding the natural 
history and aetiology of post-stroke cognitive impairment.  There also remains 
room for a qualitative study to determine the issues behind poor 
feasibility/acceptability of the IQCODE as described in chapter 2, section 2.1.   
 
9.2 Pre-stroke depression 
In chapter 2, section 2.2, I outlined 3 areas that are fundamentally lacking basic 
information in the context of pre-stroke depression: prevalence, risk association 
with post-stroke depression, and assessment methods.  In chapter 4 I attempted 
to better establish the prevalence of pre-stroke depression and its risk 
association with post-stroke depression.  I conceived, designed and conducted a 
systematic review and meta-analyses of the prevalence rates of pre-stroke 
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depression and odds ratios for presence of post-stroke depression, that are 
typically reported in the stroke-depression literature.   
 
The prevalence rates I observed suggest that the stroke population may be more 
prone to depression than the general older adult population (17% vs 12%); but 
prevalence is ultimately considerably lower than the rate observed in a post-
stroke context (30% at any time point).  Moreover, the prevalence rate along 
with the apparent risk association observed adds further insight into the 
aetiology of post-stroke depression.  Specifically, my findings seem in line with 
the notion that depression after stroke is primarily driven by the psychological 
and functional consequences of the stroke itself, yet emphasises that the pre-
stroke state is a relevant predictor none-the-less.  In my opinion, that 
depression before the stroke increases odds of depression after the stroke may 
also suggest that post-stroke depression is not predominantly vascular or lesion-
location specific in nature.  That is not to say a vascular source to some cases of 
post-stroke depression can be ruled out, but it is arguable that we should not 
expect a significant association between pre and post-stroke depression, if 
depression after the stroke is exclusively driven by vascular damage.  There are 
of course limitations to my risk association meta-analysis that must temper any 
conclusions that can be drawn in this regard, but further work in this area could 
be beneficial. 
   
While my work has helped to enhance our understanding of depression in the 
pre-stroke context, there are areas for future research to explore.  Information 
regarding the predominant means of assessment of pre-stroke depression is still 
lacking.  I was able to report the methods utilised in the studies included in my 
review; however, it was not designed to establish every means of assessing pre-
stroke depression employed.  Of the studies included in the review, I found 
medical records to be the most commonly employed method for identification of 
pre-stroke depression.  I also found evidence to suggest that this may be a 
suboptimal means of detecting pre-stroke depression based on the significantly 
lower prevalence rates reported when utilising this method as compared to 
clinical interviews.  In chapter 5 I therefore explored the use of informant tools 
as an alternative approach for pre-stroke depression assessment.  I found some 
preliminary evidence that an informant approach to pre-stroke depression 
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assessment may be a useful approach.  One particular tool, the GDS-SF, may 
have the pattern of sensitivity and specificity to be of clinical use in detecting 
pre-stroke depression.  The validity of the GDS-SF has been questioned in the 
past however and the limited sample size in this study warrants a need for 
further investigation.  There were also questions over the 
feasibility/acceptability of the GDS_SF based upon a high ratio of ‘unknown’ 
responses from informants when evaluating their relative’s mood.  The 
feasibility/acceptability and other psychometric properties of pre-stroke 
informant depression scales therefore require further study.  I would argue that, 
at present, adopting an informant approach to pre-stroke depression assessment 
may only be advisable when the patient themselves cannot report upon their 
own mood. 
 
9.3 Pre-stroke disability 
In chapter 2, section 2.3, I discussed how pre-stroke disability may be relevant 
to post-stroke psychological outcomes but also that its relevance stretches 
beyond this.  Pre-stroke disability is frequently assessed both clinically and in 
research to determine suitability for aggressive treatments and stroke trials.  
However, it is most commonly assessed via the mRS which was not designed for 
pre-stroke use and had not been well validated for this purpose.  In chapter 6 I 
looked at the validity of the pre-stroke mRS through secondary analysis of 
clinical data held in an existing database.  The findings of that study suggest 
that the pre-stroke mRS has modest validity based on correlations with other 
markers of function.  It also showed that it has use as a prognostic indicator 
based upon associations with a number of poor outcomes.  Moreover, these 
associations could not be explained by a difference in post-stroke care-pathway.  
Overall, the results suggested that the pre-stroke mRS is a valid measure for pre-
stroke disability assessment; however, it is not optimally suited for this purpose.   
 
These findings demonstrate a need for further work in relation to pre-stroke 
functional assessment.  I think that the pre-stroke mRS would benefit from 
standardised instructions for its use. This could help not only improve its 
validity, but also important additional psychometric properties such as inter-
rater reliability and is an approach that already exists for post-stroke mRS 
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assessment.(245) The field may also benefit from exploring alternatives to the 
mRS as a means of assessing pre-stroke disability.  A more comprehensive pre-
stroke functioning assessment could be of particular use as there is limited 
availability of gold standard assessments with which to evaluate the diagnostic 
test accuracy of the pre-stroke mRS.   
 
In addition, the prevalence and risk associations between pre-stroke functioning 
and post-stroke psychological outcomes remain relatively unstudied.  Future 
work in this area would benefit our wider understanding of psychological issues 
in stroke and the relevant factors associated with this.   
 
9.4 Pre-stroke frailty 
Frailty is a largely unstudied condition in stroke.  It differs from pre-stroke 
function in that it implies a state of heightened vulnerability but does not 
necessarily involve disability.  Frailty has demonstrated associations with 
cognitive conditions within the older adult population and in chapter 2, section 
2.4, I discussed the need to establish prevalence and assessment methods for 
pre-stroke frailty along with a potential risk association with post-stroke 
cognition. I conceived and conducted 2 studies in chapters 7 and 8 to address 
these gaps in the literature. In chapter 7 I utilised a patient database at the 
Glasgow Royal Infirmary and conducted a secondary analysis of collected clinical 
data in order to investigate the prevalence of pre-stroke frailty and validate a 
commonly used frailty measure: the Rockwood ‘Frailty Index’.   
 
My results indicate a substantial burden of frailty in acute stroke, possibly 
occurring in as many as ~80% of patients if the ‘pre-frailty’ state is considered.  
The Frailty Index measure also appears to be valid as a measure of frailty and 
can be completed in the vast majority of stroke patients, in contrast to self-
report frailty phenotype measures.   
 
In chapter 8 I explored a possible risk association between pre-stroke frailty and 
acute post-stroke cognition, utilising the same approach as in chapter 7.  My 
results indicated that frailty, as defined by the Frailty Index, was associated 
with lower acute post-stroke cognition and that this association was independent 
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of other established risk factors known to effect post-stroke cognition.  This 
study was limited by difficulties of cognitive assessment in stroke and limitations 
regarding how accurately some of the covariates could be measured.  However, 
it demonstrates an as yet previously unidentified variable as potentially being 
relevant to the post-stroke cognitive state.   
 
Further work around frailty in stroke, particularly in relation to frailty and 
longer-term cognitive outcomes and trajectories could be of particular benefit 
to our understanding of the natural history and aetiology of post-stroke cognitive 
impairment.  What is more, the influence of phenotypical frailty on post-stroke 
cognitive outcomes remains to be established and would also be a useful avenue 
for further research in this field.  
 
9.5 Conclusion 
In conclusion, I have investigated the pre-stroke state in order to better 
understand psychological problems in stroke.  I have identified and addressed a 
number of gaps in the literature, but many remain.  It is important for future 
research to consider the pre-stroke state as it can be informative of 
psychological problems in stroke generally.  I have provided statistics indicative 
of prevalence rates of important pre-stroke conditions and investigated possible 
risk factors that were previously unstudied or inconclusive in their proposed 
association.  The information I have established should help in understanding the 
natural history and aetiology of psychological problems in stroke, but more work 
of this kind is still needed. 
 
I also conducted a number of studies designed to improve assessment of the pre-
stroke state.  This is an area of particular significance.  Pre-stroke assessment 
can be challenging due to the frequent practical necessity that requires it to be 
determined retrospectively.  This general limitation however is often 
exacerbated by heterogeneity in approach to assessment, which is largely down 
to a lack of knowledge and guidance for tool selection and application.  I have 
attempted to strengthen our understanding of the psychometric properties of 
various tools that can be used to assess pre-stroke conditions and looked at how 
they compare in this regard.  Our findings should assist clinicians and researchers 
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alike as to optimal selection and utilisation of pre-stroke assessment tools.  
However, there is still considerable work required in this area—particularly in 
relation to the psychometric properties of the tools beyond validity.  Further 
improving how we assess the pre-stroke state should be beneficial to the field of 
psychology in stroke and I would encourage more work of this nature to build 
upon the findings presented in this thesis.  
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Appendices 
 
Appendix1: APPLE protocol 
Improving our assessment and understanding of the short, medium and  
longer term neuropsychological consequences of stroke 
 
Running Title: Assessing Post-stroke Psychology 
Longitudinal Evaluation (APPLE) 
Lay Title: Understanding the emotional, thinking and 
memory problems that can follow a stroke 
Protocol Version:    1.5 
Date:      08.12.17 
REC Reference Number:  16/SS/0105 
Sponsors Protocol Number:  GN14NE496 
Protocol registration:  researchregistry1018 
Sponsor: NHS Greater Glasgow and Clyde  
Funders Reference:  PPA 2015/01_CSO 
Funder: Joint Stroke Association and Chief Scientist 
Office Programme Grant 
 
 
Amendment number Date Protocol version 
AM01 19.09.16 1.3 (GN14NE496) 
AM02 22.05.17 1.4 (GN14NE496) 
AM03 08.12.17 1.5 (GN14NE496) 
   
 
 
 
 
 
 
This study will be performed according to the Research Governance Framework for 
Health and Community Care (Second edition, 2006) and WORLD MEDICAL 
ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research 
Involving Human Subjects 1964 (as amended). 
168 
 
Contacts  
Chief Investigator 
Dr Terry Quinn 
Stroke Association / Chief Scientist Office Senior Clinical Lecturer   
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
University of Glasgow    
Room 2.44 New Lister Building       
Glasgow Royal Infirmary 
Glasgow G4 0SF 
Tel: 0141 201 8510 
Email: terry.quinn@glasgow.ac.uk 
 
Co-Investigators 
Professor Peter Langhorne 
Professor in Stroke Care 
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
Level 2, New Lister Building       
Glasgow Royal Infirmary 
Glasgow G4 0SF 
Tel: 0141 201 8510 
Email: peter.langhorne@glasgow.ac.uk 
 
Professor David Stott 
Professor in Geriatric Medicine 
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
Level 2, New Lister Building       
Glasgow Royal Infirmary 
Glasgow G4 0SF 
Tel: 0141 201 8510 
Email: david.j.stott@glasgow.ac.uk 
 
Professor Matthew Walters 
Professor in Clinical Pharmacology 
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
Queen Elizabeth University Hospital  
1345 Govan Road 
Glasgow G51 4TF     
Tel: 0141 201 1100 
Email: matthew.walters@glasgow.gla.ac.uk 
 
Professor Kennedy Lees 
Professor of Cerebrovascular Medicine 
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
Queen Elizabeth University Hospital  
1345 Govan Road 
Glasgow G51 4TF     
Tel: 0141 201 1100 
169 
 
Email: kennedy.lees@glasgow.gla.ac.uk 
 
Dr Jesse Dawson 
Reader in Clinical Pharmacology 
College of Medicine, Veterinary & Life Sciences 
Institute of Cardiovascular and Medical Sciences 
Queen Elizabeth University Hospital  
1345 Govan Road 
Glasgow G51 4TF     
Tel: 0141 201 1100 
Email: jesse.dawson@glasgow.ac.uk 
 
Dr Niall Broomfield 
Honorary Clinical Teacher 
Institute of Health and Wellbeing 
Primary Services HQ 
Gartnavel Royal Hospital 
Glasgow G12 0XH 
Tel: 211 2134 
Email: Niall.Broomfield@glasgow.ac.uk 
 
Professor Jonathan Evans 
Professor of Applied Neuropsychology 
Institute of Health and Wellbeing 
R212 Level 2, Mental Health & Wellbeing,  
Gartnavel Royal Hospital,  
Glasgow G12 0XH  
Tel: 0141 211 3978 
Email: Jonathan.Evans@glasgow.ac.uk 
 
Professor Gillian Mead 
Professor of Geriatric Medicine 
University of Edinburgh 
Room S1642, Royal Infirmary of Edinburgh,  
Little France Crescent,  
Edinburgh EH16 4SA     
Tel: 0131 242 6481 
Email: gmead@staffmail.ed.ac.uk 
 
Professor Sarah T Pendlebury 
Associate professor in Medicine and Old Age Neuroscience 
Nuffield Department of Clinical Neurosciences 
University of Oxford 
Level 6 West Wing John Radcliffe Hospital,  
Oxford, OX2 7RX    
Tel: 01865 231606 
Email: Sarah.pendlebury@ndcn.ox.ac.uk 
 
Dr Christine McAlpine 
Consultant in Stroke and Managed Clinical Network Lead 
Centre Block     
Glasgow Royal Infirmary 
170 
 
Glasgow G4 0SF 
Tel: 0141 211 4843 
Email: Christine.mcalpine@ggc.scot.nhs.uk 
 
Trial Statistical Lead 
Professor Ian Ford 
Professor of Medical Statistics      
Robertson Centre for Biostatistics 
University of Glasgow, Boyd Orr Building 
University Avenue,  
Glasgow, G12 8QQ 
Tel: 0141 330 4744 
Email: Ian.Ford@glasgow.ac.uk 
 
Data Centre 
Robertson Centre for Biostatistics 
University of Glasgow 
Boyd Orr Building 
University Avenue 
Glasgow  G12 8QQ 
Tel: 0141 330 4744 
 
 
Sponsor: 
The sponsors is NHS Greater Glasgow and Clyde. 
Contact: Emma-Jane Gault 
Research Governance Officer 
University of Glasgow 
Clinical Research and Development 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow G3 8SW 
Tel: 0141 232 1819 
Email: emmajane.gault@glasgow.ac.uk 
 
Funding Body 
Funded via a Stroke Association / Chief Scientist Office Joint Programme Grant. 
Administered by: The Stroke Association  
Research Department  
Stroke House  
240 City Road  
London, EC1V 2PR 
171 
 
Protocol Approval 
Improving our assessment and understanding of the short, medium and  
longer term neuropsychological consequences of stroke 
 
Chief Investigator:   Dr Terry Quinn 
Clinical Senior Lecturer  
College of Medicine, Veterinary & Life Sciences 
Room 2.44 New Lister Building, Glasgow Royal Infirmary 
Glasgow G4 0SF      
 
     
Signature: 
    
Date:     
 
 
Sponsor Representative:  Emma-Jane Gault 
Research Governance Officer 
University of Glasgow 
Clinical Research and Development 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow G3 8SW 
    
Signature: 
    
Date:     
 
  
172 
 
ABBREVIATIONS 
AD8 Ascertaining Dementia 8 Question Screener 
AE Adverse Event 
AMT Abbreviated Mental Testing  
ASU Acute Stroke Unit 
BI Barthel Index  
CAM Confusion Assessment Method 
CDR Clinical Dementia Rating  
CRF Case Report Form 
DISCS Depression Intensity Scale Circles 
DSM Diagnostic and Statistical Manual of Mental Disorders 
E-ADL Extended Activities of daily living  
EQ-5D Euro-QOL 5 Dimensions  
GAD-2 Generalised anxiety disorder (2 question screener) 
GCP Good Clinical Practice 
GDS Geriatric Depression Scale 
IQCODE Informant Questionnaire Cognitive Decline in the Elderly 
MCN Managed Clinical Network  
mRS Modified Rankin Scale 
NE-ADL Nottingham Extended Activities of Daily Living  
NIHSS National Institutes of Health Stroke Scale  
NPI-Q Neuropsychiatric Inventory Questionnaire  
OCS Oxford Cognitive Screen  
PHQ-2/SADS Patient Health Questionnaire (2 question screener) (structured assessment)  
PI Principal Investigator 
PIS Patient Information Sheet 
PRECiS Patient Reported Evaluation Cognitive Impairment Scale   
QEUH  Queen Elizabeth University Hospital  
RAH Royal Alexendra Hospital  
SADQ-10 Stroke Aphasia Depression Questionnaire  
SCID Structured Clinical Interview for DSM 
SF-SIS  Short Form Stroke Impact Scale  
SOP Standard Operating Procedure  
SRN Stroke Research Nurse 
SSRN Scottish Stroke Research Network  
STARD Strengthening Transparency and Reporting in Diagnostic Studies  
TIA Transient ischaemic attack 
VCI-H National Institute of Neurological Disorders and Stroke–Canadian Stroke Network 
Vascular Cognitive Impairment Harmonization Standards 
WP Work Package 
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STUDY SYNOPSIS 
Title of Study: Improving our assessment and understanding of the 
short, medium and  
longer term neuropsychological consequences of stroke 
Study Centre: Glasgow Royal Infirmary and associated hospitals of the 
Managed Clinical Network for Stroke or Stroke Research 
Network. 
Duration of Study: 4 years 
Objectives: To establish a prospective inception cohort, recruited 
early after stroke and followed for up to 18 months with 
a focus on psychological outcomes.   
Primary Objective: There are three distinct work packages (WP). 
WP 1. To assess the prevalence of psychological 
problems that pre-date stroke. (A separate 
complementary study will describe test accuracy of short 
questionnaires for assessing pre-stroke psychological 
problems).  
WP 2.  To assess test accuracy and utility of brief 
cognitive and mood tests short for assessment of short 
and longer term psychological outcomes.  
WP 3.  To describe change in cognition and mood over 
time following a stroke, with assessments at one, six, 
twelve and eighteen months.   
Secondary Objectives: The secondary objective is to create a resource that can 
be used for future studies of psychological impact of 
stroke.  To this end we will ask participants if they wish 
to have blood taken for biobanking; if we can hold their 
anonymised data (clinical, laboratory and radiological) in 
a secure database and if we can access de-identified 
data from electronic health records. 
Main Study Endpoints Pre-stroke cognitive and physical function (based on 
CDR and SCID structured interviews). 
Change in cognition or mood symptoms based on 
repeated neuropsychological assessment (using VCI 
Harmonization Standard).  
Development of incident cognitive or mood disorder 
(consensus agreement based on collected materials).  
Rationale: National stroke guidance recommends early cognitive 
and mood screening but this policy lacks evidence-base. 
Building on previous work, we will create a programme 
of research designed to inform practice and policy. We 
will major on themes of “natural history” of 
neuropsychological problems; screening test 
accuracy/feasability; prognosis and user experience. 
Methodology: Prospective, observational cohort with nested test 
accuracy studies. 
Sample Size: 500 participants recruited to primary study, with plans 
for pooled analyses with other studies. Attrition is 
expected and we have based sample size on 200 
participants completing 18 month assessments. 
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The pre-stroke assessment diagnostic study is based on 
a separate sample size calculation and requires 100 
informant interviews and diagnostic assessments. 
Screening Case note review of in-patient / outpatient attendees to 
the Acute Stroke Services by clinicians. A full log will be 
maintained. 
Inclusion Criteria 1. Clinical diagnosis of stroke or transient ischaemic 
attack (TIA) at time of assessment. 
2. Age greater than 18 years. 
3. Treating clinician happy that the patient would have 
some form of psychological assessment as part of usual 
care.  
Exclusion Criteria 1. Non-stroke diagnosis at time of assessment. 
2 Unable to consent and no suitable proxy available.  
4. No spoken English pre-stroke. 
4. Prisoners. 
Statistical Analysis  WP 1,2: Accuracy of screening tools will be described in 
terms of usual test accuracy metrics against a reference 
standard of semi-structured baseline clinical assessment 
(WP1) or prospective assessment with 
neuropsychological battery (WP2). We will employ an 
“intention to diagnose” approach. 
WP 3: Outcomes of interest are change in scores on 
neuropsychological battery and incident clinical mood 
disorder or cognitive impairment.  
We will use generalized linear models for prospective 
data to describe associations of baseline characteristics 
with change across repeated neuropsychological 
measures and use varying competing risk survival 
models. We will describe univariate and adjusted 
independent predictors of “outcomes” using odds-ratios 
for binary “outcomes” at chosen time-points. We will 
create prognostic models and if data allow predictive risk 
scores for outcomes, describing calibration; 
discrimination and validation using bootstrapping. 
 
175 
 
STUDY FLOW CHART 
 
 
 
 
 
 
NB. All aspects of the study are optional, participants can chose to contribute to all or 
only one part of the study.  Some sites may not be able to offer biobanking.  
Key: Red boxes: short screening assessments; blue boxes: detailed screening 
assessments; green: structured psychology assessment with clinician input.  
Details of all the neuropsychological battery assessments in appendix.  
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PARTICIPANT SCHEDULE 
 
 
NB. All aspects of the study are optional, participants can chose to contribute to all or 
only one part of the study.  Some sites may not be able to offer biobanking.  
Detailed Participant Schedule  
 
 
ASU Follow up 
Week 1 
1  
month 
6 
months  
12 
months 
18 
months 
Review Eligibility √     
Consent √     
Blood / Urine for Biobanking  
(separate optional study) 
√ √ √ √ √ 
Patient assessment √     
Informant assessment √     
Structured clinical interview study 
(separate optional study) 
√    
Consent re-assessed  √    
Patient psychological screen  √    
Patient neuropsychological battery   √ √ √ 
Informant questionnaires   √ √ √ 
Clinical assessment 
(separate optional study) 
   √ 
Consensus assessment     √ 
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1 INTRODUCTION 
1.1 Background 
We propose a programme of work designed to improve our understanding of 
neuropsychological effects of stroke. We will focus on themes of assessment, prognosis 
and natural history. Outputs will have immediate relevance and impact, providing an 
evidence base to policy and practice around early cognitive and mood screening and 
informing the design and conduct of future studies. The prospective cohort and 
biobank/big data resources created through this work will act as foundation for an 
ongoing portfolio, creating cross institutional research synergy; encouraging new 
researchers and providing the “substrate” for ongoing interdisciplinary work.  
 
People affected by stroke have consistently highlighted the importance of 
neuropsychological issues.[1] However, the field remains relatively under researched. 
Important evidence gaps collated at a Stroke Association convened priority setting 
workshop, were around the “natural history” of neuropsychological change after stroke; 
utility of early assessments and predicting who will require later specialist input.[2] Our 
proposed body of research is designed to address these priority areas.  Specifically, we 
will create a “real world” acute stroke inception cohort, offering prospective cognitive 
and mood testing to progress inter-related themes (Work Packages). We will also offer 
related complementary, optional studies looking at pre-stroke assessment and 
facilitating biobanking and ‘big data’ approaches.  
 
Despite the importance of psychological issues, memory, thinking and mood have not 
received as much attention in stroke research as other areas.[3,4] For this reason there 
are still fundamental questions that we don’t know the answer to. These include: 
● How do memory thinking and mood change after stroke? 
● What happens to memory, thinking and mood in the longer term after stroke? 
● Can we predict which people will have problems with memory, thinking and mood? 
● What is the best way to look for problems with memory, thinking and mood? 
● When should we perform tests of memory, thinking and mood? 
These are the questions we wish to answer with this programme of research. 
 
1.2 Pilot data to support the creation of a cohort  
The proposed programme of work builds on our previous systematic review and original 
research. Our national questionnaire and literature review has shown inconsistency in 
neuropsychological assessment strategies both in clinical practice and in research.[3,4] 
Subject responses from stroke units across Scotland suggest that clinical teams are 
looking for guidance around method and timing of neuropsychological assessment and 
around prognosis.   
Our systematic review work has highlighted a lack of data around cognitive and mood 
screening tools in acute care, albeit this is where the majority of initial assessment is 
performed.[5]   
With the Standards for Reporting of Diagnostic accuracy in Dementia 
(STARDdem)working group, we have creating guidance for conduct and reporting of 
diagnostic test accuracy studies and have used this to inform the proposed work.[6] 
Importantly, our pilot work has shown that studies of early neuropsychological 
assessment with prospective follow up can recruit rapidly and efficiently.[7,8] 
 
1.3 Involvement of stroke-survivors and others affected by stroke 
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This body of work has been created with input from stroke survivors and others 
affected by stroke. Input from stroke survivors and those affected by stroke will 
continue for the lifespan of the study. 
 
The researchers involved in this application were part of a national research priority 
setting group that collated feedback from various groups including strong 
representation from stroke survivors and care-givers. The number one research 
priority identified through this work was around problems with memory and thinking 
that can occur after stroke. This feedback was the inspiration behind this work.[1] 
 
The Stroke Association ran their own workshop around memory and mood problems, 
the lead applicant in this work was part of this group, that also included stroke 
survivors and representation from various professional groups. The conversations and 
experiences shared as part of this workshop and our daily clinical work in stroke units 
helped us create a body of work that we believe is relevant to stroke survivors and is 
in keeping with the issues that they feel are important.  The project was further 
reviewed by Stroke Association lay members as part of the grant review process. 
 
The research plan outlined in this application has been previously assessed by panel 
members of the UK Stroke Research Network CSG (acute and rehabilitation groups). 
This group includes clinicians from various disciplines and representation from those 
affected by stroke.  The insightful suggestions and comments we received, particularly 
around the conduct and reporting of the work, have improved the proposal 
considerably. 
 
In designing a study, researchers always need to balance their desire to collect 
detailed information with not over-burdening the person taking part in the study. With 
a stroke group based in Edinburgh we have shared the various tests of memory, 
thinking and mood that we propose to use. Feedback from the group helped us refine 
our set of tests to a selection that should be acceptable to stroke survivors while still 
giving us the necessary information we need to answer our research questions. 
 
As part of the study we will create an advisory group, who will meet once yearly. The 
advisory group will include two stroke survivors as well as representation from 
doctors, nurses and therapists. The group will act as a forum for stroke survivors and 
others to comment on the design of the study; the progress of the study; the 
“meaning” of the results obtained and how to share these results with the wider stroke 
community including stroke survivors. (advisory group members detailed in appendix)  
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1.4 Principal research questions 
This application is towards a programme of work supported by the Stroke Association 
and Chief Scientist Office Scotland. 
Within the programme are three distinct work packages (WP) designed to offer rich data 
that answer a number of important questions in stroke care. 
 
WP 1. The primary aim is to assess the prevalence of memory and thinking (cognitive) 
and mood problems that pre-date the stroke.  A complementary (optional) study seeks 
to describe the test accuracy of short questionnaires for assessing pre-stroke 
psychological problems.  
 
WP 2.  The primary aim is to assess how useful short tests are for detecting cognitive 
and mood problems immediately after a stroke and for detecting persisting cognitive 
and mood problems.  
 
WP 3.  The primary aim is to describe change in cognition and mood over time following 
a stroke, with assessments at around one month, six months, twelve months and 
eighteen months.   
 
A further important objective is to create a resource that can be used for future studies 
of psychological impact of stroke.  To this end we will ask participants if they wish to 
have blood taken for biobanking (optional); if we can hold their anonymised clinical, 
laboratory and imaging data in a secure database (optional) and if we can access de-
identified data from electronic health records (optional).  All these aspects are optional 
and may not be available in certain centres.  
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1.5  Summary of Risk Assessment 
We recognise the potential issues associated with this project; we have worked with 
patient groups, lay representatives and clinical study advisory groups to create a 
methodology that minimises issues while maintaining the research potential of the 
programme of research.  We have listed the potential issues and steps taken to minimise 
their impact.  
 
Test burden: The project involves cognitive and mood testing of patients and 
informants at various stages in the stroke journey.  We recognise the importance of 
minimising test burden.  Our pilot work suggests that patients struggle with standard, 
multidomain cognitive tests in the first days post stroke.  In this study we will 
concentrate on very brief tests.  As the brief tests share a number of questions, we can 
assess the performance of several tests at once by simply adding some questions to the 
short cognitive assessment that is used as standard in our clinical service.   
 
As part of our preparatory work we asked a stroke group based in Edinburgh to look at 
the tests we proposed for the acute study and they were happy that the tests were not 
overly burdensome.  Piloting the acute test battery with an Edinburgh research group 
suggests that completion should take around 20 minutes at most. Patients are not 
required to complete all the tests and they can ask to stop testing at any time.  Testing 
can be performed in two sessions or more depending on patient preference.  Feasibility 
of using brief tests is an important metric of this work and we will record how many 
patients attempt and complete tests.  If a participant becomes distressed or frustrated 
and it is clear that they are unable to complete testing, testing will be stopped. Any 
distress will be handled through reassurance and ending the assessment. 
 
Informants (family, friends, carers) will also be asked to complete paper based 
questionnaires.  We have chosen brief assessments that should take around 20 minutes 
and can be completed at a time that suits the participant.  
 
The prospective arm of the study will use a longer test battery.  Completing the study 
follow-up will involve four assessment visits over 18 months (one month; six months; 
twelve months; eighteen months).  We have chosen cognitive and mood tests 
recommended for stroke cohorts and which we use in clinical practice.  There is 
considerable experience of using these tests with stroke survivors.  The first session 
using these longer test batteries will not begin before six months post stroke to allow 
time for recovery.  Again testing can be performed in split sessions if the patient prefers.  
Completion of the tests is not mandatory and the patient can request to stop testing at 
any time. Where completion of the full assessment is not possible, we have specified a 
short form assessment protocols for use in person or over telephone. 
 
Opportunity cost: We recognise that while a patient is working on cognitive 
assessment they will not be able to work with ward staff / allied health professionals on 
other rehabilitation tasks. We will work with the ward team to minimise disruption. We 
will be performing an activity, cognitive and mood testing screen, that is a recommended 
part of routine care.  We will share the inpatient test results with ward staff on request 
and this should release their time for other activities. 
 
Disclosure of sensitive information: We will be assessing mood (emotions and 
feelings) we recognise that this can be a sensitive area.  If we detect probable 
depression, or other mood disorder we would advise the clinical team to refer to the 
Stroke Psychology service. In the event that suicidal thoughts/ideations are disclosed 
assessment will be stopped and a member of the treating clinical team will be informed 
immediately.  This action will also be documented in the patient's case notes.  The study 
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has input from the local Clinical Stroke Psychology service and they are happy to be 
contacted in the event of suicidal ideation or any other disclosures that may require 
clinical input. 
Patients may ask for their scores on the cognitive or mood tests.  We will share these 
data with the patient but we will also explain that these tests in and of themselves are 
not diagnostic of dementia / depression or other serious psychological problems. Rather 
they are part of an assessment that will be shared with the treating clinical team. If 
there is concern regarding a patients cognitive function or mood, the research team can 
access the stroke clinical psychology services and referrals can be made to Memory 
Clinic services. 
 
Informed consent: We want our study to produce results that reflect “real world” 
stroke care.  Previous studies of cognition and mood in stroke have limited themselves 
to consenting patients.  This gives a biased sample and produces results that lack 
external validity and clinical utility.  We propose a more generalizable approach, where 
we potentially include all patients with stroke unless the clinical team feel that any form 
of testing is inappropriate.  There will be a proportion of patients who may struggle to 
provide informed consent to research.  For a study with a cognitive focus, it is important 
that these patients are included.  In this instance we will seek consent from a suitable 
proxy (family, friend, carer).  For those patients who are included in the study with 
proxy consent; we will reassess capacity to consent and seek informed consent at one 
month follow-up visit.   
 
Test environment: For follow-up testing we will recommend that testing is performed 
within one of the clinical research facilities of the participating hospitals.  We have a 
budget to cover patient travel by taxi to allow this.  Some patients may be unable to 
attend the research facility or may for any reason choose to be assessed at home.  
Telephone based assessment is possible if required.  For home assessments, we will 
follow NHS GG&C and GU lone working procedures for safety.  
 
Use of participant data: Our cohort will provide a unique resource for understanding 
post-stroke psychological problems.  We wish to maximise the potential of the data 
collected, so that it can be used to answer clinically important questions beyond those 
outlined in the primary study.  Certain centres will invite participants to give a blood 
samples that will be stored for future analyses.  Participants can decline this biobanking 
aspect at any stage of the study and still help with other aspects.  The Robertson Centre 
for Biostatistics will hold anonymised patient data within a secure resource.  Our study 
follow-up is limited to eighteen months.  We will ask participants permission to link their 
study data to anonymised data from electronic health-records (clinical, laboratory, 
imaging).  This will allow future studies to look at longer term outcomes.  Again, 
participants can chose to decline this aspect of the study but contribute to the other 
aspects. 
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2 STUDY OBJECTIVES AND PURPOSE  
We propose a study that has been designed to answer pressing clinical questions. 
National and international stroke guidelines recommend early cognitive and mood 
screening but this policy is based on expert opinion and lacks evidence-base. Building 
on our previous pilot work, we will create a programme of research designed to inform 
practice and policy. We will major on themes of “natural history” of neuropsychological 
problems following stroke; screening test accuracy/feasibility and prognosis. 
 
We anticipate that at study completion we will be able to offer:   
• Guidance on the optimal methods to assess for pre-stroke cognitive and mood 
problems.  
• Guidance on the optimal methods to assess for cognitive and mood problems in 
the acute stroke setting and in early follow-up. 
• Descriptions on the natural history of cognitive and mod symptoms following 
stroke.  
• An understanding of clinical, demographic features that predict poor and good 
psychological outcomes following stroke.  
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STUDY DESIGN 
This study will be performed according to the Research Governance Framework for 
Health and Community Care (Second edition, 2006) and WORLD MEDICAL 
ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research 
Involving Human Subjects 1964 (as amended). All investigators and key study 
personnel will undergo biennial GCP training. 
The study design is detailed below and is summarised in the flow chart and schedule. 
The programme of work is based on a prospective observational cohort, recruited at 
time of stroke and followed up with assessments focussing on neuropsychological 
aspects.  The cohort will allow for studies of test properties, studies of prognosis and 
epidemiology.  Inclusion of a biobank and consent to future electronic data linkage 
increases the research potential of the cohort. 
 
3.1 Study Population 
The study will involve participants aged over 18 years with clinical diagnosis of stroke 
or transient ischaemic attack (TIA) who meet the inclusion criteria and have none of the 
specified exclusion criteria. All will give full informed consent or have consent provided 
by appropriate proxy. 
Participants will be consecutive, stroke patients over 18 month recruitment. Primary 
sites will be Glasgow Royal Infirmary (GRI); Royal Alexandra Hospital (RAH) and Queen 
Elizabeth University Hospital (QEUH), with additional recruitment from other Scottish 
Stroke Research Network (SSRN) sites or research active stroke centres in other parts 
of the UK. To allow descriptions of generalizability and feasibility we will adopt an 
inclusive policy, offering testing to all adult (over 18 years) stroke survivors except 
where clinical team feel that any form of testing is inappropriate (for example end of 
life care). We will define stroke using World Health Organisation criteria. Our stroke 
rubric will include TIA and minor stroke and recruitment from outpatient clinics will be 
possible.  Co-recruitment with other observational or investigational trial will be 
possible. 
We will include patients with varying levels of communication problems. Our national 
ethics application will allow us to seek proxy consent for assessment and follow up where 
participant is unable to give direct consent at time of recruitment. The context is disease 
orientated and so will include new TIA/minor stroke seen at clinics as well as inpatients. 
Eligibility screening and recruitment will be performed by stroke research nurses or 
trained researchers. Initial assessment of capacity and willingness to be approached will 
be determined by the clinical team. 
 
3.2 Main Study Inclusion Criteria 
1. Clinical diagnosis of stroke or TIA at time of assessment 
2. Age greater than 18 years. 
3. Clinical team happy that patient is suitable for some form of psychological testing.  
Stroke will be diagnosed by a stroke specialist, defined as a focal neurological event of 
presumed vascular cause.  We will operate no time or imaging based inclusion criteria.  
 
3.3 Main Study Exclusion Criteria 
1. Non-stroke diagnosis at time of assessment. 
2. Unable to consent and no suitable proxy available.  
4. No spoken English pre-stroke. 
4. Prisoners.  
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3.4 Description of the work packages 
We propose a programme of work themed around improving cognitive and mood 
assessment. 
The portfolio is described as interlinked work-packages each with distinct aims and 
objectives.  In addition we offer optional, complementary studies.   
 
Work package one: Assessing pre-stroke psychological problems. 
• To describe prevalence of pre-stroke psychological problems (specifically, 
cognitive decline and depression) in an acute stroke cohort. 
• A separate (optional) study will assess the feasibility of using informant based 
screening tools for pre-stroke depression (GDS-informant scale; SADQ-10) and 
cognitive decline (IQCODE, AD-8) in an acute stroke setting. 
• A separate (optional) study will assess the accuracy of informant based screening 
tools for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) against a reference standard of semi-structured clinical assessment 
(using the Structured Clinical Interview [SCID] for DSM mood disorder and the clinical 
dementia rating [CDR] for cognitive assessment). 
 
Published research describing cognitive and mood problems following stroke assumes 
that the person had no problems prior to the stroke event.  This is overly reductionist 
approach fails to appreciate the complex relationship between psychological symptoms 
and cerebrovascular disease.  Stroke is predominantly a disease of older age and older 
people will show varying degrees of cognitive decline and mood problems.  These may 
be sufficient to warrant a diagnostic label, albeit often a diagnosis of dementia or mood 
disorder is not made in the community.[9]  Both cognitive decline and mood disorder 
seem to be associated with increased risk of stroke.[10]   
To understand the psychological picture seen after stroke we need robust methods of 
capturing the pre-stroke state.  A common approach is to conduct a questionnaire based 
interview with informants (family, friends, carers) and use the description of past 
cognitive and mood symptoms to assign a retrospective label.  Scales are available and 
are used in stroke care, for example the Informant Questionnaire for Cognitive Decline 
in the Elderly (IQCODE).  Our recent systematic review has shown that while test 
properties of informant scales are good in community dwelling older adults, no informant 
questionnaire has been validated in a stroke population.[11,12]   
We will use a classical test accuracy study design to describe the properties of informant 
tools in acute stroke. Stroke research nurses (SRN) or trained researchers will interview 
informants with short questionnaires looking to describe pre-stroke depression and 
cognition.  Within one month of this assessment, a trained member of the research team 
will conduct a semi-structured interview (based on standardised questionnaires of SCID 
and CDR (sum of boxes scoring https://www.alz.washington.edu/cdrnacc.html) with 
patient and family and formulate a clinical assessment of pre-stroke problems.  
Following discussion with a clinician, results will be operationalised as pre-stroke 
dementia or depression probable; possible; unlikely; unable to assess.  
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index test questionnaires will be 
compared against each other and against a reference standard of semi-structured 
clinical assessment. To describe feasibility we will collate numbers completing each test 
fully and partially; time and assistance required for completion. To incorporate feasibility 
into analyses, we will employ an “intention to diagnose” approach, including those 
unable to complete tests.[13] 
 
Work package two: Test accuracy and prognostic utility of brief screening tools 
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• To describe feasibility of using brief screening tools for diagnosis of cognitive and 
mood problems in acute stroke. 
• To describe accuracy of brief screening tools for diagnosis of cognitive and mood 
problems in acute stroke; comparing to each other and to a one month multi-domain 
assessment.  
• To describe prognostic accuracy of a one month multi-domain cognitive and 
mood assessments against detailed assessment at six, twelve, eighteen months.  
• To describe neuropsychological “case-mix” with reference to incident/prevalent 
delirium and impairments that may complicate cognitive and mood testing. 
 
The first step to management of neuropsychological problems is recognition and 
diagnosis. At present we have no agreed method on how or when to assess for these 
problems. Our pilot data suggests that standard multi-domain assessment tools are not 
feasible as a universal screen in the first days post stroke.[5,8] Thus, we suggest a 
neuropsychological assessment paradigm where brief assessments are used in the 
hyperacute period with increasingly detailed assessment at later time period.  
Various brief (less than five minutes) assessment tools for cognition and mood are 
available. Such tools are suited to acute settings and indeed are often used in the ASU, 
however data on test properties are limited.[5] Many of these brief assessments have 
shared items. We have created an instrument that combines elements from popular 
brief tests in a single assessment, allowing derivation of various scores while minimising 
test burden. Our brief mood testing includes a depression and anxiety questionnaire; 
pictorial assessment and single question. Tests for delirium are also included. We have 
not modified assessments for those with communication problems, as describing 
feasibility of tests across a range of stroke related impairment is an important outcome 
of our work. However, the tests used should be feasible for those with mild to moderate 
aphasia. At one month, a longer test battery will include multi-domain screening tool. 
(Assessments described in appendix). 
Our methodology is based on best practice in conduct and reporting guidance for 
dementia test accuracy studies (STARDdem).[6] Index test will be brief screening tools 
(acute assessment) and multi-domain screening tools (one month and beyond). Given 
the dynamic early changes in cognition and mood seen early after stroke, purpose of 
early testing should be to predict later problems. Thus our reference (gold) standard 
comparator will be mood disorder and multi-domain cognitive impairment as described 
by our neuropsychological battery at six, twelve and eighteen months with expert 
consensus diagnosis based on all collated materials at end of study. We recognise that 
these assessments are not diagnostic, rather they offer a suitable compromise between 
validity of assessment and suitability post stroke where formal diagnosis of dementia or 
mood disorder can be challenging. As an optional study, at 12/12 and 12/18 follow-up 
a random selection of participants, will be offered additional face to face clinical 
assessment with a senior stroke neuropsychologist or clinician blinded to other 
assessment scores.  At completion all 6,12,18 month study materials will be reviewed 
by the senior investigators (TQ, NB, JD, DJS) and a consensus diagnosis assigned for 
incident mood disorder and/or incident cognitive disorder, using descriptors of:probable, 
possible, unlikely.  
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index tests will be acute and one 
month assessments and will be compared against each other and reference standard of 
follow up assessment data. From the acute assessments, we will describe the accuracy 
of brief screening tests used in isolation and combined with Boolean operators of 
“OR”/”AND”. To describe feasibility we will collate numbers completing each test fully 
and partially; time and assistance required for completion. To incorporate feasibility into 
analyses, we will employ an “intention to diagnose” approach, including those unable to 
complete tests.[13] 
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Work package three: Describing and predicting neuropsychological prognosis 
• To describe serial change in cognition/mood test scores and to describe 
prevalence of cognitive and mood diagnoses at time points of one month; six month; 
twelve months and eighteen months. 
• To describe univariate and adjusted independent predictors of both post stroke 
cognitive decline and post stroke mood disorder. 
• To develop, calibrate and validate predictive models for post stroke 
neuropsychological factors. 
• To estimate likely recruitment, “event rates” and loss to follow up for future 
cognitive/mood studies. 
Systematic reviews suggest substantial post stroke neuropsychological burden, however 
these data may have limited generalizability to acute settings.[14] Problems include 
selection bias; non-acute sampling and lack of data on important comorbidities such as 
delirium and prevalent dementia. Our pilot data describes a high incidence of 
cognitive/mood problems in first days post stroke with trajectories of improvement, 
stabilisation and decline.[8] We need “real world” data on baseline and natural history 
of neuropsychological change to inform practice, research and policy in this regard.  
Follow up will be at six, twelve and eighteen months, time-points chosen to reflect 
common clinical and study assessment times. Assessments will be face-to-face and 
performed in study centres or in participant’s home as required/requested. There will 
be opportunity for telephone assessment if required.  The six/twelve/eighteen month 
assessments will be performed by trained members of the research team. We make no 
assumptions around the pathology underlying post stroke cognitive change and so we 
have devised a battery of assessment that will allow derivation of scores for “vascular” 
dementia and Alzheimer’s Disease dementia.[15,16] While our principal mood interest 
is depression we have chosen a mood assessment that screens for various other 
disorders using structured clinical interview.[17] (see appendix for full details of all 
assessments)  After 12 and 18 month follow-up, a proportion of participants will be 
asked if they wish to take part in an optional  study, where they are assessed by a 
clinician and assigned a clinical label.  These results will be compared to our standard 
assessments. 
The work is modelled around the “fundamental” prognosis research paradigm as 
described by MRC PROGRESS prognosis research group.[18] Taking acute stroke as 
start-point, we will create an inception cohort, collecting clinical, demographic and 
neuropsychological “phenotyping” data at baseline and then prospectively following up 
with serial cognitive and mood assessments. 
For prospective follow up, outcomes of interest are change in scores on cognitive and 
mood screening tools and incident clinical mood disorder or multi-domain cognitive 
impairment. Multi-domain tools will be analysed as ordinal data and dichotomised at 
varying thresholds. Neuropsychological battery data will be transformed into z scores, 
with impairment defined as greater than 1.5 standard deviations below age and sex 
based norms. We will collect data on recurrent stroke, complications (falls, seizure, 
infection) hospitalisation/institutionalisation and death.  
We will explore repeated measures analyses adjusting for baseline covariates and 
describe temporal change in test scores. We will create prognostic models and if data 
allow predictive risk scores for the various cognitive and mood outcomes, describing 
calibration; discrimination and validation using bootstrapping.  
 
3.5 Identification of Participants and Consent 
Potential participants will be identified (by clinical or case note review by a member of 
the clinical team or attending Doctor) whilst in-patients or in a cerebrovascular out-
patient clinic. If the patient asks not to be approached no further action will be taken.  
The clinical team will make an assessment of capacity to consent to inclusion in the 
study. The principal criterion for entry into the study is that the treating team believe 
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an attempt at cognitive and mood assessment is appropriate.  We have used this 
approach in previous pilot studies and it has worked well.  
Following identification, potential participants will be approached in person and asked 
whether they would wish to consider taking part in the trial. Those who are willing to 
hear more will be given the participant information sheet (PIS) and a date (at least 24 
hours later) arranged for further discussion with a member of the research team. 
Eligibility will be confirmed by an investigator.  
At this second meeting, subjects will be asked if they have any questions and those who 
wish to participate will be asked to sign the consent form. Two copies will be signed 
(one each for the participant and the site file) and a copy of the signed consent form 
will be inserted into the casenotes. 
Consent will be taken by one of the investigators, research nurse or trained researcher. 
Consent will be staged to ensure that participation in the study is always voluntary and 
fully informed. At all points we will stress that taking part in the study is voluntary and 
if patients wish to terminate the cognitive testing early we will respect this wish which 
will not impact on the clinical care that they receive. 
For patients unable to provide informed consent, we will seek consent from a legal proxy 
or family, carer, friend.  We have outlined the details of this approach in the section on 
adults lacking capacity (see below). 
We offer additional complementary studies looking at informant assessment; blood 
taking for biobanking; prospective follow-up; clinical diagnostic study; data storage and 
linkage.  Participants will be given the option to consent to all aspects of the study or to 
limit their participation to certain aspects only.  In centres where biobanking is not 
possible this will not be included in consent form. 
We recognise that cognition can change over time.  Our pilot data suggests that 
immediately after stroke patients can have cognitive impairments that improve over the 
first weeks.[8]  At early follow-up (around 4 weeks post stroke) the participant’s 
capacity to consent will be reassessed.   
 
3.5.1 Including participants unable to provide informed consent  
We wish to include a representative sample of stroke survivors. For a study that is 
concerned with post stroke psychological problems we need to include a spectrum of 
cognitive abilities and impairments.  Previous work in this area has been limited by 
including non-representative populations and so results have lacked real world validity.   
To ensure our results have clinical utility, we will be maximally inclusive in our 
recruitment strategy.  
Patients may have cognitive problems, problems with communication/language or 
physical impairments. Some may have severe communication or cognitive difficulties.  
The assessment battery we propose, while not specific to aphasia, should be suitable 
for those with mild to moderate communication problems.    We will only assess those 
patients where the clinical team feel that an attempt at assessment of mood or cognition 
is appropriate. 
We do not wish to deny stroke survivors involvement in a study that might lead to 
benefit for those like them.  We believe the risk of participation in this observational 
study is minimal. 
Decisions on patient capacity to consent will be made by the Consultant/senior members 
of the Acute Stroke team at daily ward rounds or on first assessment. This is a standard 
part of usual clinical practice for stroke clinical teams. 
Where the ward clinical team determine a patient does not have capacity to consent, 
we would seek informed consent from a close relative/welfare guardian. We would still 
include the patient in decision making around the study as possible.  Choice of proxy 
will be made by the patient, either at the time of testing or based on previously 
expressed wishes.  
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We will involve the nearest relative/guardian/welfare attorney in the study, regardless 
of patient ability to consent as some of our measures require to be completed by an 
informant that knows the patient well. We have developed a specific information leaflet 
(PIS) for this purpose. 
Capacity to consent will be re-assessed at one month follow-up.  If a patient has been 
included using proxy consent but it is felt the patient now has capacity, consent will be 
rechecked at the follow-up visit.  In this scenario, if the participant does not give consent 
the participant would be withdrawn from the study. No further data or tissue would be 
collected or any other research procedures carried out on or in relation to the 
participant.  We would ask if those identifiable data or tissue already collected with 
consent could be retained and used in the study.  If the participant does not agree to 
this, the data and biobank samples will be removed from study registers.  
If the patient is felt to no longer have capacity to consent, the assessor will follow 
procedures outlined for including a patient that lacks capacity.  In this scenario, if a 
relevant proxy does not give consent the participant would be withdrawn from the study. 
Identifiable data or tissue already collected with consent would be retained and used in 
the study. No further data or tissue would be collected or any other research procedures 
carried out on or in relation to the participant. 
At subsequent follow-up visits, capacity to consent will not be formally reassessed but 
we will check that the participant is still happy to continue with the study and emphasise 
that the participant can withdraw at any time and not give a reason 
 
3.5.2 Withdrawal of subjects 
Participants will be told that they can withdraw their consent at any time without 
giving a reason and that this will not affect their care in any way.  Participants will be 
informed that they can participate in any or all of the follow up assessments. 
 
3.6 Assessment Schedule 
The study will comprise a maximum of seven patient assessments.  A short baseline 
assessment; (optional) semi-structured clinical interview within first month; one month 
follow-up with short screening tests; then six, twelve, eighteen month follow-ups with 
multi-domain assessments with an optional clinical diagnostic assessment. Following the 
baseline assessments, each visit has a two week time window either side of the 
scheduled date during which it can be completed.  Other than baseline assessment, 
assessments will be preferentially performed in the Clinical Research Facility of the 
participating hospital.  There is the option for home assessment or for telephone 
assessment if required.  
 
3.6.1 Baseline assessment  
This will be completed as soon as possible following index stroke but not before 24 
hours to allow participants sufficient time to read study materials.  Initial assessment 
will confirm eligibility and consent.  Clinical and demographic details will be extracted 
from case-notes.  Clinical assessment will include National Institute of Health Stroke 
Scale (NIHSS) score, modified Rankin Scale (mRS); Barthel Index (BI): five question 
assessment for frailty (Fried), Lawton Extended Activities of Daily Living (E-ADL) a 
short questionnaire around physical activity (Brief Physical Activity Assessment [BPAA] 
and a measure of social inclusion (Medical Outcome Study Social Support 
Scale[MOSS-SSS] 4 item).   
The cognitive assessment (AMT-plus) will comprise the 10 point abbreviated mental 
test and clock drawing test, supplemented by a recall question, one letter fluency test 
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and naming months of the year backwards.  This battery allows us to derive the score 
from 9 different screening tests without performing each test individually.  We will 
assess for delirium using Confusion Assessment Method (CAM-ICU).  We will assess 
for mood symptoms using Depression Intensity Scale Circles (DISCS) and the short 
forms of Patient Health Questionnaire PHQ-2/GAD-2.  If patient agrees and facility is 
available, bloods and urine will be taken for biobanking. 
Informants will be chosen by the stroke patient or ward staff if stroke patient unable 
to make this decision.  Informants will complete brief questionnaires describing the 
patient’s mood and cognition pre-stroke.  Questionnaires will comprise the Informant 
Questionnaire for Cognitive Decline in the Elderly (IQCODE); the Ascertain Dementia 
screener (AD-8).  The Geriatric Depression Scale informant version (GDS-i) and 
Stroke Aphasia Depression Questionnaire (SAD-Q).  Patients pre-stroke functional 
ability will be assessed using the BI, Fried and E-ADL.  The baseline visit will confirm a 
suitable time to organise the semi-structured clinical interview. 
 
3.6.1.1 Semi-structured clinical interview 
This optional study interview will be performed within one month of baseline 
assessment.  A trained member of the research team will interview the patient and 
informant.  Interview will cover diagnostic criteria necessary to assign a label of major 
neurocognitive disorder; delirium and major depression.  The content will be based on 
the operationalised structured clinical interview for DSM-5 (SCID) and the Clinical 
Dementia Rating (CDR – sum of boxes scoring 
https://www.alz.washington.edu/cdrnacc.html).  The interviewer will not have access 
to previous cognitive and mood screening assessment results.  Results of the interview 
will be discussed with the study team and a final consensus label will be 
operationalised as: probable cognitive/mood disorder pre-stroke; possible disorder; 
unlikely disorder; unable to assign a label.  We will emphasise that the assessments 
are not diagnostic but will share the information with the treating clinical team on 
request.   
3.6.2 One month assessment  
The one month assessment will be performed at a time convenient for the patient and 
informant.  One month assessments will comprise a repeat of the short patient cognitive 
battery performed at baseline (AMT-plus, CAM-ICU), the Oxford Cognitive Screen (OCS) 
and the complete Patient Health Questionnaire (PHQ-SADS). We will collect information 
on post stroke complications (stroke, cardiac, seizure, infection, falls, fatigue [using 
brief fatigue inventory]) and any change in medication.  If the patient is agreeable and 
if available then further samples for biobanking will be taken.  
  
3.6.3 Six, twelve, eighteen month visit 
Assessments at six, twelve and eighteen months will be performed by researchers 
trained in the various assessments.  Patients will be assessed according to Vascular 
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network 
vascular cognitive impairment harmonization standards (VCI-H).[15,16]  Function will 
be assessed with mRS, BI, EADL and BPAA, MOSS-SSS at 12 and 18 month.  The patient 
will be asked about specific stroke complications of interest.  List of medication will be 
updated. 
At the six month assessment the assessor  will use the 30 minute version of the VCI-H  
If the patient struggles with this assessment, does not wish such a lengthy assessment 
or the assessment is not possible for any other reason, we have proposed a shorter 
assessment based on the VCI-H five minute battery.  For twelve and eighteen month 
assessments the patient will be offered the choice of full VCI-H (around 45 minutes) or 
shorter assessments. Choice of assessment used will be at the discretion of the 
researcher in discussion with participant and informant.   
In addition at the twelve and eighteen month visits the patient will complete generic 
and stroke specific quality of life measures: Euro-Qol 5 domains (EQ-5D); Short Form 
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of the Stroke Impact Scale (SIS) and Patient Reported Evaluation of Cognitive Status 
(PRECiS). 
The informant will complete a caregiver burden scale (Zarit Caregiver Burden) and will 
complete the generic quality of life EQ-5D.  At 12 and 18 months the informant will 
complete the cognitive and mood questionnaires employed at baseline (IQCODE,Yes 
include  GDS-i) and will complete the neuropsychiatric inventory questionnaire (NPI-Q). 
Completion of the eighteen month visit marks the end of the study.  
 
3.7 Biobanking 
Urine and blood samples will be obtained as outlined in the appendix and then will be 
stored in the NHS GG&C biorepository; all aspects of collection and storage will be in 
line with NHS Greater Glasgow and Clyde policies.  Biobanking samples will be from 
GG&C participants only.  
Venepuncture will be performed from the antecubital fossa where possible (using a ~ 
19G (green needle) vacutainer (or similar) system). Three lavender top EDTA tube (or 
similar), a gold top clot activator (or similar) for serum chemistry measures and two 
grey tube (or similar) for glucose determination will be collected (ca 40 mls in total) 
 
3.8 Team Expertise and Project Management 
NHS Greater Glasgow and Clyde have agreed to act as sponsor. All protocols will be 
stored in publically accessible registers. Creation of case report forms (CRF), data 
management, archiving and analyses will be supported by Robertson Centre for 
Biostatistics. 
Terry Quinn (Glasgow) will lead the work and act as principal investigator (PI). He has 
particular expertise in stroke study methodology; test accuracy and cognitive/functional 
assessments. The core research team will include stroke research nurses at both sites; 
new researcher posts, designed to allow study towards PhD and dedicated statistical 
support. The multifaceted nature of the topic requires knowledge and skills in various 
areas and our collaborators bring this multidisciplinary expertise. Our experienced site 
leads have international reputations for excellent multicentre, prospective research: 
Peter Langhorne (GRI); Kennedy Lees (QEUH). Ian Ford (Glasgow) will support all 
aspects of statistical analysis. Niall Broomfield (clinical lead for Glasgow stroke 
psychology services) will provide training for research nurses and doctoral students and 
will facilitate clinical assessments.  
We will form an advisory group who will provide oversight and guidance, the group will 
have representation from stroke survivors (x2); primary care; research networks 
(SSRN, SCDRN); neuropsychology (Jonathan Evans, Glasgow); the local stroke 
managed clinical network lead (Christine McAlpine) and an external expert on 
neuropsychological outcomes in stroke (Sarah Pendlebury, Oxford). 
 
4. Rater training  
We propose assessments using a battery of differing neuropsychological and functional 
tests.  We have extensive experience of training researchers in use of assessment 
scales.  Our previous work around outcomes assessments for large clinical trials has 
shown the importance of offering training, standardisation and quality control, even 
for those tests considered “routine” in stroke research.[19] 
 
We will use training materials produced for use with the assessments of interest.  
Online training resources will be available for functional outcomes (NIHSS, mRS. BI).  
For the neuropsychological tests we will offer face-to-face training.  Educational 
materials will be complemented by an investigator work book and Standard operating 
Procedures (SOPs) for all of the assessments required in the study.   To accompany 
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the SOPs we will create study-specific case report forms to facilitate standardised 
assessment and scoring.  For PhD student assessors, the first three assessments will 
be supervised.  There is scope for further direct assessment and training as required. 
Contact details of the principal investigator and research team will be made available 
to all the sites should issues arise. 
 
 
5. PHARMACOVIGILENCE 
We propose an observational study with no intervention or change to usual care.  
There are no pharmacovigilance issues specific to this work.  
 
 
6 STATISTICS AND DATA ANALYSIS 
6.1 Primary Outcomes 
We propose a programme of inter-related projects themed around improving cognitive 
and mood assessment.   
The portfolio is described as work-packages and optional studies each with distinct aims 
and objectives.  The outcomes and analysis plan for each will be described in turn.  
 
WP 1: Assessing pre-stroke psychological problems. 
• To describe prevalence (n, [%]) of pre-stroke psychological problems 
(specifically, cognitive decline and depression) in an acute stroke cohort. 
• As part of an optional, separate study, to assess the feasibility (n, [%] return 
rate, items complete, time for testing) of using informant based screening tools 
for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) in an acute stroke setting. 
• As part of an optional, separate study, to assess the accuracy (sensitivity, 
specificity, positive/negative predictive value) of informant based screening tools 
for pre-stroke depression (GDS-informant scale; SADQ-10) and cognitive decline 
(IQCODE, AD-8) against a reference standard of semi-structured clinical 
assessment. 
 
WP 2: Test accuracy and prognostic utility of brief screening tools 
• To describe feasibility (n, [%] items complete, time for testing) of using brief 
screening tools for diagnosis of cognitive and mood problems in acute stroke. 
• To describe accuracy (sensitivity, specificity, positive/negative predictive value) 
of brief screening tools for diagnosis of cognitive and mood problems in acute 
stroke; comparing to each other and to a one month multi-domain assessment.  
• To describe prognostic accuracy (sensitivity, specificity, positive/negative 
predictive value, ROC analyses) of a one month multi-domain cognitive and 
mood assessments against detailed assessment at six, twelve, eighteen months.  
• To describe neuropsychological “case-mix” with reference to (n, [%]) prevalence 
of pre-stroke cognitive decline; pre-stroke mood disorder (depression) and 
incident/prevalent delirium. 
 
Work package three: Describing and predicting neuropsychological prognosis 
• To describe the natural history (rates of outcomes; change over time) of post 
stroke neuropsychological problems at time points of one month; six month; 
twelve months and eighteen months. 
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• To describe univariate and adjusted independent predictors of both post stroke 
cognitive decline and post stroke mood disorder (odds ratios, with corresponding 
95% confidence intervals). 
• To develop, calibrate and validate predictive models for post stroke 
neuropsychological factors. 
• To estimate likely recruitment, “event rates” and loss to follow up for future 
cognitive/mood studies. 
 
6.2 Statistical Analysis Plan 
The study will have a comprehensive Statistical Analysis Plan (SAP), which will govern 
all statistical aspects of the study, and will be authored by the Trial Statistician.  Full 
details of all statistical issues and planned statistical analyses will be specified in the 
SAP which will be agreed before analyses begin. 
 
6.3 Overview of statistical analysis  
 
6.3.1 WP1: Assessing pre-stroke psychological problems 
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index test questionnaires will be 
compared against each other and against a reference standard of semi-structured 
clinical assessment. From the acute assessments, we will describe the accuracy of 
brief screening tests used in isolation and combined with Boolean operators of 
“OR”/”AND”. To describe feasibility we will collate numbers completing each test fully 
and partially; time and assistance required for completion. To incorporate feasibility 
into analyses, we will employ an “intention to diagnose” approach, including those 
unable to complete tests. 
 
6.3.2 WP2: Test accuracy and prognostic utility of brief screening tools 
Accuracy of screening tools will be described in terms of sensitivity; specificity; 
predictive value; receiver operating space analyses. Index tests will be acute and one 
month assessments and will be compared against each other and reference standard 
of follow up assessment data. From the acute assessments, we will describe the 
accuracy of brief screening tests used in isolation and combined with Boolean 
operators of “OR”/”AND”. To describe feasibility we will collate numbers completing 
each test fully and partially; time and assistance required for completion. To 
incorporate feasibility into analyses, we will employ an “intention to diagnose” 
approach, including those unable to complete tests.  
 
6.3.3 Work Package three: Describing and predicting neuropsychological 
prognosis 
For prospective follow up, outcomes of interest are change in scores on cognitive and 
mood screening tools and incident clinical mood disorder or multi-domain cognitive 
impairment. Multi-domain tools will be analysed as ordinal data and dichotomised at 
varying thresholds. Neuropsychological battery data will be transformed into z scores, 
with impairment defined as greater than 1.5 standard deviations below age and sex 
based norms. We will collect data on recurrent stroke, complications (falls, seizure, 
infection) hospitalisation/institutionalisation and death.  All data from 6,12,18 month 
assessments will be assessed by a panel of the senior investigators and a consensus 
assessment for incident mood disorder and incident cognitive disorder made. 
 
We will use generalized linear models for prospective data to describe associations of 
baseline characteristics with change across repeated neuropsychological measures. 
With our statistician we will use varying competing risk survival models to account for 
events that may precede our neuropsychological outcomes of interest (mortality). 
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We will describe univariate and adjusted independent predictors of “outcomes”. We 
will describe odds-ratios for binary “outcomes” at chosen time-points, using 
multivariate Poisson regression. 
 
We will explore repeated measures analyses adjusting for baseline covariates and 
describe temporal change in test scores. We will create prognostic models and if data 
allow predictive risk scores for the various cognitive and mood outcomes, describing 
calibration; discrimination and validation using bootstrapping.  
 
 
6.4 General Considerations 
In general we will apply parametric statistical methods; any variable not suitable for 
parametric analysis will be analysed using non-parametric methods. 
Descriptive statistics by study centre will be provided. A summary and listing of patients 
with protocol violations will be produced.  
 
6.5 Software for Statistical Analysis 
All statistical analysis will be performed using SAS version 9.1 or later. 
 
6.6 Sample Size 
We anticipate recruiting n=500 participants across the three sites over 18 months 
recruitment.  We expect substantial attrition (death, loss to follow-up, development of 
cognitive problems that preclude further assessment) and anticipate n=400 one month; 
n=350 six month; n=300 twelve month and n=200 eighteen month follow up data. 
Data to allow sample size calculations for future studies is an intended output of this 
work. Recognising the uncertainty, we do not offer definitive “power” calculation per se, 
but our recruitment estimates suggest we will have sufficient patients to achieve our 
research aims.  
Scottish Stroke Care Audit reports over 1500 stroke discharges per annum across our 
three Glasgow sites. Our pilot data suggest that over 18 month recruitment, at a 
conservative estimate 500 will be suitable and agree to early assessment and follow up. 
Based on Information Services Division stroke data, we project estimates of n=400 one 
month; n=350 six month; n=300 twelve month and n=200 eighteen month follow up 
data. These numbers make our study equivalent to or larger than other international 
neuropsychological focused studies. By using research nurses for initial assessments 
and three full time PhD student assessors for follow up, daily maximum number of 
assessments per team member would be two. 
For the optional study describing accuracy of informant questionnaires we have a 
separate power calculation.  Using a nomogram approach [20] describing test properties 
of informant questionnaires, based on estimated prevalence of pre-stroke problems of 
20% and anticipated specificity of around 0.8, recruiting n=100 gives sufficient power 
to assess the scales. 
WP1 and WP2. Our recruitment is designed mindful of potential attrition.  For the test 
accuracy work, using a nomogram [20] based on prevalence of 40% cognitive 
impairment at one month, (α=0.05); our estimate of 400 participants would allow 
description of accuracy across a full range of plausible sensitivity/specificity. 
WP3. Based on published data on mood we would anticipate annual rates of outcomes 
at around 30% with n=125 “outcomes” in survivors at end of follow up (although our 
data suggests rates of cognitive/mood disorder may be considerably higher in 
unselected cohorts).  This gives sufficient power for the prospective models we have 
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planned.   Based on our anticipated recruitment and retention, prognostic models will 
have power to describe multiple covariates.   
The optional subgroup study where results on neuropsychological assessment are 
compared to clinical assessment will be performed on n=25 in the first instance.  This 
is a pragmatic sample size.  Recruitment will be of sequential consenting participants 
from the Glasgow sites.  
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6.7 Procedures for Accounting for Missing Data 
There will be no imputation of missing data for the primary or secondary endpoints in 
the first instance.  As part of the analyses we will explore the effects of various 
approaches to handling missing data. 
 
6.8 Procedures for Reporting Deviations from the Original 
Statistical Plan  
A detailed statistical analysis plan (SAP) will be agreed before analyses begin. Any 
deviations from this plan will be documented and justified in the final study report. 
 
6.9 Selection of Subjects to be Included in the Analyses 
We will run analyses including those with full test data and those with missing data, 
using intention to diagnose approaches.  
 
7 STUDY CLOSURE / DEFINITION OF END OF STUDY 
The study will end when the last patient has their last study visit. 
 
8 Source Data/Documents 
8.1 Case Report Forms / Electronic Data Record 
Primary data collection will use paper based case report form (CRF).  Inpatient 
assessment scores will be shared with the hospital team on request. For out-
patient/community assessments, screening test summary results will not be shared with 
the General Practitioner (GP).  This approach was suggested by the Scotland A Research 
Ethics Committee and recognises that the screening tests are not diagnostic If 
assessment suggests a serious cognitive or mood disorder that requires urgent 
treatment results will be shared with the appropriate team.  
All participant data will be identified by the participant study identification number. CRF 
data will be securely transferred to the Robertson Centre for Biostatistics (RCB) for 
electronic entry. Data will be validated at the point of entry into and at regular intervals 
during the study.  Data discrepancies will be flagged to the study site by the statistician 
and any data changes will be recorded in order to maintain a complete audit trail (reason 
for change, date change made, who made change). 
 
8.1.1 Data Handling and Record Keeping 
All CRF data will be held in the RCB. The RCB manages all studies to the highest 
standards in accordance with its internal Standard Operating Procedures, ICH Good 
Clinical Practice, the European Union Clinical Trials Directive 2001/20/EC, the ICH 
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Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9 and all other 
industry legal and regulatory guidelines. It has extensive experience of managing data 
in the context of privacy and data protection legislature, including the Data Protection 
Act 1998 and EU Data Protection Directive 95/46/EC. The Centre is certified for ISO 
9001:2008 for its quality systems, has TickIT accreditation for its software development 
and is BS7799 compliant.  
Only the study investigators will have access to participant identifiable data. We will 
permit trial-related monitoring, audits and regulatory inspections and will provide direct 
access to source data and documents. 
 
8.1.3 Data Security 
The RCB systems are fully validated in accordance with industry and regulatory 
standards, and incorporate controlled access security. High volume servers are firewall 
protected and preventative system maintenance policies are in place to ensure no loss 
of service. Web servers are secured by digital certificates. Data integrity is assured by 
strictly controlled procedures, including secure data transfer procedures. 
 
8.1.4 Database Software 
Data will be stored in MS SQL Server. 
 
8.1.5 Record Retention 
To enable evaluations and/or audits from regulatory authorities, the investigator agrees 
to keep records, including the identity of all participating subjects (sufficient information 
to link records), all original signed informed consent forms, source document in 
accordance with ICH GCP, local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer.  Data will be retained at the Data Centre for a minimum 
of 10 years. 
 
8.1.6 Archiving 
CRF data will be stored by the Robertson Centre for Biostatistics for 10 years after 
completion of the study.  
 
9 STUDY MANAGEMENT 
The trial management teams will be in place before recruitment begins.  
 
9.1 Routine Management of Study 
The study will be co-ordinated from the Glasgow Royal Infirmary, Glasgow by the PI. 
The study will be subject to review at any time by the West Glasgow Local Research 
Ethics Committee. 
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9.2 Trial Management Committee (TMC) 
There will be no DSMC for this observational trial.  Independent oversite will be provided 
by the study advisory group.  
 
9.3 Data Safety Monitoring Committee (DSMC) 
There will be no DSMC for this observational trial.  
 
10 Study Monitoring and Auditing 
Study monitoring visits will be conducted according to a study-specific monitoring plan 
devised by NHS Greater Glasgow and Clyde and subsequent monitoring reports will be 
reviewed by NHS Greater Glasgow and Clyde. The Sponsor, NHS Greater Glasgow and 
Clyde, audit a randomly selected 10% of studies conducted under the Research 
Governance Framework per annum, as well as those identified using a risk assessment 
tool as specifically requiring assessment. Investigators and site staff will notified in 
advance of any audit and/or monitoring visits. 
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11 Protocol Amendments 
Any change in the study protocol will require an amendment. Any proposed protocol 
amendments will be initiated by the Chief Investigator and any required amendment 
forms will be submitted to the regulatory authority, ethics committee and sponsor. The 
Sponsor will determine whether an amendment is non-substantial or substantial. All 
amended versions of the protocol will be signed by the Chief Investigator and sponsor 
representative. Before the amended protocol can be implemented (or sent to other 
participating sites) favourable opinion/approval must be sought from the original 
reviewing REC and Greater Glasgow & Clyde Health Board Research and Development 
(R & D) office. The Chief Investigator will sign any amended versions of the protocol. 
All protocol versions and their amendments must be notified to the study team and to 
the data centre. 
 
12 ETHICAL CONSIDERATIONS 
12.1 Ethical Conduct of Study  
Study will be carried on accordance with the World Medical Association Declaration of 
Helsinki (1964) and it revisions (Tokyo (1975), Venice (1983), Hong Kong (1989), South 
Africa (1996), Edinburgh (2000), Seoul (2008) and Fortaleza (2013). 
There are no special ethical considerations pertaining to this study. Favourable ethical 
opinion will be sought before patients are entered into this study. The Chief Investigator 
will update the ethics committee of any new information related to the study. 
 
12.2 Informed Consent 
The clinical team will assess study participant’s ability to provide informed consent.  
Where possible we will obtain written informed consent from both study patient and 
informant. 
Where a patient is unable to provide informed consent but clinical team are still happy 
for the person to participate in the study, informed consent will be sought from a suitable 
proxy.  Choice of proxy will be guided by patient preference expressed at time of 
assessment or expressed pre-stroke.  
The research nurse or trained member of the research team will explain the exact nature 
of the study in writing, provide patient and carer information sheets, and verbal 
information.  Study participants will be informed that they are free to withdraw their 
consent from the study or study treatment at any time.  
 
13 INSURANCE AND INDEMNITY 
The study is sponsored by NHS Greater Glasgow and Clyde. The sponsors will be liable 
for negligent harm caused by the design of the trial. NHS Indemnity is provided under 
the Clinical Negligence and Other Risks Indemnity Scheme (CNORIS). As the 
substantive employer of the CI, The University of Glasgow also has insurance with 
Newline. It will be confirmed prior to the study starting that insurance cover will be 
provided automatically under the current policy. The insurance cover will be subject to 
NHS indemnity being in place and Ethics Committee approval being obtained. 
The NHS has a duty of care to patients treated, whether or not the patient is taking 
part in a clinical trial, and the NHS remains liable for clinical negligence and other 
negligent harm to patients under this duty of care.  
As this is a clinician-led study there are no arrangements for no-fault compensation. 
 
14 FUNDING 
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The study is funded by a Chief Scientist Office / Stroke Association Programme grant. 
 
15 ANNUAL REPORTS 
The funders mandate progress report and outputs to be submitted electronically via the 
Researchfish resource; these will be updated in real time and reviewed annually. Annual 
reports will be submitted to the ethics committee, regulatory authority and sponsor with 
the first submitted one year after the date that all trial related approvals are in place. 
 
17 Dissemination of Findings 
Study results will be submitted to an International Conference and will be submitted for 
publication in a peer review journal. No personal data will be used when publishing the 
results.  A lay summary and other material as appropriate will be offered to those 
participants who wish to receive it.  Participants will be asked at their last study visit if 
they are happy to be contacted and the preferred method for contact.  These data will 
be held securely in the CRF in a password protected file that is separate from the main 
study archive. 
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Appendix 2: Informant Questionnaire on Cognitive 
Decline in the Elderly- Short form (IQCODE-SF) 
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Appendix 3: Acquired Dementia 8 (AD8) 
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Appendix 4: AMT10 and Mini-MoCA Assessment 
*Mini MoCA questions were 3, 10,11 & 14. Scoring for Mini-Moca: question 3= 1 point for each part of date (day, month 
and year) recalled correctly (out of 3); question 10= 1 point for each word (face, velvet, church, daisy, red) recalled 
correctly (out of 5); question 11= 1 point for each part of clock (face, numbers, hands) drawn correctly (out of 3); 
question 14= 1 point if >10 words in 1 minute. 
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Appendix 5: Chapter 4, search syntax for 
systematic review 
Search A 
Pre-stroke depression focus search:  
1. pre-stroke.mp.  
2. prestroke.mp.  
3. premorbid.mp.  
4. 1 or 2 or 3  
5. Mood Disorder Questionnaire/ or mood change/ or "Profile of Mood States"/ or 
mood/ or mood stabilizer/ or mood.mp. or mood disorder/ or mood disorder 
assessment/  
6. depression/  
7. 5 or 6  
8. 4 and 7  
9. limit 8 to human  
10. (depressi$ adj2 "before the stroke").mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier]  
11. (depressi$ adj2 "history of").mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier] 
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12. 1 or 2 or 3 or 10 or 11 
13. 12 and 7  
14. limit 13 to human  
15. stroke/  
16. 14 and 15 
Search B 
Post-stroke depression search: 
1. exp Cerebrovascular Disorders/ 
2. stroke*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
3. poststroke*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
4. cerebrovascular*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
5. cerebral vascular.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
6. 2 or 3 
7. 4 or 5 
8. infarct*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
9. isch?emi*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
10. thrombo*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
11. emboli*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
12. apoplexy.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
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13. 8 or 9 or 10 or 11 or 12 
14. cerebral.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
15. intracerebral.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
16. intracranial.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
17. brain*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
18. cerebellar.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
19. vertebrobasilar.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
20. 14 or 15 or 16 or 17 or 18 or 19 
21. h?emorrhage.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
22. bleed.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
23. 21 or 22 
24. 13 and 20 
25. 20 and 23 
26. 1 or 6 or 7 or 24 or 25 
27. Depression/ 
28. Depressive Disorder/ 
29. 27 or 28 
30. 26 and 29 
31. limit 30 to human 
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Appendix 6: Chapter 4 Risk of bias assessment 
rationale 
Prevalence:- 
Specifically, studies were assessed based upon 1) whether the study had a 
particular focus upon assessment of pre-stroke depression, 2) if the studies 
cohort was recruited in an acceptable way, 3) if the study population’s stroke 
diagnosis was consistent with WHO criteria, 4) risk of over/under estimation in 
reported pre-stroke depression rates, and 5) the generalisability of their study 
population:   
1) A study was required to explicitly state intention to investigate pre-stroke 
depression (or at least pre-stroke psychological functioning) as a primary 
variable of interest (either to determine prevalence or association with a post-
stroke outcome) to be considered to have a particular focus on pre-stroke 
depression.  If a study assessed pre-stroke depression simply to control for it as a 
covariate, it was not deemed to have a particular focus on pre-stroke 
depression. 
2)  Recruitment was required to be based upon consecutive admissions to a given 
setting; i.e. a non-pre-selected stroke population.  Studies that failed to do this 
would be scored as being high risk of bias. 
3)  Stroke diagnosis was considered to be consistent with WHO if explicitly 
stated, or if diagnosis was described in sufficient detail as to be likely to be 
consistent with WHO. If no information was given regarding how the stroke was 
defined, studies were classified as being of unclear risk of bias. If diagnosis was 
inconsistent with WHO, it was deemed to be at high risk of bias. 
4) Risk of over/underestimation was based upon means of assessment and 
restriction placed within those assessments.  For instance, if studies assessed 
pre-stroke depression using medical records, they were deemed to be at risk of 
underestimating pre-stroke depression since receiving a formal diagnosis of 
depression requires patients to seek help for their depression, which not 
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everyone will do.  Similarly, self-report methods that asked patients if they had 
ever been diagnosed with depression suffer in this same way, but with added 
recall or social desirability influences that could further affect reported rates.  
Informant questionnaires were limited in that they require an informant to know 
about the patient’s prior psychiatric history; and screening tools are liable to 
overestimate cases of depression. On this basis, assessment via a comprehensive 
clinical interview that established cases of depression based on reported 
symptoms meeting DSM criteria—rather than simply existent diagnosis, evidence 
of treatment for depression, or symptoms not well defined enough to establish 
DSM criteria (e.g. screening tool cut-offs)—was deemed to be the only method 
that minimised bias to an acceptable level and as such would be scored as low-
ROB.  All other assessment methods were scored as high-ROB.  Studies in which 
the assessment method was unclear were scored as unclear ROB. 
5) Since our exclusion criteria rejected studies with particularly poor population 
generalisability, generalisability assessments in the ROB review were 
predominantly based upon the exclusion of patients whose issues may affect 
reported pre-stroke depression rates.  For example, pre-stroke dementia, pre-
stroke disability, first ever strokes only, concurrent psychiatric disorders, 
previous alcohol or drug misuse were deemed as being high risk of bias; age 
restrictions or exclusion of TIA’s were deemed unclear risk of bias due to 
reduced overall generalisability of population.   Studies were also scored as 
having a high risk of bias in this category if there was uncertainty regarding the 
overall generalisability of their inclusion criteria. 
 
Model assessment:- 
Of the covariates controlled for, the most commonly cited variable associated 
with post-stroke depression across four systematic reviews was ‘post-stroke 
functional impairment’ or ‘stroke severity’. [1-4]  As post-stroke functional 
impairment and stroke severity are highly linked [5], we required all studies to 
control for one of these variables to achieve a positive ROB review in this 
category.  The ‘event-covariate ratio’ category required studies to have 10 
events (i.e. cases of PSD) per covariate controlled for in their model [6,7].  For 
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‘collinearity control’, studies were deemed to meet this criterion if they ran 
their multiple regression using stepwise measures or alternatively ran explicit 
collinearity tests.  We also judged the quality of the statistical model based 
upon control for changes in care pathway.  Altered care-pathway has been 
demonstrated to be a potential consequence of detection of pre-stroke 
depression in clinical practice.  Specifically, reports suggest that patients with 
pre-stroke depression are more likely to be administered prophylactic 
(preventative) treatment for post-stroke depression, in addition to an increased 
likelihood to be referred for psychological consult [8,9].  We felt that both of 
these variables could impact any reported associations between pre-stroke 
depression and post-stroke depression, but were unlikely to be controlled for in 
studies (via records of post-stroke care accessed by each patient).  As such, it 
was included as a secondary attribute for RoB assessment. 
 
Sub group categorisation details 
Assessment method classification: 
Assessment methods were classified as follows: ‘self-report’ (any method that 
simply required a patient to inform as to a prior diagnosis of- or treatment for- 
depression, as part of a questionnaire or non-clinical interview), ‘medical 
records’ (hospital charts, admin records etc.), ‘clinical interview’ (both 
structured, semi-structured and unstructured in depth interviews conducted by a 
clinician; or alternatively, by a researcher using a tool such as the Structured 
Clinical Interview for Depression), ‘informant report’ (any assessment method in 
which only the informant was asked for pre-stroke depression information), 
‘screening tool’ (validated tools for assessing depressive symptoms, such as the 
CESD).  Where studies utilised more than one assessment method, we classified 
the assessment type via the method that we felt was most likely to have 
identified the highest number of pre-stroke depression cases reported in each 
study’s sample.  Generally, Clinical Interviews took precedence over all other 
assessment types apart from screening tools.   Based on findings from previous 
research [10], medical records took precedence over self-reports.  A breakdown 
of the methods of assessment utilised in included studies can be seen in Table 3.   
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Appendix 7: Chapter 4, prevalence GRADE table 
 
Quality criteria 
Rating  
(circle one for 
each criterion) 
Footnotes 
(explain reasons for up- or 
downgrading) 
Quality of the 
evidence  
(Circle one per 
outcome) 
 Outcome # 1: Pre-stroke depression prevalence 
Risk of bias serious (-1)  
All studies were graded as 
having a risk of bias in at least 
one category of the ROB 
assessment. 
 
  
High 
 
 
Moderate 
 
 
 
Low 
 
 
Very Low 
Inconsistency very serious (-2) 
Very high I-squared and 
variability in reported rates. 
Indirectness serious (-1)  
Majority of studies did not have 
a specific interest in assessing 
pre-stroke depression. 
Imprecision No  
Confidence intervals are 
narrow. 
Publication Bias Unlikely  
No reason to base publication 
on basis of reported pre-stroke 
depression prevalence rate. 
 
Large effect 
 
NA NA 
 
Dose-response 
gradient 
 
No  NA 
Plausible 
confounding would 
change the effect 
No  NA 
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Appendix 8: Chapter 4, included Studies that 
reported on the association between pre-stroke 
depression and post-stroke depression 
 
Total studies that 
describe the 
association between 
pre-stroke 
depression and post-
stroke depression 
Studies that reported 
a significant 
(p<0.05) association 
between pre-stroke 
depression and post-
stroke depression 
Studies that 
assessed pre-
stroke 
depression/post-
stroke 
depression 
association 
using multiple 
regression 
analysis 
Studies that 
report a 
significant 
association 
between pre-
stroke 
depression and 
post-stroke 
depression 
using multiple 
regression 
analysis 
McCarthy et al., 2016; 
Schottke & Giabbiconi, 
2015; De Ryck et al., 
2013; White et al., 
2014; Aben et al., 
2006; Prisnie et al., 
2016; Tang et al., 
2011; Zhang et al., 
2010; Bara et al., 
2016; Cairo et al., 
2006; Gillen et al., 
2001; Hackett et al., 
2006; Jorgensen et al., 
2016; Kim et al., 2014; 
Kootker et al., 2016; 
Liu et al., 2017; Ng et 
al., 1995; Paolucci et 
al., 2006; Pohjasvarra 
et al., 1998; 
Sienkiewicz-Jarosz et 
al., 2010; Singh et al., 
2000; Tang et al., 
2005; Tse et al., 2017; 
Verdelho et al, 2004 
McCarthy et al., 2016; 
De Ryck et al.,  2013; 
Prisnie et al., 2016; 
Tang et al., 2011; 
Zhang et al., 2010; 
Caeiro et al., 2006; 
Gillen et al., 2001; 
Kim et al., 2014; Ng et 
al., 1995; Paolucci et 
al., 2006; Pohjasvarra 
et al., 1998; Verdelho 
et al., 2004 
McCarthy et al., 
2016; Schottke & 
Giabbiconi, 
2015; De Ryck et 
al., 2013; White 
et al., 2014; 
Aben et al., 
2006; Tang et 
al., 2011; Zhang 
et al., 2010; Bara 
et al., 2016; 
Cairo et al., 
2006; Hackett et 
al., 2006; 
Jorgensen et al., 
2016; Ng et al., 
1995; Paolucci et 
al., 2006; 
Pohjasvarra et 
al., 1998; 
Verdelho et al, 
2004 
McCarthy et al., 
2016; De Ryck 
et al.,  2013; 
Tang et al., 
2011; Zhang et 
al., 2010; Cairo 
et al., 2006; 
Hackett et al., 
2006; Jorgensen 
et al., 2016; Ng 
et al., 1995; 
Paolucci et al., 
2006; 
Pohjasvarra et 
al., 1998; 
Verdelho et al, 
2004 
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Appendix 9: Chapter 4, table of Pre-stroke 
depression/post-stroke depression risk 
association study heterogeneity 
 
Study Pre-stroke 
depression 
assessment method 
Post-stroke 
depression 
assessment method 
Covariates 
controlled for 
Aben et al. (2006) 
 
SCID* SCID Sex; Somatic 
comorbidity; family 
history of depression 
Barra et al. (2016) 
 
Medical records HADS$ Age; sex; mRSD; 
previous stroke. 
Caiero et al. (2006) 
 
Semi-structured 
clinical interview 
MADRS^ (Cut-off 7) Age; sex; aphasia. 
De Ryck et al. (2013) 
 
1)Self-report  
2)Medical 
records/charts 
3)Screening (CSD%) 
CSD and MADRS  BIE; NIHSSF; mRS; 
GFIM; HMMSE; ISIS 
Hackett et al. (2006) 
 
Self-report  GHQ-28+ Sex; age; 
comorbidity; BI; 
premorbid 
dependency; loss of 
consciousness. 
Jorgensen et al. 
(2016) 
 
Medical records Medical records Age; sex; education; 
cohabitation status; 
diabetes. 
Mcarthy et al. (2016) 
 
Medical records and 
self-report 
CESD# Sex; race; marital 
status; education; 
NIHSS; mRS; age;  
Ng et al. (1995) 
 
Clinical Interview Clinical interview 
(DSMIIIB) and HDRSA 
Age; sex; Lesion type; 
functional status. 
Paolucci et al. (2006) 
 
Self-report BDI (>10) or “sad 
face” on VAMS 
Sex; prev stroke; 
mRS; aphasia; BI. 
Pohjasvarra et al. 
(1998) 
 
Medical records Neuropsychiatric 
inventory (DSMIII and 
ICD10C) 
Dependence; BI; 
Stroke severity scale. 
Schottke et al. (2015) 
 
SCID SCID Life-time anxiety 
disorders. 
Tang et al. (2011) 
 
Medical records and 
self-reports 
SCID Sex; lesion location; 
education; NIHSS; 
Social network; Life 
events. 
Verdelho et al. 
(2004) 
 
Medical Records and 
self-reports 
CAMDEX£ and MADRS Sex; prev stroke; prev 
dementia; stroke 
characteristics; mRS; 
Orgozo score; post-
stroke dementia. 
White et al. (2014) 
 
Medical records HADS Time; age; mRS; 
social support; Sex; 
activities; anxiety; 
baseline depression.  
Zhang et al. (2010) 
 
CIDI! CIDI Gender; marital 
status; Hypertension; 
mRS; HDRS. 
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Appendix 10: Chapter 4, pre-stroke 
depression/post-stroke depression risk 
association GRADE table 
 
 
 
Quality criteria 
Rating  
(circle one for 
each criterion) 
Footnotes 
(explain reasons for up- or 
downgrading) 
Quality of the 
evidence  
(Circle one per 
outcome) 
 Outcome #2: Risk association with post-stroke depression 
Risk of bias serious (-1)  
Most studies had potential 
sources of bias in primary ROB 
categories.  All studies were at 
risk of bias based upon possible 
variations in care pathway. 
 
  
High 
 
 
Moderate 
 
 
 
Low 
 
 
Very Low 
Inconsistency No  
Vast majority of studies suggest 
similar sized odds ratios. 
Indirectness serious (-1)  
Pre-stroke depression was 
assessed as a covariate in a 
number of regression models 
and hence was not a primary 
variable of interest. 
Imprecision No  
Confidence intervals are 
narrow. 
Publication Bias very likely (-2) 
Studies often do not provide 
odds ratios if not significant. 
 
Large effect 
 
Large (+1)  >3 odds ratio 
 
Dose-response 
gradient 
 
No  NA 
Plausible 
confounding would 
change the effect 
No  
Confounders such as care 
pathway could conceivably 
increase or decrease effect size. 
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Appendix 11: Stroke Aphasic Depression 
Questionnaire (SADQ-H10) 
 
218 
 
Appendix 12: Geriatric Depression Scale- Short 
Form Informant version (GDS-SF Informant) 
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Appendix 13: pre-stroke modified Rankin Scale 
(mRS) 
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Appendix 14: Chapter 6, associations between 
factors and death within 1 year 
 Unadjusted Adjusted 
 OR (95% CI) p-value OR (95% CI) p-value 
Age (by year)  1.08 (1.07,1.09) <0.001 1.04 (1.02,1.06) <0.001 
Male 0.65 (0.55,0.77) <0.001 0.79 (0.6,1.06) 0.111 
Pre-stroke 
rankin 
 Trend:<0.001  Trend:<0.001 
  1 vs 0 2.23 (1.69,2.94) <0.001 1.88 (1.29,2.74) 0.001 
  2 vs 0 2.82 (2.03,3.92) <0.001 1.85 (1.2,2.85) 0.005 
  3 vs 0 5.48 (3.99,7.51) <0.001 3.43 (2.24,5.25) <0.001 
  4 or 5 vs 0 11.97 
(8.4,17.04) 
<0.001 6.84 
(4.24,11.03) 
<0.001 
ICH 2.28 (1.79,2.89) <0.001 3.99 (2.69,5.9) <0.001 
MEWS 1.32 (1.23,1.41) <0.001 1.18 (1.07,1.31) 0.001 
Glucose 1.07 (1.04,1.10) <0.001 1.06 (1.02,1.11) 0.008 
AF 2.08 (1.73,2.52) <0.001 1.59 (1.2,2.12) 0.001 
Charlson index 1.37 (1.32,1.43) <0.001 1.17 (1.08,1.26) <0.001 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 15: Chapter 6, associations between 
factors and death within 7 days.   
 Unadjusted Adjusted 
 OR (95%CI) p-value OR (95%CI) p-value 
Age 1.04 
(1.03,1.05) 
<0.001 1.02 (1,1.04) 0.11 
Male 0.77 
(0.59,0.99) 
0.045 1.01 
(0.64,1.58) 
0.98 
Pre-
stroke 
Rankin 
 Trend:<0.001  Trend:<0.001 
1 vs 0 1.62 
(1.04,2.50) 
0.031 1.83 
(0.97,3.44) 
0.06 
2 vs 0 1.79 
(1.06,3.01) 
0.029 2.24 
(1.11,4.5) 
0.024 
3 vs 0 2.12 
(1.30,3.46) 
0.003 2.54 
(1.3,4.96) 
0.006 
4 or 5 vs 
0 
5.58 
(3.68,8.46) 
<0.001 4.39 
(2.32,8.28) 
<0.001 
ICH 5.03 
(3.75,6.75) 
<0.001 8.22 
(5.14,13.15) 
<0.001 
MEWS 1.68 
(1.53,1.85) 
<0.001 1.6 
(1.38,1.84) 
<0.001 
Glucose 1.09 
(1.05,1.13) 
<0.001 1.06 (1,1.12) 0.035 
AF 1.48 
(1.12,1.95) 
0.006 1.16 
(0.74,1.81) 
0.518 
Charlson 
index 
1.16 
(1.10,1.22) 
<0.001 1.09 
(0.97,1.21) 
0.137 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 16: Chapter 6, association between 
factors and Urinary Tract Infection. 
 Unadjusted Adjusted 
 OR (95%CI) p-value OR (95%CI) p-value 
Age 1.02 
(1.01,1.04) 
0.005 1.04 
(1.02,1.07) 
0.002 
Male 0.58 
(0.41,0.82) 
0.002 0.6 
(0.37,0.97) 
0.036 
Pre-
stroke 
Rankin 
 Trend: 
0.090 
 Trend: 
0.231 
1 vs 0 2.32 
(1.44,3.72) 
<0.001 2.18 
(1.2,3.96) 
0.01 
2 vs 0 2.93 
(1.72,4.99) 
<0.001 3.42 
(1.79,6.53) 
<0.001 
3 vs 0 1.79 
(0.97,3.28) 
0.062 1.47 
(0.68,3.16) 
0.323 
4 or 5 vs 
0 
1.04 
(0.48,2.26) 
0.916 1.21 
(0.49,2.96) 
0.682 
ICH 0.93 
(0.56,1.54) 
0.772 0.96 (0.46,2) 0.922 
MEWS 0.89 
(0.77,1.03) 
0.109 0.86 
(0.71,1.03) 
0.097 
Glucose 0.99 
(0.93,1.05) 
0.674 0.97 
(0.89,1.06) 
0.552 
AF 1.57 
(1.10,2.26) 
0.014 1.48 
(0.93,2.35) 
0.097 
Charlson 
index 
1.02 
(0.95,1.09) 
0.683 0.77 
(0.64,0.92) 
0.004 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 17: Chapter 6, association between 
factors and Pneumonia. 
 Unadjusted Adjusted 
 OR (95%CI) p-value OR (95%CI) p-value 
Age 1.04 
(1.03,1.06) 
<0.001 1.04 
(1.02,1.07) 
<0.001 
Male 0.86 
(0.67,1.11) 
0.243 1.09 
(0.75,1.6) 
0.639 
Pre-
stroke 
Rankin 
 Trend: 
0.001 
 Trend: 
0.001 
1 vs 0 1.56 
(1.02,2.38) 
0.04 1.32 
(0.78,2.23) 
0.307 
2 vs 0 2.06 
(1.27,3.33) 
0.003 1.67 
(0.94,2.98) 
0.081 
3 vs 0 2.74 
(1.76,4.26) 
<0.001 1.53 
(0.86,2.75) 
0.15 
4 or 5 vs 
0 
4.12 
(2.7,6.29) 
<0.001 2.79 
(1.62,4.82) 
<0.001 
ICH 1.09 
(0.76,1.56) 
0.642 1.24 
(0.74,2.08) 
0.416 
MEWS 1.31 
(1.20,1.43) 
<0.001 1.18 
(1.04,1.34) 
0.012 
Glucose 1.06 
(1.02,1.10) 
0.002 1.06 
(1.01,1.11) 
0.025 
AF 1.61 
(1.24,2.11) 
<0.001 1.38 
(0.96,1.99) 
0.086 
Charlson 
index 
1.14 
(1.09,1.20) 
<0.001 0.96 
(0.86,1.06) 
0.425 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 18: Chapter 6, association between 
factors and Length of Stay. 
 Unadjusted Adjusted 
 Beta (95%CI) p-value Beta (95%CI) p-value 
Age 0.26 
(0.20,0.32) 
<0.001 0.2 
(0.09,0.31) 
<0.001 
Male -3.28 (-4.85,-
1.71) 
<0.001 -1.56 (-
3.72,0.59) 
0.155 
Pre-
stroke 
Rankin 
 Trend: 
<0.001 
  
1 vs 0 6.01 
(3.78,8.24) 
<0.001 5.68 
(2.71,8.65) 
<0.001 
2 vs 0 6.11 
(3.32,8.9) 
<0.001 4.39 
(0.81,7.96) 
0.016 
3 vs 0 9.28 
(6.51,12.05) 
<0.001 6.38 
(2.77,10) 
0.001 
4 or 5 vs 
0 
3.58 
(0.68,6.49) 
0.016 1.06 (-
2.87,4.98) 
0.597 
ICH 1.52 (-
0.83,3.87) 
0.204 2.79 (-
0.4,5.97) 
0.086 
MEWS 0.01 (-
0.62,0.64) 
0.971 -0.15 (-
0.96,0.65) 
0.707 
Glucose 0.19 (-
0.10,0.48) 
0.192 0.18 (-
0.17,0.52) 
0.313 
AF 5.53 
(3.77,7.30) 
<0.001 4.11 
(1.83,6.4) 
<0.001 
Charlson 
index 
0.85 
(0.51,1.19) 
<0.001 -0.38 (-
0.98,0.22) 
0.219 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 19: Chapter 6, association between 
factors and discharge destination (‘Home’ vs any 
one of ‘Sheltered housing’, ‘Rehabilitation Centre’ 
or ‘Care home’). 
 Unadjusted Adjusted 
 OR (95%CI) p-value OR (95%CI) p-value 
Age 1.04 
(1.03,1.05) 
<0.001 1.03 
(1.02,1.05) 
<0.001 
Male 0.59 
(0.49,0.70) 
<0.001 0.64 
(0.49,0.83) 
0.001 
Pre-stroke 
Rankin 
 Trend: 
<0.001 
 Trend: 
<0.001 
1 vs 0 1.81 
(1.41,2.33) 
<0.001 2 (1.42,2.83) <0.001 
2 vs 0 2.17 (1.57,3) <0.001 2.25 
(1.47,3.45) 
<0.001 
3 vs 0 3.13 
(2.15,4.57) 
<0.001 2.62 
(1.61,4.28) 
<0.001 
4 or 5 vs 0 3.61 
(2.28,5.73) 
<0.001 2.24 
(1.2,4.19) 
0.011 
ICH 2.73 
(2.10,3.56) 
<0.001 3.7 
(2.47,5.54) 
<0.001 
MEWS 1.24 
(1.16,1.34) 
<0.001 1.17 
(1.06,1.29) 
0.002 
Glucose 1.08 
(1.04,1.11) 
<0.001 1.06 
(1.01,1.11) 
0.011 
AF 1.95 
(1.60,2.38) 
<0.001 1.69 
(1.28,2.24) 
<0.001 
Charlson 
index 
1.16 
(1.12,1.21) 
<0.001 0.98 
(0.91,1.06) 
0.614 
ICH= Intracerebral haemorrhage; MEWS= Modified Early Warning Score; AF= 
Atrial fibrillation 
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Appendix 20: Frailty Index 
Frailty Index 
 
Depression 
Anxiety 
Polypharmacy 
Hypertension 
Atrial Fibrilation 
Previous cerebrovascualar 
disease 
Diabetes 
Vascular disease 
Hyperlipidaemia 
Heart failure 
Previous Myocardial 
infarction 
 
Haemoglobin (low) 
Care-home resident 
Carers 
Hearing aid 
Sensory impairment (e.g. 
blind/deaf) 
Continence bladder 
Continence bowel 
Falls 
Fracture 
Chronic Obstructive 
Pulmonary Disease 
Cancer 
 
Liver disease 
Peptic ulcer 
Arthritis 
Impaired external ADL 
Impaired ADL  
Mobility aid 
Assistance walking 
Calcium 
Albumin (low) 
High glucose 
Renal failure 
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Appendix 21: Frailty Phenotype self-report 
assessment 
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